Enhanced chimeric antigen receptors and uses thereof

By designing a new CAR, including modified CD3ζ polypeptides and hinges/spacers, the problem of low signaling efficiency and cell depletion of existing CAR therapies is solved, achieving a more lasting and efficient immune response, and enhancing cancer and pathogens Attack ability.

CN118955737APending Publication Date: 2024-11-15MEMORIAL SLOAN KETTERING CANCER CENT
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411218240.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-12-29
Filing Date
2018-12-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing chimeric antigen receptor (CAR) therapies have inefficiencies in signaling and cell depletion, making it difficult to maintain an immune response to cancer and pathogens for a long time.

Method used

A novel CAR is designed that contains modified CD3ζ polypeptides, missing or containing loss-of-function ITAM variants, and combines hinge/spacer and transmembrane domains to build engineered immune response cells that enhance their antigen binding capabilities and durability.

Benefits of technology

It improves the durability and therapeutic efficacy of immune response cells, reduces cell depletion, enhances the specific recognition and attack ability of tumor antigens, and prolongs the duration of the immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955737A_ABST
    Figure CN118955737A_ABST
Patent Text Reader

Abstract

The presently disclosed subject matter provides methods and compositions for enhancing an immune response to cancer and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immune response cells comprising the same. Engineered immune response cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with the invention name “Enhanced chimeric antigen receptor and its use” submitted to the State Intellectual Property Office of the People’s Republic of China on August 28, 2020, the application date of December 31, 2018, and the application number of “201880090507.7”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Application No. 62 / 612,031, filed on December 29, 2017, the entire contents of which are incorporated by reference and claim priority. Technical Field

[0004] The subject matter of the present disclosure provides methods and compositions for enhancing immune responses against cancer and pathogens. It relates to a novel design of a chimeric antigen receptor (CAR) and an engineered immune response cell including the chimeric antigen receptor. The engineered immune response cell comprising the novel CAR is antigen-guided and has extended persistence without compromising function. Background Art

[0005] Chimeric antigen receptor (CAR) therapy has achieved great clinical success against hematological malignancies (PMID: 23515080). It is based on a synthetic receptor with both antigen recognition and signal transduction functions (PMID: 20467460). The single-chain variable fragment (scFv) in CAR retains the antigen recognition specificity of the heavy and light chain variable regions of the original monoclonal antibody. At the same time, the signal transduction of the CAR construct depends largely on the signaling domain of the original immune receptor. Currently, all versions of second-generation CARs in clinical trials have two signaling capabilities / modes because they contain domains from two immune receptors, one is CD3ζ and the other is a co-stimulatory receptor, such as CD28 or 41BB (PMID: 26129802). In essence, it merges two signals transduced by separate receptors into one synthetic receptor. It is speculated that the signal transduction in CAR may be similar to that in CD3ζ and CD28 / 41BB.

[0006] CD3ζ is part of the multimeric T cell antigen receptor (TCR) complex, which binds to antigens and transduces this binding across the plasma membrane into an intracellular signal. While the TCRαβ (or TCRγδ) subunit recognizes antigens through its specific extracellular region, CD3ζ performs the main signal transduction function in the complex through its three conserved immunoreceptor tyrosine-based activation motifs (ITAMs) (PMID: 20516133). First, based on sequence homology, ITAMs are composed of two consecutive YxxL / I motifs, which are composed of a defined number of amino acids (YxxL / IX 6-8 -YxxL / I) (PMID: 2927501). ITAMs are commonly found in receptors expressed by hematopoietic cells and are particularly well studied in the context of TCR signaling. Binding of the TCR to peptide-MHC leads to the activation of the Src family kinase Lck, which phosphorylates two tyrosine residues in each of the three ITAMs in CD3ζ (PMID: 25861978). Each doubly phosphorylated ITAM then acquires the ability to bind to two tandem SH2 domains of the Syk family kinase ZAP-70. This interaction brings ZAP-70 into close proximity with Lck, resulting in the phosphorylation and activation of ZAP-70 by Lck. Activated ZAP-70 further phosphorylates its downstream targets, such as the adaptor proteins LAT and SLP-76. Phosphorylated LAT and SLP-76 provide scaffolds for many other proteins such as PLC-γ, Grb2 / Sos, Gads and Itk, Vav and Nck, ultimately leading to calcium mobilization, Ras / Erk activation and actin cytoskeleton rearrangement, and ultimately activating gene expression (PMID: 20516133). Therefore, the three ITAMs in CD3ζ are not only the signal transduction part of TCR signal transduction, but also the main one.

[0007] On the other hand, CD28 does not contain any ITAMs. Instead, its cytoplasmic domain contains a YMNM motif that becomes phosphorylated upon binding of CD28 to its ligands CD80 / CD86 and can bind to the p85 subunit of PI3K and Grb2 / Gads (PMID: 20534709). In addition, the proline-rich region of CD28 can interact with Itk, Tec, Lck, Grb2 / Vav, and filamin A (PMID: 20534709). Therefore, TCR signaling initiated by antigen binding of CD3ζ and CD28 signaling initiated by CD80 / 86 binding share many common players, such as Grb2, Vav, Gads, Lck, Itk, making crosstalk between the two pathways possible. Moreover, activation of both pathways occurs in signaling complexes assembled near the plasma membrane at the immune synapse, which physically brings signaling molecules from both pathways together in space. Last but not least, CD28-induced calcium signaling occurs seconds after the TCR-initiated intracellular calcium rise (if not faster), reflecting the temporal proximity of the two pathways (PMID: 18848472). Summary of the invention

[0008] The present disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. CAR can bind to a tumor antigen or a pathogen antigen. In certain non-limiting embodiments, CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 ζ polypeptide.

[0009] In certain embodiments, the modified CD3ζ polypeptide lacks all or part of an immunoreceptor tyrosine-based activation motif (ITAM), wherein ITAM is ITAM1, ITAM2 and ITAM3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also comprises a deletion of ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also comprises a deletion of ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM1 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide further comprises a deletion of ITAM3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM3 or a portion thereof.

[0010] In certain embodiments, the modified CD3ζ polypeptide also lacks all or part of the basic-rich extension (BRS) region, wherein the BRS region is BRS1, BRS2 and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof and BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also comprises a deletion of BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide comprises a deletion of ITAM2, ITAM3, BRS2, ​​and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2, ITAM3, BRS2, ​​and BRS3. In certain embodiments, the CAR comprises the amino acid sequence shown in SEQ ID NO: 45 or SEQ ID NO: 47.

[0011] In certain embodiments, the modified CD3ζ polypeptide lacks all or part of a basic-rich stretch (BRS) region, wherein the BRS region is BRS1, BRS2, ​​and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof.

[0012] In certain embodiments, the modified CD3zeta polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, wherein the BRS variant comprises one or more loss-of-function mutations.

[0013] In certain embodiments, any of the various CARs disclosed above further include hinges / spacers, wherein hinges / spacers include CD8 polypeptides, CD28 polypeptides, CD3 ζ polypeptides, CD40 polypeptides, 4-1BB polypeptides, OX40 polypeptides, CD84 polypeptides, CD166 polypeptides, CD8a polypeptides, CD8b polypeptides, ICOS polypeptides, ICAM-1 polypeptides, CTLA-4 polypeptides, CD27 polypeptides, CD40 / My88 peptides, NKGD2 peptides, or combinations thereof. In certain embodiments, hinges / spacers include CD166 polypeptides. In certain embodiments, hinges / spacers include CD166 polypeptides having SEQ ID NO:3 amino acids 489 to 527.

[0014] In certain embodiments, the transmembrane domain of any one of the various CARs disclosed above includes CD8 polypeptides, CD28 polypeptides, CD3 ζ polypeptides, CD40 polypeptides, 4-1BB polypeptides, OX40 polypeptides, CD84 polypeptides, CD166 polypeptides, CD8a polypeptides, CD8b polypeptides, ICOS polypeptides, ICAM-1 polypeptides, CTLA-4 polypeptides, CD27 polypeptides, CD40 / My88 peptides, NKGD2 peptides, or a combination thereof. In certain embodiments, the transmembrane domain includes CD166 polypeptides. In certain embodiments, the transmembrane domain includes CD166 polypeptides having amino acids 528 to 527 of SEQ ID NO:3.

[0015] In certain embodiments, the transmembrane domain and hinge / spacer are derived from the same molecule. In certain embodiments, the hinge / spacer comprises a CD28 polypeptide, and the transmembrane domain comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer comprises a CD84 polypeptide, and the transmembrane domain comprises a CD84 polypeptide. In certain embodiments, the hinge / spacer comprises a CD166 polypeptide, and the transmembrane domain comprises a CD166 polypeptide. In certain embodiments, CAR comprises amino acids 489 to 553 of SEQ ID NO: 3.

[0016] In certain embodiments, the hinge / spacer comprises a CD8a polypeptide and the transmembrane domain comprises a CD8a polypeptide. In certain embodiments, the hinge / spacer comprises a CD8b polypeptide and the transmembrane domain comprises a CD8b polypeptide.

[0017] In certain embodiments, the transmembrane domain and hinge / spacer are derived from different molecules. In certain embodiments, the hinge / spacer comprises a CD28 polypeptide and the transmembrane domain comprises an ICOS polypeptide.

[0018] In certain embodiments, the intracellular signaling domain of any of the various CARs disclosed above further comprises a co-stimulatory signaling domain. In certain embodiments, the co-stimulatory signaling domain comprises a CD28 polypeptide.

[0019] The subject matter of the present disclosure also provides a chimeric antigen receptor (CAR), which comprises an extracellular antigen binding domain, a hinge / spacer, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises an ITAM variant comprising a mutation of one or more loss of function, wherein the ITAM variant is selected from ITAM1 variants, ITAM2 variants, and ITAM3 variants. In certain embodiments, the hinge / spacer comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD40 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD84 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, a NKGD2 peptide, or a combination thereof. In certain embodiments, the ITAM2 variant has the amino acid sequence shown in SEQ ID NO: 29. In certain embodiments, the ITAM3 variant has the amino acid sequence shown in SEQ ID NO: 33. In certain embodiments, CAR comprises a hinge / spacer region of a CD166 polypeptide and a transmembrane domain of a CD166 polypeptide. In certain embodiments, CAR comprises SEQ ID NO:3 amino acids 489 to 553. In certain embodiments, the modified CD3 ζ polypeptide has SEQ ID NO:43 amino acids 374 to 485. In certain embodiments, CAR comprises an amino acid sequence shown in SEQ ID NO:43.

[0020] The subject matter of the present disclosure also provides an immune response cell comprising a CAR disclosed herein. In certain embodiments, CAR is recombinantly expressed. In certain embodiments, CAR is expressed by a vector. In certain embodiments, CAR is placed at an endogenous locus of an immune response cell. In certain embodiments, the endogenous locus is a TRAC locus, a TRBC locus, or a TRGC locus. In certain embodiments, the endogenous locus is a TRAC locus. In certain embodiments, the placement of CAR destroys or eliminates endogenous expression of TCR.

[0021] The subject matter of the present disclosure also provides immune response cells comprising two or more CARs. In certain embodiments, the immune response cell comprises: a) a first CAR comprising a first extracellular antigen binding domain, a first transmembrane domain and a first intracellular signaling domain that binds to a first antigen; and b) a second CAR comprising a second extracellular antigen binding domain, a second transmembrane domain and a second intracellular signaling domain that binds to a second antigen, wherein the first CAR is a CAR disclosed above or the first intracellular signaling domain comprises a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprises one or more ITAM variants, the ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from ITAM1 variants, ITAM2 variants and ITAM3 variants. In certain embodiments, the first CAR further comprises a first hinge / spacer. In certain embodiments, the second CAR further comprises a second hinge / spacer. In certain embodiments, each of the first and second hinge / spacers can be independently selected from any one of the hinge / spacers disclosed herein.

[0022] In certain embodiments, the second CAR is a CAR disclosed above. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3 ζ polypeptide comprising one or more ITAM variants, the ITAM variant comprising one or more loss-of-function mutations, wherein the ITAM variant is selected from ITAM1 variants, ITAM2 variants, and ITAM3 variants. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3 ζ polypeptide, which is identical to the modified CD3 ζ polypeptide contained in the first intracellular signaling domain of the first CAR. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a modified CD3 ζ polypeptide, which is different from the modified CD3 ζ polypeptide contained in the first intracellular signaling domain of the first CAR. In certain embodiments, the second intracellular signaling domain of the second CAR comprises a natural CD3 ζ polypeptide.

[0023] In some embodiments, the first intracellular signaling domain of the first CAR is the same as the second intracellular signaling domain of the second CAR. In some embodiments, the first intracellular signaling domain of the first CAR is different from the second intracellular signaling domain of the second CAR.

[0024] In certain embodiments, the first antigen is different from the second antigen.

[0025] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof.

[0026] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0027] In certain embodiments, the cell further comprises a third CAR comprising a third extracellular antigen binding domain that binds to a third antigen, a third transmembrane domain, and a third intracellular signaling domain.

[0028] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0029] In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0030] In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0031] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0032] In some embodiments, the cell is selected from T cells, natural killer (NK) cells, human embryonic stem cells and pluripotent stem cells from which lymphoid cells can be differentiated. In some embodiments, the cell is a T cell. In some embodiments, the T cell is selected from cytotoxic T lymphocytes (CTL), regulatory T cells and natural killer T (NKT) cells. In some embodiments, the immune response cell is a myeloid cell, such as a macrophage. In some embodiments, the immune response cell is autologous. In some embodiments, the antigen is a tumor antigen. In certain embodiments, the tumor antigen is selected from CD19, MUC16, MUC1, CA1X, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2,3,4, FBP, fetal acetylcholine receptor, folate receptor alpha, GD2, GD3, HER-2, hTERT, IL-13R-a2, kappa light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, ERBB2, MAGEA3, p 53, MART1, GP100, proteinase 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, NY-ES0-1, tumor embryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII and CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME, CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A and ERBB. In certain embodiments, the antigen is CD19.

[0033] The subject matter of the present disclosure also provides a pharmaceutical composition, which comprises an effective amount of the immune response cells disclosed herein and a pharmaceutically acceptable excipient. In certain embodiments, the pharmaceutical composition is used to treat a tumor.

[0034] The subject matter of the present disclosure also provides a method for reducing the tumor burden of a subject, the method comprising administering to the subject an effective amount of an immune response cell or a pharmaceutical composition disclosed herein. The subject matter of the present disclosure also provides a method comprising administering to the subject an effective amount of an immune response cell or a pharmaceutical composition thereof, wherein the immune response cell comprises a chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants, the ITAM variant comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM2 variant and an ITAM3 variant. In certain embodiments, one or both of the ITAM2 variant and the ITAM3 variant comprise two loss-of-function mutations. In certain embodiments, the ITAM2 variant has the amino acid sequence shown in SEQ ID NO: 29. In certain embodiments, the ITAM3 variant has the amino acid sequence shown in SEQ ID NO: 33. In certain embodiments, one or more loss-of-function mutations are located at a tyrosine amino acid residue. In certain embodiments, the intracellular signaling domain further comprises a co-stimulatory signaling domain. In certain embodiments, the co-stimulatory signaling domain comprises a CD28 polypeptide.

[0035] In certain embodiments, the method reduces the number of tumor cells. In certain embodiments, the method reduces the size of a tumor. In certain embodiments, the method eradicates a tumor in a subject.

[0036] The subject matter of the present disclosure also provides a method for treating or preventing a tumor. In some embodiments, the method includes administering an effective amount of an immune response cell or a pharmaceutical composition disclosed herein to a subject. In some embodiments, the method includes administering an effective amount of an immune response cell or a pharmaceutical composition thereof to a subject, wherein the immune response cell comprises a chimeric antigen receptor (CAR), which comprises an extracellular antigen binding domain, a hinge / spacer, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 ζ polypeptide, wherein the modified CD3 ζ polypeptide comprises one or more ITAM variants, and the ITAM variants comprise one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from ITAM1 variants, ITAM2 variants, and ITAM3 variants.

[0037] The subject matter of the present disclosure also provides a method for treating a subject with tumor recurrence, wherein the subject has received an immune response cell comprising an antigen recognition receptor, wherein the antigen recognition receptor comprises a 4-1BB co-stimulatory signal. In certain embodiments, the method includes administering an effective amount of an immune response cell or a pharmaceutical composition disclosed herein to the subject. In certain embodiments, the method includes administering an effective amount of an immune response cell or a pharmaceutical composition thereof to the subject, wherein the immune response cell comprises a chimeric antigen receptor (CAR), which comprises an extracellular antigen binding domain, a hinge / spacer, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants, the ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant. In certain embodiments, the intracellular signaling domain also comprises a co-stimulatory signaling domain. In certain embodiments, the co-stimulatory signaling domain comprises a CD28 polypeptide.

[0038] In some embodiments, tumor (neoplasm) or tumor (tumor) is selected from blood cancer, B cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma and ovarian cancer.In some embodiments, the tumor is B cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia or non-Hodgkin's lymphoma, and the CAR is combined with CD19.In some embodiments, the tumor is CD19+ALL.In some embodiments, the tumor comprises tumor cells with low expression levels of tumor-specific antigens.

[0039] The subject of the present disclosure also provides a method for producing antigen-specific immune response cells, the method comprising introducing a nucleic acid sequence encoding a CAR disclosed herein into an immune response cell. In certain embodiments, the nucleic acid sequence is contained in a vector. In certain embodiments, the vector is a retroviral vector.

[0040] The subject matter of the present disclosure also provides an isolated nucleotide encoding the CAR disclosed herein. In certain embodiments, the isolated nucleotide further comprises the nucleotide sequence shown in SEQ ID NO: 45 and SEQ ID NO: 47.

[0041] The subject matter of the present disclosure also provides a nucleic acid composition comprising a CAR disclosed herein. In certain embodiments, the nucleic acid sequence is contained in a vector. In certain embodiments, the vector is a retroviral vector.

[0042] The presently disclosed subject matter also provides a vector comprising the nucleic acid composition disclosed herein.

[0043] The subject of the present disclosure also provides a kit comprising CAR, immune response cells, pharmaceutical compositions, nucleic acid compositions or vectors disclosed herein. In certain embodiments, the kit further comprises written instructions for treating and / or preventing tumors, pathogen infections, autoimmune diseases or allogeneic transplants. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] The following detailed description, given by way of example only, may be read in conjunction with the accompanying drawings and is not intended to limit the disclosed subject matter to the particular embodiments described.

[0045] Figure 1 describes the cytoplasmic region of wild-type, mutant and truncated 1928ζ (1928z) CAR. A) The cytoplasmic region of different 1928ζ (1928z) CARs. The ζ chain of the original 1928ζ CAR is mutated to construct a 1928ζ CAR T cell with a unique ζ signaling domain. From the proximal to the distal direction of the membrane, the three ITAM motifs in the ζ domain are named ITAM1, ITAM2 and ITAM3. In 1XX, X2X, XX3 and X23 CARs, the two tyrosine residues (Y) in the corresponding ITAM are point mutated to two phenylalanine residues (F) of the ITAM shown. In D12 and D23, deletion mutations are performed to remove ITAM1 and ITAM2 (D12) or ITAM2 and ITAM3 (D23). B) The cytoplasmic region of 1928z CAR with improved anti-tumor efficacy compared to the original 1928z structure. In 1XX, the ζ chain of the original 1928ζCAR is point mutated in ITAM2 and ITAM3 (from tyrosine (T) to phenylalanine (F)), while the basic stretch of amino acids (BRS-1, -2, -3) remains. In D12 and D23, ITAM1 and ITAM2 (D12) or ITAM2 and ITAM3 (D23) are deleted; D23 includes a BRS region (BRS-1), while BRS is absent in D12. C) Representative flow cytometry analysis showing the expression levels of CAR and LNGFR of 1928ζ and the indicated 1928ζ mutants. UT: Untransduced T cells were used as a control.

[0046] Figure 2A-2B The therapeutic efficacy of T cells containing the novel CAR design or the control 1928ζ (1928z) CAR is described. The therapeutic efficacy of 1928ζ (1928z) CAR T cells can be improved by mutation of the CD3ζ chain in the CAR construct. 6Tumor burden (mean radiated) of NALM-6 mice treated with CAR T cells (n = 9-10, pooled data from 2 independent experiments). A) In vivo responses of the 1928ζ mutant with unmodified CD3ζ, ITAM3 (XX3), ITAM2 (X2X), or a combination of ITAM2 and ITAM3 (X23) and mutations of the remaining ITAM motifs in its original CAR position. B) Tumor burden of NALM-6 mice treated with the 1928ζ mutant, which consists of a single unmutated CD3ζ sequence at the first position (ITAM3 for D12 and ITAM1 for D23) and a deletion of the remaining ζ chain domain.

[0047] Figure 3A-3B Survival of CAR T cells treated with the same dose of 1928ζ control or novel CAR constructs is described. 4 CAR + T cell therapy of Nalm-6-bearing mice. A) and B) Kaplan-Meier analysis of mouse survival comparing the in vivo efficacy of a single dose of 1928z WT and 1928z mutants XX3, X23 and X2X (A) or 1928z mutants D12, D23 and 1XX (B). Pooled data from 2 independent experiments, representing n=10 mice. Control refers to untreated mice (n=3). *p<0.05 (log-rank Mantel-Cox test).

[0048] Figure 4 The enumeration of CAR T cells in tumor-bearing mice is described. 5 × 10 4 NALM-6-bearing mice were treated with CAR T cells (n = 10 per group; pooled data from 2 independent experiments) and euthanized on day 17 after infusion; bone marrow CAR T cells and NALM-6 cells were analyzed and counted by FACS. All data are mean ± SD. *P < 0.05, ***p < 0.001, ****p < 0.0001 (unpaired Student's t test).

[0049] Figures 5A-5CAnalysis of T cell differentiation is described. Phenotypes of CD4+ and CD8+ CAR T cells in mouse bone marrow 10 days after CAR infusion (data are mean ± SEM, each column represents n = 5 mice). A) Compared with 1928ζWT, the percentage of CD62L / CD45RA expression of the 1928ζ mutants shown on CAR T cells. B) Central memory (CD62L+CD45RA-) and C) effector cells (CD62L-CD45RA+) in CD4+ and CD8+ CAR T cells. The data were compared with 1928ζWT. **P<0.01, ***P<0.001 (unpaired Student's t test).

[0050] Figure 6 Describes the cell number analysis of central memory CD4+CAR cells (CAR+CD4+CD62L+CD45RA-) and CD4+CAR T cells expressing IL7R in the mouse bone marrow 10 days and 17 days after T cell administration (data are mean ± SEM, each column represents n = 5 mice). **P<0.01, ***P<0.001 (unpaired Student's t test).

[0051] Figure 7 The analysis of T cell depletion is described. 5 × 10 4 NALM-6-bearing mice were treated with CAR T cells (n = 9-10 per group; pooled data from two independent experiments) and euthanized on day 10 after CAR infusion; bone marrow CAR T cells were analyzed by FACS. + and CD8 + Percentage of CAR T cells. Data are mean ± SEM, and each point represents one mouse. *P < 0.05, **P < 0.01, ***P < 0.001, (unpaired Student's t test).

[0052] Figure 8 depicts in vitro functional testing of CAR T cell potency. A) Using EL4-CD19 as a target, the cells were cultured for 4 hours. 51 Cytotoxic activity measured by Cr release assay (n = 2 independent experiments, repeated three times, data are mean ± SEM). B) and C) Cytotoxic activity of 18-hour bioluminescence assay using NALM-6 expressing firefly luciferase (FFL) as target. Data are mean ± SEM (n = 5 independent experiments, repeated three times). Experiments were performed one week after effector cells were expanded on irradiated 3T3-CD19.

[0053] Figure 9 depicts the in vitro cytokine profile of CAR T cells. CD4 T cells with single (A) and double positive Th1 cytokine expression as determined by intracellular cytokine staining 18 hours after the second round of stimulation with 3T3-CD19 + and CD8 + Percentage of CAR T cells (data are mean ± SEM and compared with 1928ζWT, paired Student's t-test, n = 3-5 independent experiments). *P < 0.05, **P < 0.01.

[0054] Fig.10 Schematic diagram of 1XX CARs with different hinge (H) and transmembrane domains (TM) is depicted. Flow cytometry shows CAR and LNGFR expression using goat IgG anti-mouse IgG (F(ab')2) fragments and anti-LNGFR, respectively. The 1928z-LNGFR CAR containing the CD28 / CD28 H / TM region was used as a control.

[0055] Fig.11 Describes the weekly stimulation from 10 6 Cells / ml CAR T cells were counted at the beginning of the accumulation of CAR T cells. Arrows indicate stimulation time points. Data are mean ± SEM. n = 3.

[0056] Fig.12 The in vitro cytotoxicity of CAR T cells was described. The cells were used for 4 hours at the end of the third stimulation (D21). 51 Cr release assay measures cytotoxic activity of CAR T cells. T cells and EL-4-CD19+ target cells were used at different effector: target ratios (E:T). Data are mean ± SEM. Data represent 4 independent experiments.

[0057] Fig.13 Describes the in vivo anti-tumor ability of different H / TM CART cells using NOD.Cg PrkdcscidI12rgtmlWj1 / SzJ (NSG) mice. Upper figure, after tumor burden, quantitative bioluminescent signals weekly. Indicates the CAR construct for each treatment. Lower figure, Kaplan-Meier analysis of tumor-free survival of mice in the same experiment. Survival comparisons were performed using the log-rank (Mantel-Cox) test, with n=7 mice per group.

[0058] Fig.14 An exemplary deimmunization strategy for novel CAR constructs is described. J1 and J2: no modification from the WT junction. J3: substitution of the last amino acid Ser (S) of CD28 with Lys (K). J: junction; X: point mutation.

[0059] Fig.15 Various survival curves of mice treated with CAR T cells are described. NSG mice were injected with 5 × 10 5 FFLuc-GFP NALM6 cells (pre-B ALL cell line), and 2 × 10 5 Ten days after the first T cell injection (ineffective dose only delayed tumor progression), mice were injected with 19BBz CAR T cells again or alternately with 1928z or (5×10 5 / mouse). Arrows indicate the time of CAR T cell infusion. Upper panel, bioluminescent signal was quantified weekly after tumor burden. Lower panel, Kaplan-Meier analysis of tumor-free survival of mice in the same experiment. Survival comparison was performed using the log-rank (Mantel-Cox) test, n=7 mice per group.

[0060] Figures 16A-16E The 1928ζiTAMs are described to differentially regulate CAR T cell potency. A) Cytoplasmic regions of wild-type and mutated 1928ζCARs. The ζ chain of the 1928ζCAR is mutated in one or two of its three ζ signaling domains (named ITAM1, ITAM2, and ITAM3 from the membrane proximal to the membrane distal direction). In 1XX, X2X, XX3, and X23 CARs, for the indicated ITAMs, the two tyrosine (Y) point mutations in each ITAM were mutated to two phenylalanines (F). B) Flow cytometry analysis showing the expression levels of CAR and LNGFR of the constructs described in A). The data represent at least five independent experiments with similar results. Untransduced T (UT) cells were used as controls. C)-E) 5×10 4 CAR+T cell treatment of Nalm6 mice. C) shows the tumor burden (mean radiance) of mice, comparing the in vivo efficacy of wild-type 1928ζ, 1XX, X2X, XX3 and X23 (n=10 mice per group, results are a summary of two independent experiments). Control refers to untreated mice (n=6). D) The number of CAR T cells in the bone marrow of mice on day 17 after infusion (results are from two independent experiments, n=10 mice per group). E) The phenotype of CAR T cells in the bone marrow of mice 10 days after CAR infusion, as determined by T CM and T EFF The percentage of cells is illustrated. Representative results of two independent experiments are shown (n=5 mice per group). All data are mean±sem. In D) and E), P values ​​were determined by two-tailed Mann-Whitney U test.

[0061] Figures 17A-17EFigure 3 depicts the position of the iTAM in the 1928ζCAR that determines antitumor efficacy. A) The cytoplasmic domain of the 1928ζCAR with its CD3ζ chain deleted. In D12, the deletion mutation deleted ITAM1 and ITAM2, while in D23 ITAM2 and ITAM3 were deleted. B) Flow cytometry analysis showing the expression levels of CAR and LNGFR for the indicated constructs. Data are representative of at least five independent experiments with similar results. UT, untransduced T cells were used as control. C)-E) 5×10 4 CAR+T cell treatment of Nalm6-bearing mice. C) Tumor burden (mean radiance) of mice treated with wild-type 1928ζ, D12 or D23 (wild-type 1928ζ and D23: n=10; D12: n=9; pooled data from two independent experiments). D) Number of CAR T cells in the bone marrow of mice on day 17 after infusion (results from two independent experiments, n=10 mice per group). E) Phenotype of CAR T cells in the bone marrow of mice 10 days after CAR infusion, as determined by T CM and T EFF The percentage of cells is shown (pooled data from two independent experiments, n=10 mice per group). All data are mean±sem. In D) and E), P values ​​were determined by two-tailed Mann-Whitney U test.

[0062] Figures 18A-18H TRAC-1XX is described to enhance T cell potency by reducing T cell exhaustion and developing long-lived memory T cells with effective recall responses. A)-D), 1×10 5 or 5×10 5 TRAC-CAR T cells were used to treat Nalm6-bearing mice. A) Compared with TRAC-1928ζ (TRAC-1928ζ and TRAC-XX3: n = 5 mice per group; TRAC-1XX: n = 7), 1×10 5 Kaplan-Meier analysis of survival of mice treated with TRAC-1XX or TRAC-XX3. Control refers to untreated mice (n=3). P values ​​were determined by one-sided log-rank Mantel-Cox test. B) 5×10 5 (n = 5 mice per group) or l×10 5(TRAC-1928ζ: n = 10 mice, TRAC-1XX: n = 5 mice) Kaplan-Meier analysis of survival of mice treated with TRAC-CAR T cells. P values ​​were determined by one-sided log-rank Mantel-Cox test. C) and D) The number of cells (C) and expression of the exhaustion marker PD1+TIM3+LAG3+ on bone marrow CAR T cells of TRAC-1XX and TRAC-XX3 (D) were determined and compared with TRAC-1928ζ. Data are shown as mean ± sem, and each symbol represents one mouse (n = 5 mice per group). P values ​​were determined by two-tailed Mann-Whitney U test. E)-H) Nalm6-bearing mice were treated with 5×10 5 Treatment with TRAC-edited naive T cells and re-challenged with Nalm6 cells (n = 5 mice per group), as indicated by arrows. No further tumor attack was performed in the control (TRAC-1928ζ: n = 6 mice; TRAC-1XX: n = 7 mice). E) Tumor burden (mean radiance) of mice, comparing the in vivo efficacy of TRAC-1928ζ and TRAC-1XX after re-tumor attack and without re-tumor attack. All data are mean ± sem. Statistical analysis of tumor burden was performed using a two-tailed unpaired Student's t-test on day 59 after CAR administration (TRAC-1928ζ: n = 4; TRAC-1XX: n = 5). F) and G) Total number of CAR T cells in the bone marrow of mice treated 63 days after CAR administration (re-attack: TRAC-1928ζ: n = 4 mice, TRAC-1XX: n = 5 mice; no re-attack: n = 5 mice per group) (F), T CM , T EFF (G) Number of IL7R+CAR T cells and IL7R+CAR T cells. All data are mean ± sem. Statistical analysis was performed using a two-tailed unpaired Student's t-test. H) Expression of the exhaustion marker PD1+TIM3+LAG3+ on bone marrow CAR T cells. All data are mean ± sem. P values ​​were determined by a two-tailed unpaired Student's t-test.

[0063] Figures 19A-19DDescribes that CD3ζITAM mutations in 1928ζCAR establish unique transcriptional signatures. Gene expression profiles of CD8+TRAC-1928ζ, TRAC-1XX, and TRAC-XX3 CAR T cells (naive T cells initially sorted) 24 hours after CD19+ target cell stimulation. A) Normalized enrichment scores of gene sets significantly upregulated or downregulated in 1928ζ vs. 1XX and 1928ζ vs. XX3 (n = 3 replicates per group) as determined by GSEA using the MSigDB C7 gene ontology set. For all pathways, the false discovery rate (FDR) q≤0.02. GSE datasets are indicated in brackets. Stim, stimulated. B) Differentially expressed genes (FDR q<0.05) between sorted effectors and naive / memory T cells (left) (n = 6 replicates per group) and heat maps demonstrate the expression profiles of the same genes in CAR T cells (n = 3 replicates per group). TF, transcription factor. C) Normalized enrichment scores of significantly enriched gene sets (FDR q≤0.03) involved in phenotypic and functional T cell characteristics, identified by GSEA analysis comparing TRAC-1928ζ to TRAC-XX3, TRAC-1928ζ to TRAC-1XX and TRAC-1XX to TRAC-XX3 (n=3 replicates per group). JAK-STAT, Janus kinase signal transducer and activator of transcription. D) Effects of defined CD3z ITAM mutations in 1928ζ CAR T cells on effector and memory-related T cell attributes. 1XX CAR T cells display balanced effector and memory characteristics.

[0064] Figures 20A-20E Figure 3 The effects of ITAM-mutated 1928ζCAR on in vitro T cell function, T cell differentiation, and in vivo antitumor activity are depicted. A) One week after effector cells were expanded on irradiated 3T3-CD19, the cells were transfected with 1928ζCAR for 4 h. 51 Cytotoxic activity determined by Cr release assay (data are shown as the mean of n = 2 independent experiments performed in triplicate). B) Cumulative cell counts of the indicated CAR T cells after weekly stimulation with CD19+ target cells (n = 3 independent experiments). All data are mean ± sem. P values ​​were calculated by two-tailed paired Student's t-test. C) 5 × 10 4CAR+T cell therapy of NALM6-bearing mice. Kaplan-Meier survival analysis comparing the in vivo efficacy of wild-type 1928ζ or specified 1928ζ mutants (n=10 mice, pooled data from two independent experiments). Control (Ctl) refers to untreated mice (n=6). P values ​​were determined by one-sided log-rank Mantel-Cox test. D) CAR T cell phenotypes illustrated by the percentages of central memory (CD62L+CD45RA-) and effector memory (CD62L-CD45RA-) CD4+CAR T cells 48 hours after the second stimulation with CD19+ target cells. A two-tailed paired Student's t-test was performed, and data are expressed as mean ± sem, n = 4 independent experiments. E) 5×10 4 NALM6-bearing mice were treated with CAR T cells and euthanized on day 10 after infusion; bone marrow CAR T cells were analyzed by FACS. Representative flow cytometric analysis of the indicated CAR T cell phenotypes determined by CD62L / CD45RA expression, gated on CAR+CD4+ T cells. Representative of 5 mice per group from at least n=2 independent experiments with similar results.

[0065] Figures 21A-21C Analysis of effector function in 1928ζ mutants compared to wild-type 1928ζ is depicted. A) Cytotoxic activity of 1928ζ mutants compared to wild-type 1928ζ using an 18-hour bioluminescent assay of NALM6 cells expressing FFL as a target. Experiments were performed 1 week after effector cell expansion on CD19+ target cells. Data are mean ± sem (n = 4 independent experiments in triplicate). *P < 0.05 (2 1 :P=0.0273,2 -1 :P=0.0387,2 -2 :P=0.0125), **P=0.0018, calculated by a two-tailed paired Student's t-test of the mean of three replicates. B) and C) Granzyme B (GrB) expression on CD8+CAR T cells after a second stimulation with target cells expressing CD19 (n=4 independent experiments) (B) and cytokine secretion of CD4+ and CD8+CAR T cells (C). All data are mean ± sem (IFNγ and IL2, n=4; TNFα, n=5 independent experiments). Unstimulated (Unstim.) wild-type 1928ζ cells were used as controls. Significant differences compared to 1928ζ were determined by a two-tailed paired Student's t-test.

[0066] Figures 22A-22DFigure 1 shows the effect of ITAM position in 1928ζCAR on T cell function and therapeutic efficacy. A) One week after effector cells were expanded on irradiated 3T3-CD19, the cells were expressed in 4 h. 51 Cytotoxic activity determined by Cr release assay (data are mean values ​​of n = 2 independent experiments repeated three times). B) Accumulation cell counts of indicated CAR T cells after weekly stimulation with CD19+ target cells (n = 3 independent experiments). All data are mean ± sem; P values ​​were calculated by two-tailed paired Student's t-test. C) Cytotoxic activity of D12 and D23 compared with wild-type 1928ζ as determined by an 18-hour bioluminescence assay using NALM6 cells expressing FFL as targets. The experiment was performed 1 week after effector cells were amplified on CD19+ target cells. Data are mean ± sem (n = 4 independent experiments repeated three times). P values ​​were calculated by two-tailed paired Student's t-test of the mean values ​​of three replicates, and there was no significant difference between D12 / D23 and wild-type 1928ζ for all E / T ratios (P>0.05). D) 5×10 4 CAR T cell therapy of NALM6-bearing mice. Kaplan-Meier analysis of the survival of mice treated with wild-type 1928ζ or the indicated 1928ζ mutants (n = 10 mice per group). Control refers to untreated mice (n = 6). P values ​​were calculated by one-sided log-rank Mantel-Cox test.

[0067] Figures 23A-23B The effect of iTAM position in 1928ζCAR on in vitro effector function is described. A) Granzyme B (GrB) expression on CD8+CAR T cells (n=5 independent experiments). B) Cytokine secretion of CD4+ and CD8+CAR T cells after second stimulation with target cells expressing CD19. Unstimulated wild-type 1928ζ cells were used as controls. All data are mean ± sem (IFNγ and IL2, n=4; TNFα, n=5 independent experiments). Each individual symbol represents a sample. Significant differences compared to 1928ζ were determined by a two-tailed paired Student's t-test.

[0068] Figures 24A-24F T cell differentiation and effector function of the TRAC-encoded 1928ζ mutant were described. 5NALM6-bearing mice were treated with CAR T cells and euthanized on day 17 after infusion. Bone marrow and spleen CAR T cells were analyzed and counted by FACS. A) Histogram and flow cytometric analysis of CAR expression 4 days after CAR gene integration into the TRAC locus. Representative of four independent experiments with similar results. B) Cell counts of CD4+ and CD8+ CAR T cells, C) CD8+ T CM Flow cytometric analysis of the percentage of (CD62L+CD45RA-) and the expression of CD62L / CD45RA on bone marrow CD8+CAR T cells (representative of n=5 mice / group in an independent experiment). D) CAR+IL7R+ to tumor cell ratio and flow cytometric analysis of IL7R+CAR T cells in mouse bone marrow. E) Counting CAR T cells in mouse spleen. In B), C), D) and E), the data are mean ± sem, and two-tailed Mann-Whitney analysis was performed, n=5 mice / group. F) Cytotoxic activity of TRAC-1XX, TRAC-XX3 and wild-type TRAC-1928ζ (18-hour bioluminescence assay targeting NALM6 expressing FFL). The experiment was performed 4 days after transduction, 1 week and 3 weeks after weekly expansion stimulated with CD19 antigen. Symbols represent the average of three replicates (one representative donor).

[0069] Figures 25A-25G Depicts in vivo T cell depletion of TRAC-1928ζ mutants compared to wild-type TRAC-1928ζ. A) NALM6-bearing mice were treated with 1×10 5 CAR T cell therapy and euthanized on day 17 after infusion. FACS analysis of the expression of exhaustion markers on CAR+ T cells, representative of n=5 mice / group in one independent experiment. B)-G) NALM6-bearing mice were treated with 1×10 5 TRAC-edited naive T cell therapy. 16 days (B and C) and 36 days (E and G) after CAR administration, TRAC-1928ζ and TRAC-1XX cells from bone marrow and spleen were exposed to in vitro stimulation of NALM6 or PMA / ionomycin (Iono). The expression of cytokines and granzyme B (GrB) / CD107a on CAR T cells was illustrated by expression percentage and flow cytometry analysis, representing n=3 mice (B) and n=3 repetitions (G) in two independent experiments. After co-culture with NALM6 for 10 hours, the expression of the marker PD1+LAG3+ on CAR T cells (D) and the cytotoxic activity of TRAC-1XX (day 36) (F). All data are mean ± sem, n = 3 mice / group.

[0070] Figures 26A-26GT cell memory formation in TRAC-1XX compared to wild-type TRAC-1928ζ is described. 5 or 5×10 5 TRAC-edited naive T cells were used to treat NALM6-bearing mice. 5 CARs were isolated from the bone marrow and spleen 16 and 36 days after TRAC-1928ζ and TRAC-1XX. A)-B) CAR T cells (A), central memory (T CM :CD62L+CD45RA-), effector (T EFF : CD62L-CD45RA+) and IL7R-expressing bone marrow CAR T cells (B). All data are mean ± sem, n = 3 mice / group. C) Representative flow cytometric analysis of CD62L / CD45RA expression on TRAC-1928ζ and TRAC-1XX bone marrow CAR T cells at day 36 in an independent experiment (n = 3 mice per group). D)-G) NALM6-bearing mice were treated with 5×10 5 Figure 3. Treatment of mice with TRAC-edited naive T cells, or rechallenged with NALM6 cells (n = 5 mice per group), or without tumor rechallenging (TRAC-1928ζ, n = 6 mice; TRAC-1XX, n = 7 mice. D)-E) Total CAR T cells in the spleen of treated mice 63 days after CAR administration (rechallenge: TRAC-1928ζ, n = 4 mice; TRAC-1XX, n = 5 mice, no rechallenging, n = 5 mice / group). (D) T cells in the spleen of treated mice 63 days after CAR administration (rechallenge: TRAC-1928ζ, n = 4 mice; TRAC-1XX, n = 5 mice, no rechallenging, n = 5 mice / group). CM , T EFF And the number of cells of IL7R+CART cells (E). All data are mean ± sem; statistical analysis was performed using a two-tailed unpaired Student's t-test. F) FACS analysis of IL7R-, CD62L-, and CD45RA-expression on TRAC-1928ζ and TRAC-1XX CAR T cells on day 63 after CAR infusion (representing n = at least 3 mice per group in an independent experiment). G) Expression of the exhaustion marker PD1+TIM3+LAG3+ on CART cells from the spleen (again attack: TRAC-1928ζ, n = 4 mice; TRAC-1XX: n = 5 mice. No re-attack, n = 5 mice / group). All data are mean ± sem; P values ​​were determined by a two-tailed unpaired Student's t-test.

[0071] Figures 27A-27C Transcriptional profiles of TRAC-encoded 1928ζ mutant and sorted control T cells are depicted. A) Transcriptional profiles of TRAC-encoded 1928ζ mutant and sorted control T cell subsets (T) were expressed using CD19 target cells (left) and sorted control T cell subsets (right).N , T SCM and T EFF ) Principal component analysis (PCA) of the global transcriptional profiles of CD8+TRAC-1XX, TRAC-XX3, and TRAC-1928ζ after stimulation. Three technical replicates were performed for each CAR construct and six replicates were performed for each control subset. B) Representative GSEA enrichment plots (GSE10239) showing memory and naive downregulation of effector-related genes in 1928ζ vs. 1XX, 1928ζ vs. XX3 (n=3 mice / group). C) Compared with sorted control T cell subsets (T EFF , T SCM and T N ) compared to differential gene expression in CD8+ T cell subsets as described by Gattinoni et al. (left).

[0072] Figures 28A-28D Figure 3 Effects of CD3ζ ITAM mutations in TRAC-1928ζ on T cell differentiation state and effector repertoire. A) GSEA of a signature of the top 200 genes upregulated in exhausted CD8 T cells relative to naive or memory CD8 T cells derived from GSE41867, indicating TRAC-1928ζ versus TRAC-1XX or TRAC-XX3 and sorted control T cells. EFF Contrast T N and T SCM Enrichment of exhaustion markers in CAR constructs. Three technical replicates were performed for each CAR construct and six replicates were performed for each control subset. B) Gene ontology analysis showed significant enrichment of gene sets related to inflammation, cytokine and chemokine signaling in 1928ζ vs. XX3, 1XX vs. XX3, and 1928ζ vs. 1XX (n=3). Transcriptional analysis was performed after integration of the CAR gene into the TRAC locus of naive T cells and stimulation with CD19+ target cells. Results were expressed as -log 10 The order of importance is shown (corrected P value). P values ​​were determined by one-tailed Fisher's exact test, and multiple hypothesis tests were corrected using the Benjamini-Hochberg method. C) Heat map of selected differentially expressed genes related to inflammation, cytokine and chemokine activity between CAR constructs. D) Flow cytometric analysis of T cell differentiation status on CD8+CAR T cells after stimulation with CD19 antigen (representative n=2 independent experiments with similar results).

[0073] Figures 29A-29BGating strategy is depicted to analyze CAR T cells obtained from the bone marrow of treated mice. A)-B) Representative flow cytometry analysis of TRAC-1928ζ (A) compared to TRAC-1XX (B) at day 17 after CAR infusion. Gate placement was based on FMO controls. DETAILED DESCRIPTION

[0074] The subject matter of the present disclosure provides a new CAR design, which includes modified CD3ζ chains and cells, including genetically modified immune response cells (such as T cells, NK cells or CTL cells) comprising the CAR. The subject matter of the present disclosure also provides the use of such cells to induce and / or enhance the immune response to the target antigen, and / or treat and / or prevent tumors or other diseases / disorders that need to improve antigen-specific immune responses. The subject matter of the present disclosure is at least partially based on the following findings, that is, compared with control cells comprising conventional CARs, immune response cells comprising CARs of the present disclosure show improved therapeutic efficacy (e.g., reduced cell exhaustion).

[0075] 1. Definition

[0076] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art. The following references provide general definitions of many terms used in the subject matter of the present disclosure for technicians: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd edition, 1994); Cambridge Dictionary of Science and Technology (Walker ed., 1988); Genetics Vocabulary, 5th edition, R. Rieger et al. (ed.), Springer Verlag (1991); and Hale & Marham, Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise indicated, the following terms have the following meanings assigned to them.

[0077] As used herein, the term "about" or "approximately" means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within 3 or more than 3 standard deviations. Alternatively, "about" can mean a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or methods, the term can mean within an order of magnitude of a value, e.g., within 5 times or within 2 times of a value.

[0078] "Activating immune response cells" refers to the induction of signal transduction or changes in protein expression in cells, leading to the initiation of immune responses. For example, when CD3 chains aggregate in response to ligand binding and immunoreceptor tyrosine-based inhibitory motifs (IT AM), a signal transduction cascade reaction is generated. In certain embodiments, when endogenous TCR or exogenous CAR binds to an antigen, the formation of an immune synapse occurs, which includes the aggregation of many molecules near the binding receptor (e.g., CD4 or CD8, CD3γ / δ / ε / ζ, etc.). This aggregation of membrane-bound signal molecules phosphorylates the ITAM motifs contained in the CD3 chain. The phosphorylation in turn activates the T cell activation pathway, ultimately activating transcription factors such as NF-κB and AP-1. These transcription factors induce the overall gene expression of T cells, thereby increasing the production of IL-2, promoting the proliferation and expression of master regulatory T cell proteins, and then initiating T cell-mediated immune responses.

[0079] "Stimulating immune response cells" refers to a signal that causes a strong and sustained immune response. In various embodiments, this occurs after immune cells (e.g., T cells) are activated or mediated simultaneously by receptors including but not limited to CD28, CD137 (4-1BB), OX40, CD40, CD27, CD40 / My88, NKGD2, and ICOS. Receiving a variety of stimulating signals may be important for establishing a strong and long-term T cell-mediated immune response. T cells can be rapidly suppressed and are unresponsive to antigens. Although the effects of these costimulatory signals may be different, they generally result in increased gene expression, thereby producing long-lived, proliferative, and anti-apoptotic T cells, which respond strongly to antigens and can be thoroughly and continuously eradicated.

[0080] As used herein, the term "antigen recognition receptor" refers to a receptor that can activate immune or immune response cells (e.g., T cells) in response to its binding to an antigen. Non-limiting examples of antigen recognition receptors include natural or endogenous T cell receptors ("TCR") and chimeric antigen receptors ("CAR").

[0081] As used herein, the term "antibody" refers not only to complete antibody molecules, but also to fragments of antibody molecules that retain the ability to bind to immunogens. Such fragments are also well known in the art and are often used both in vitro and in vivo. Therefore, as used herein, the term "antibody" refers not only to complete immunoglobulin molecules, but also to the well-known active fragments F(ab')2 and Fab. F(ab')2 and Fab fragments lacking the Fc fragment of a complete antibody are cleared from the circulation faster and may have less non-specific tissue binding of a complete antibody (Wahl et al., J.Nucl.Med.24:316-325 (1983)). As used herein, antibodies include complete natural antibodies, bispecific antibodies; chimeric antibodies; Fab, Fab', single-chain V region fragments (scFv), fusion polypeptides and unconventional antibodies. In certain embodiments, an antibody is a glycoprotein comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (referred to herein as V H ) and heavy chain constant (C H The heavy chain constant region is composed of three domains: CH1, CH2 and CH3. Each light chain is composed of a light chain variable region (referred to herein as V L ) and light chain constant C L The light chain constant region consists of a domain C L Composition. H Area and V L The V region can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L It consists of three CDRs and four FRs, which are arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

[0082] As used herein, "CDR" is defined as the complementary determining region amino acid sequence of an antibody, which is a hypervariable region of an immunoglobulin heavy chain and light chain. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 4th edition, U.S. Department of Health and Human Services, National Institutes of Health (1987). Typically, an antibody comprises three heavy chain and three light chain CDRs or CDR regions in the variable region. CDRs provide most of the contact residues to allow the antibody to bind to an antigen or epitope. In certain embodiments, the CDR regions are outlined using the Kabat system (Kabat, EA, et al. (1991) Sequences of Proteins of Immunological Interest, 5th edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242).

[0083] As used herein, the term "single-chain variable fragment" or "scFv" is a fragment of a polypeptide that is covalently linked to form a V H ::V L Heterodimer of immunoglobulin heavy chain (V H ) and light chain (V L )'s variable region. H and V L Directly linked or linked via a peptide encoded linker (e.g., 10, 15, 20, 25 amino acids) that connects V H The N-terminal and V L C-terminal or V H The C-terminus and V L The linker is usually rich in glycine to improve flexibility and rich in serine or threonine to improve solubility. Despite the removal of the constant region and the introduction of the linker, the scFv protein still retains the specificity of the original immunoglobulin. The single-chain Fv polypeptide antibody can be composed of V as described by Huston et al. (Proc. Nat. Acad. Sci. USA, 85: 5879-5883, 1988). H and V LNucleic acid expression of coding sequences. See also U.S. Patent Nos. 5,091,513, 5,132,405 and 4,956,778. And U.S. Patent Publication Nos. 20050196754 and 20050196754. Antagonistic scFvs with inhibitory activity have been described (see, e.g., Zhao et al., Hyrbidoma (Larchmt) 2008 27(6):455-51; Peter et al., J Cachexia Sarcopenia Muscle 2012 Aug 12; Shieh et al., J Imunol 2009 183(4):2277-85; Giomarelli et al., Thromb Haemost 2007 97(6):955-63; Fife et al., J Clin Invst 2006 116(8):2252-61; Brocks et al., Immunotechnology 1997 3(3):173-84; Moosmayer et al., Ther Immunol 1995 2(10:31-40). Agonistic scFvs with stimulatory activity have been described (see, e.g., Peter et al., J Biol Chern 2003 25278(38):36740-7; Xie et al., Nat Biotech 1997 15(8):768-71; Ledbetter et al., Crit Rev Immunol 1997 17(5-6):427-55; Ho et al., BioChim Biophys Acta 2003 1638(3):257-66).

[0084] As used herein, the term "affinity" refers to a measure of binding strength. Affinity may depend on the tightness of the stereochemical fit between the antibody binding site and the antigenic determinant, the size of the contact area between them and / or the distribution of charged and hydrophobic groups. As used herein, the term "affinity" also includes "avidity", which refers to the strength of the antigen-antibody bond after the formation of a reversible complex. Methods for calculating the affinity of an antibody for an antigen are known in the art, including but not limited to various antigen binding experiments, such as functional assays (e.g., flow cytometry assays).

[0085] As used herein, the term "chimeric antigen receptor" or "CAR" refers to a molecule comprising an extracellular antigen binding domain and a transmembrane domain fused to an intracellular signaling domain capable of activating or stimulating an immune response cell. In certain embodiments, the extracellular antigen binding domain of CAR comprises scFv. ScFv can be derived from the variable heavy and light regions of a fusion antibody. Alternatively or in addition, scFv can be derived from Fab's (rather than antibodies, e.g., obtained from a Fab library). In certain embodiments, scFv is fused to a transmembrane domain and then fused to an intracellular signaling domain. In certain embodiments, CAR is selected to have a high binding affinity or avidity to an antigen.

[0086] As used herein, the term "nucleic acid molecule" includes any nucleic acid molecule encoding a polypeptide of interest or a fragment thereof. Such nucleic acid molecules do not require 100% homology or identity with endogenous nucleic acid sequences, but can exhibit substantial identity. Polynucleotides having "substantial identity" or "substantial homology" with endogenous sequences are generally capable of hybridizing with at least one chain of a double-stranded nucleic acid molecule. "Hybridization" refers to the formation of a pairing of double-stranded molecules between complementary polynucleotide sequences (e.g., genes described herein) or portions thereof under various stringent conditions. (See, e.g., Wahl, GM and SL Berger (1987) Methods Enzymol. 152: 399; Kimmel, AR (1987) Methods Enzymol. 152: 507).

[0087] For example, stringent salt concentrations will typically be less than about 750 mM NaCl and 75 mM trisodium citrate, such as less than about 500 mM NaCl and 50 mM trisodium citrate, or less than about 250 mM NaCl and 25 mM trisodium citrate. Hybridization with low stringency can be obtained in the absence of organic solvents such as formamide, while hybridization with high stringency can be obtained in the presence of at least about 35% formamide, such as at least about 50% formamide. Stringent temperature conditions will typically include a temperature of at least about 30°C, at least about 37°C, or at least about 42°C. It is well known to those skilled in the art to vary other parameters, such as hybridization time, the concentration of detergents (e.g., sodium dodecyl sulfate (SDS)), and the inclusion or exclusion of carrier DNA. Various stringencies are achieved by combining these various conditions as needed. In certain embodiments, hybridization will be carried out in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS at 30°C. In certain embodiments, hybridization will be performed in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In certain embodiments, hybridization will be performed in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA at 42° C. Useful variations on these conditions will be apparent to those skilled in the art.

[0088] For most applications, the stringency of the washing step after hybridization will also vary. Washing stringency conditions can be defined by salt concentration and temperature. As described above, washing stringency can be increased by reducing the salt concentration or by increasing the temperature. For example, the stringent salt concentration of the washing step can be less than about 30mM NaCl and 3mM trisodium citrate, for example, less than about 15mM NaCl and 1.5mM trisodium citrate. The stringent temperature conditions of the washing step will generally include a temperature of at least about 25°C, at least about 42°C, or at least about 68°C. In certain embodiments, the washing step will be performed at 25°C with 30mM NaCl, 3mM trisodium citrate, and 0.1% SDS. In certain embodiments, the washing step will be performed at 42°C with 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. In certain embodiments, the washing step will be performed at 68°C with 15mM NaCl, 1.5mM trisodium citrate, and 0.1% SDS. Other variations of these conditions will be apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Rogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Methods in Molecular Biology, Wiley Science Publishers, New York, 2001); Berger and Kimmel (A Manual of Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.

[0089] "Substantial identity" or "substantial homology" refers to a polypeptide or nucleic acid molecule that exhibits at least about 50% homology or identity to a reference amino acid sequence (e.g., any amino acid sequence described herein) or nucleic acid sequence (e.g., any nucleic acid sequence described herein). In certain embodiments, such a sequence is at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, or at least about 100% homology or identity to the amino acid or nucleic acid sequence used for comparison.

[0090] Sequence identity can be measured by using sequence analysis software (e.g., Sequence Analysis Software Package, Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wisconsin 53705, BLAST, BESTFIT, GAP or PILEUP / PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions and / or other modifications. Conservative substitutions generally include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine lysine, arginine; and phenylalanine, tyrosine. In an exemplary method for determining the degree of identity, the BLAST program can be used, wherein a probability score between e-3 and e-100 indicates a closely related sequence.

[0091] An "analog" refers to a structurally related polypeptide or nucleic acid molecule that possesses the function of a reference polypeptide or nucleic acid molecule.

[0092] As used herein, the term "ligand" refers to a molecule that binds to a receptor. In certain embodiments, a ligand binds to a receptor on another cell, thereby allowing intercellular recognition and / or interaction.

[0093] As used herein, the term "constitutive expression" or "constitutively expressed" refers to expression or expressed under all physiological conditions.

[0094] "Disease" refers to any condition, illness or disorder that damages or interferes with the normal function of cells, tissues or organs, such as neoplasia and pathogen infection of cells.

[0095] "Effective amount" refers to an amount sufficient to have a therapeutic effect. In certain embodiments, an "effective amount" is an amount sufficient to prevent, improve or inhibit the continued proliferation, growth or metastasis (eg, invasion or migration) of neoplasia.

[0096] "Enhancing tolerance" refers to preventing the activity of autoreactive cells or immune responsive cells that target the transplanted organ or tissue.

[0097] "Endogenous" refers to a nucleic acid molecule or polypeptide that is normally expressed in a cell or tissue.

[0098] "Exogenous" refers to nucleic acid molecules or polypeptides that are not endogenous in cells. Therefore, the term "exogenous" will encompass any recombinant nucleic acid molecules or polypeptides expressed in cells, such as exogenous, heterologous and overexpressed nucleic acid molecules and polypeptides. "Exogenous" nucleic acid refers to nucleic acids that do not exist in natural wild-type cells. For example, exogenous nucleic acids can be different from endogenous counterparts by sequence, position / location or both. For clarity, exogenous nucleic acids can have the same or different sequences relative to their natural endogenous counterparts. It can be introduced into the cell itself or its progenitor cell by genetic engineering, and it can be optionally connected to an alternative control sequence, such as a non-natural promoter or secretory sequence.

[0099] "Heterologous nucleic acid molecule or polypeptide" refers to a nucleic acid molecule (e.g., cDNA, DNA, or RNA molecule) or polypeptide that is not normally present in a cell or a sample obtained from a cell. The nucleic acid may be from another organism, or may be, for example, an mRNA molecule that is not normally expressed in a cell or sample.

[0100] An "immune response cell" refers to a cell that plays a role in an immune response or a progenitor cell or its progeny.

[0101] "Modulation" refers to a positive or negative change. Exemplary modulations include changes of about 1%, about 2%, about 5%, about 10%, about 25%, about 50%, about 75%, or about 100%.

[0102] "Increase" refers to a positive change of at least about 5%. The change can be about 5%, about 10%, about 25%, about 30%, about 50%, about 75%, about 100% or more.

[0103] "Decrease" refers to a negative change of at least about 5%. The change can be about 5%, about 10%, about 25%, about 30%, about 50%, about 75% or even about 100%.

[0104] An "isolated cell" refers to a cell that is separated from molecules and / or cellular components that naturally accompany the cell.

[0105] The terms "isolated", "purified" or "biologically pure" refer to substances that are free to varying degrees from components that normally accompany them in their original state. "Isolated" means a degree of separation from the original source or environment. "Purified" means a degree of separation greater than separation. A "purified" or "biologically pure" protein is sufficiently free of other substances so that any impurities do not substantially affect the biological properties of the protein or cause other adverse consequences. That is, if a nucleic acid or peptide is produced by recombinant DNA technology and is substantially free of cellular material, viral material or culture medium, or is substantially free of chemical precursors or other chemicals by chemical synthesis, it is purified. Purity and homogeneity are generally determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can mean that a nucleic acid or protein produces essentially one band in an electrophoretic gel. For proteins that can be modified (e.g., phosphorylated or glycosylated), different modifications can produce different isolated proteins, which can be purified separately.

[0106] As used herein, the term "antigen binding domain" refers to a domain that is capable of specifically binding to a particular antigenic determinant or group of antigenic determinants present on a cell.

[0107] As used herein, "linker" shall refer to a functional group (e.g., chemical or polypeptide) that covalently links two or more polypeptides or nucleic acids to connect them to each other. As used herein, "peptide linker" refers to a peptide used to couple two proteins together (e.g., to couple V H and V L In certain embodiments, the linker comprises the sequence shown in GGGGSGGGGSGGGGS [SEQ ID NO: 66].

[0108] "Neoplasm" refers to a disease characterized by pathological proliferation of cells or tissues and their subsequent migration or invasion to other tissues or organs. The growth of a tumor is usually uncontrolled and progressive, and occurs without causing normal cell proliferation or causing normal cell proliferation to stop. A tumor can affect a variety of cell types, tissues or organs, including but not limited to organs selected from the following: bladder, bone, brain, breast, cartilage, glial, esophagus, fallopian tube, gallbladder, heart, intestine, kidney, liver, lung, lymph node, nervous tissue, ovary, pancreas, prostate, skeletal muscle, skin, spinal cord, spleen, stomach, testicle, thymus, thyroid, trachea, urogenital tract, ureter, urethra, uterus and vagina or its tissue or cell type. Tumors include cancers, such as sarcomas, tumors or plasmacytomas (malignant tumors of plasma cells).

[0109] "Receptor" refers to a polypeptide or a portion thereof present on a cell membrane that selectively binds one or more ligands.

[0110] "Recognition" means selectively binding to a target. T cells that recognize tumors can express receptors (such as TCR or CAR) that bind to tumor antigens.

[0111] "Reference" or "control" refers to a standard of comparison. For example, the scFv-antigen binding level of cells expressing CAR and scFv can be compared to the scFv-antigen binding level of corresponding cells expressing only CAR.

[0112] "Secreted" refers to the release of a polypeptide from a cell through the secretory pathway through the endoplasmic reticulum, the Golgi apparatus, and as vesicles that transiently fuse at the plasma membrane, releasing the protein outside the cell.

[0113] "Signal sequence" or "leader sequence" refers to a peptide sequence (eg, 5, 10, 15, 20, 25 or 30 amino acids) present at the N-terminus of newly synthesized proteins that directs them into the secretory pathway. Exemplary leader sequences include, but are not limited to, IL-2 signal sequence: MYRMQLLSCIALSLALVTNS [SEQ ID NO: 67] (human), MYSMQLASCVTLTLVLLVNS [SEQ ID NO: 68] (mouse), kappa leader sequence: METPAQLLFLLLLWLPDTTG [SEQ ID NO: 69] (human), METDTLLLWVLLLWVPGSTG [SEQ ID NO: 70] (mouse); CD8 leader sequence: MALPVTALLLPLALLLHAARP [SEQ ID NO: 71] (human); truncated human CD8 signal peptide: MALPVTALLLPLALLLHA [SEQ ID NO: 72] (human); albumin signal sequence: MKWVTFISLLFSSAYS [SEQ ID NO: 73] (human); prolactin signal sequence: MDSKGSSQKGSRLLLLLVVSNLLLCQGVVS [SEQ ID NO: 74] (human). In certain embodiments, the leader sequence may be an IgG signal peptide or a GM-CSF signal peptide. "Soluble" refers to a polypeptide that is freely diffusible in an aqueous environment (eg, not membrane-bound).

[0114] "Specific binding" means that a polypeptide or a fragment thereof recognizes and binds to a target biological molecule (eg, a polypeptide) but does not substantially recognize and bind to other molecules in a sample (eg, a biological sample, which naturally includes a polypeptide disclosed in the present invention).

[0115] As used herein, the term "tumor antigen" refers to an antigen (e.g., polypeptide) that is uniquely or differentially expressed on tumor cells compared to normal or non-IS neoplastic cells. In certain embodiments, the tumor antigen includes any polypeptide expressed by a tumor that can activate or induce an immune response through CAR (e.g., CD19, MUC-16) or can inhibit an immune response through receptor-ligand binding (e.g., CD47, PD-L1 / L2, B7.1 / 2).

[0116] The terms "comprising," "including," and "including" are intended to have the broadest meanings given them in U.S. patent law, and may mean "containing," "including," and the like.

[0117] As used herein, "treatment" refers to clinical intervention that attempts to alter the course of a disease in the individual or cell being treated, and can be used for prevention or performed during clinical pathology. The therapeutic effects of treatment include, but are not limited to, preventing the occurrence or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. By preventing the progression of a disease or condition, treatment can not only prevent deterioration caused by the condition in an affected or diagnosed subject or a subject suspected of having the condition, but treatment can prevent the onset of the condition or symptoms of the condition in a subject at risk of the condition or suspected of having the condition.

[0118] An "individual" or "subject" herein is a vertebrate, such as a human or a non-human animal, such as a mammal. Mammals include, but are not limited to, humans, primates, farm animals, sports animals, rodents, and pets. Non-limiting examples of non-human animal subjects include rodents, such as mice, rats, hamsters, and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cattle; horses; and non-human primates, such as apes and monkeys. As used herein, the term "immunocompromised" refers to a subject with an immune deficiency. The subject is highly susceptible to opportunistic infections caused by organisms that do not normally cause disease in people with healthy immune systems, but can affect people with poor immune function or suppressed immune systems.

[0119] Other aspects of the disclosed subject matter are described in the following disclosure and are within the scope of the disclosed subject matter.

[0120] 2. Chimeric Antigen Receptor

[0121] The present disclosure provides a chimeric antigen receptor (CAR) that binds to an antigen of interest. CAR can bind to a tumor antigen or a pathogen antigen.

[0122] 2.1. Antigens

[0123] In certain embodiments, CAR binds to a tumor antigen. Any tumor antigen (antigenic peptide) can be used in the embodiments described herein in relation to tumors. Antigen sources include, but are not limited to, oncoproteins. Antigens can be expressed as peptides or complete proteins or portions thereof. Complete proteins or portions thereof can be natural or mutagenic. Non-limiting examples of tumor antigens include carbonic anhydrase IX (CA1X), carcinoembryonic antigen (CEA), CD8, CD7, CD 10, CD19, CD20, CD22, CD30, CD33, CLL1, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, CD123, CD44V6, antigens of cytomegalovirus (CMV) infected cells (e.g., cell surface antigens), epithelial glycoprotein-2 (EGP-2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpC AM), receptor tyrosine protein kinase erb-B2,3,4 (erb-B2,3,4), folate binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-α, ganglioside G2 (GD2), ganglioside G3 (GD3), human epidermal growth factor receptor 2 (HER-2), human telomerase reverse transcriptase (hTERT), interleukin 13 receptor subunit α-2 (IL-13Rα2), kappa-light chain, kinase insert domain receptor (KDR), Lewis Y (LeY), L1 cell adhesion molecule (L1CAM), melanoma antigen family A, 1 (MAGE-A1), mucin 16 (MUC16), mucin 1 (MUC1), mesothelin (MSLN), ERBB2, MAGEA3, p53, MART1, GP100, proteinase 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, cancer-testis antigen NY-ES0-1, tumor embryonic antigen (h5T4), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), ROR1, tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2) and Wilms tumor protein (WT-1), BCMA, NKCS1, EGF1R, EGFR-VIII, CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A and ERBB.

[0124] In some embodiments, the CAR binds to a CD19 polypeptide. In some embodiments, the CAR binds to a human CD19 polypeptide. In some embodiments, the human CD19 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 75.

[0125]

[0126] In certain embodiments, the CAR binds to the extracellular domain of the CD19 protein.

[0127] In certain embodiments, CAR binds to pathogen antigens, for example, for the treatment and / or prevention of pathogen infection or other infectious diseases, for example, in immunocompromised subjects. Non-limiting examples of pathogens include viruses, bacteria, fungi, parasites, and protozoa that can cause disease.

[0128] Non-limiting examples of viruses include Retroviridae (e.g., human immunodeficiency viruses, such as HIV-1 (also known as HDTV-III, LAVE or HTLV-III / LAV or HIV-III; and other isolates, such as HIV-LP); Picornaviridae (e.g., poliovirus, hepatitis A virus, enterovirus, human coxsackievirus, rhinovirus, echovirus); Calciviridae (e.g., strains that cause gastroenteritis); Togaviridae (e.g., equine encephalitis virus, rubella virus) ; Flaviridae (e.g., dengue virus, encephalitis virus, yellow fever virus); Coronoviridae (e.g., coronavirus); Rhabdoviridae (e.g., vesicular stomatitis virus, rabies virus); Filoviridae (e.g., Ebola virus); Paramyxoviridae (e.g., parainfluenza virus, mumps virus, measles virus, respiratory syncytial virus); Orthomyxoviridae (e.g., influenza virus); Bunyaviridae (e.g., influenza virus); dae (e.g., hantaviruses, bunga viruses, phleboviruses, and nairaviruses); Arenaviridae (hemorrhagic fever viruses); Reoviridae (e.g., reoviruses, orbiviruses, and rotaviruses); Birnaviridae; Hepadnaviridae (hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae (papillomaviruses, polyomaviruses); Adenoviridae (Adenoviruses); viridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella-zoster virus, cytomegalovirus (CMV), herpesviruses); Poxviridae (smallpox virus, vaccinia virus, poxviruses); and Iridoviridae (e.g., African swine fever virus); as well as unclassified viruses (e.g., the causative agent of hepatitis D (thought to be a defective satellite of hepatitis B virus), the causative agents of non-A, non-B hepatitis (class 1 = transmitted internally; class 2 = transmitted parenterally (i.e., hepatitis C); Norwalk and related viruses, and astroviruses).

[0129] Non-limiting examples of bacteria include Staphylococci, Streptococcus, Escherichia coli, Pseudomonas species, and Salmonella species. Specific examples of infectious bacteria include, but are not limited to, Helicobacter pylori, Borelia burgdorferi, Legionella pneumophilia, Mycobacteria sp. (e.g., M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M. gordonae), Staphylococcus aureus, Neisseria gonorrhoeae, Neisseria meningitidis, Listeria monocytogenes, Streptococcus pyogenes (Group A Streptococcus), Streptococcus agalactiae (Streptococcus pyogenes), Streptococcus pyogenes ... agalactiae (group B Streptococcus), Streptococcus (viridans group), Streptococcus faecalis, Streptococcus bovis, Streptococcus (anaerobic), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus antracis, corynebacterium diphtheriae, corynebacterium sp.), Erysipelothrix rhusiopathiae, Clostridium perfringers, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema pertenue, Leptospira, Rickettsia, and Actinomycesis raelii.

[0130] In certain embodiments, the pathogen antigen is a viral antigen present in cytomegalovirus (CMV), a viral antigen present in Epstein Barr Virus (EBV), a viral antigen present in human immunodeficiency virus (HIV), or a viral antigen present in influenza virus.

[0131] 2.2. Chimeric Anti-Receptor (CAR)

[0132] CARs are engineered receptors that transfer or confer target specificity to immune effector cells. CARs can be used to transfer the specificity of monoclonal antibodies onto T cells; transfer of their coding sequences is facilitated by retroviral vectors.

[0133] There are three generations of CARs. “First generation” CARs typically consist of an extracellular antigen binding domain (e.g., scFv) fused to a transmembrane domain fused to a cytoplasmic / intracellular signaling domain. “First generation” CARs can provide de novo antigen recognition and activate CD4 via the CD3 ζ chain signaling domain in a single fusion molecule. + and CD8 +T cells, and have nothing to do with HLA-mediated antigen presentation. "Second generation" CAR adds intracellular signaling domains from various costimulatory molecules (such as CD28, 4-1BB, ICOS, OX40, CD27, CD40 / My88 and NKGD2) to the cytoplasmic tail of CAR to provide other signals to T cells. "Second generation" CAR includes CARs that provide costimulation (such as CD28 or 4-1BB) and activation (CD3ζ). In some embodiments, CAR is a second generation CAR. In some embodiments, CAR includes an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain bound to an antigen, wherein the intracellular signaling domain includes a costimulatory signaling domain. In some embodiments, CAR further includes a hinge / spacer.

[0134] In certain non-limiting embodiments, the dissociation constant (K) of the extracellular antigen binding domain of the CAR (embodied as, for example, scFv or its analog) binding to the antigen is d ) is about 2×10 -7 M or less. In certain embodiments, K d About 2×10 -7 M or smaller, about 1×10 -7 M or smaller, about 9×10 -8 M or smaller, about 1×10 -8 M or smaller, about 9×10 -9 M or smaller, about 5×10 -9 M or smaller, about 4×10 -9 M or smaller, about 3×10 -9 M or smaller, about 2×10 -9 M or smaller, or about 1×10 -9 M or less. In certain non-limiting embodiments, K d About 3×10 -9 M or less. In certain non-limiting embodiments, K d About 1×10 -9 M is about 3×10 -7 M. In certain non-limiting embodiments, K d About 1.5×10 -9 M is about 3×10 -7 M. In certain non-limiting embodiments, K d About 1.5×10 -9 M is about 2.7×10 -7 M. In certain non-limiting embodiments, K d About 1×10 -4 M is about 1×10 -6 M. In certain non-limiting embodiments, Kd About 1×10 -13 M is about 1×10 -15 M.

[0135] The binding of the extracellular antigen binding domain (e.g., in scFv or its analogs) can be determined by, for example, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), FACS analysis, bioassay (e.g., growth inhibition) or Western Blot assay. Each of these assays is typically detected by using a labeling agent (e.g., antibody or scFv) specific to the target complex to detect the presence of a specific target protein-antibody complex. For example, scFv can be radiolabeled and used for radioimmunoassay (RIA) (see, e.g., Weintraub, B., Principles of Radioimmunoassay, Seventh Training Course of Radioligand Assay Technology, Endocrine Society, March 1986, incorporated herein for reference). Radioisotopes can be detected by methods such as using a gamma counter or a scintillation counter or by autoradiography. In some embodiments, the extracellular antigen binding domain of CAR is labeled with a fluorescent marker. Non-limiting examples of fluorescent markers include green fluorescent protein (GFP), blue fluorescent proteins (eg, EBFP, EBFP2, Azurite, and mKalamal), cyan fluorescent proteins (eg, ECFP, Cerulean, and CyPet), and yellow fluorescent proteins (eg, YFP, Citrine, Venus, and YPet).

[0136] 2.2.1. Extracellular antigen binding domain of CAR

[0137] In certain embodiments, the extracellular antigen binding domain specifically binds to an antigen. In certain embodiments, the extracellular antigen binding domain is a scFv. In certain embodiments, the scFv is a human scFv. In certain embodiments, the scFv is a humanized scFv. In certain embodiments, the scFv is a mouse scFv. In certain embodiments, the extracellular antigen binding domain is a Fab, which is optionally cross-linked. In certain embodiments, the extracellular antigen binding domain is a F(ab)2. In certain embodiments, any of the aforementioned molecules may be included in a fusion protein with a heterologous sequence to form an extracellular antigen binding domain. In certain embodiments, scFv is identified by screening a scFv phage library with an antigen-Fc fusion protein. scFv can be derived from mice carrying human VL and / or VH genes. scFv can also be replaced by a camelid heavy chain (e.g., VHH of camels, alpacas, etc.) or a portion of a natural ligand of a cell surface receptor. In certain embodiments, the antigen is a tumor antigen, such as one disclosed herein. In certain embodiments, the antigen is a pathogen antigen, such as one disclosed herein.

[0138] In certain embodiments, the extracellular antigen binding domain is a murine scFv. In certain embodiments, the extracellular antigen binding domain is a murine scFv that binds to a human CD19 polypeptide. In certain embodiments, the extracellular antigen binding domain is a murine scFv that comprises the amino acid sequence of SEQ ID NO: 84 and specifically binds to a human CD19 polypeptide (e.g., a human CD19 polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 75). In certain embodiments, the nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 84 is set forth in SEQ ID NO: 85. In certain embodiments, the murine scFv comprises a heavy chain variable region (V H ), which comprises the amino acid sequence shown in SEQ ID NO: 82. In certain embodiments, the murine scFV comprises a light chain variable region (V L ), which comprises the amino acid sequence shown in SEQ ID NO: 83. In certain embodiments, the mouse scFv comprises V H and V L , where V H comprising the amino acid sequence shown in SEQ ID NO: 82, V L comprising the amino acid sequence as shown in SEQ ID NO: 83, optionally in V H and V L There is (iii) a linker sequence, such as a linker peptide, between them. In some embodiments, the linker comprises an amino acid sequence having a sequence as shown in SEQ ID NO: 66. In some embodiments, the extracellular antigen binding domain comprises V H , which comprises an amino acid sequence having at least about 80% (e.g., at least about 85%, at least about 90%, or at least about 95%) homology to SEQ ID NO: 82. For example, the extracellular antigen binding domain comprises V H , which comprises an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology to SEQ ID NO: 82. In certain embodiments, the extracellular antigen binding domain comprises V H , which comprises the amino acid sequence shown in SEQ ID NO: 82. In certain embodiments, the extracellular antigen binding domain comprises V L , which comprises an amino acid sequence having at least about 80% (e.g., at least about 85%, at least about 90%, or at least about 95%) homology to SEQ ID NO: 83. For example, the extracellular antigen binding domain comprises VL , which comprises an amino acid sequence having about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% homology to SEQ ID NO: 83. In certain embodiments, the extracellular antigen binding domain comprises V L , which comprises the amino acid sequence shown in SEQ ID NO: 83. In certain embodiments, the extracellular antigen binding domain comprises V H and V L , V H comprising an amino acid sequence having at least about 80% (e.g., at least about 85%, at least about 90%, or at least about 95%) homology or identity to SEQ ID NO: 82, V L The extracellular antigen binding domain comprises an amino acid sequence having at least about 80% (e.g., at least about 85%, at least about 90%, or at least about 95%) homology or identity to SEQ ID NO: 83. In certain embodiments, the extracellular antigen binding domain comprises a V comprising the amino acid sequence set forth in SEQ ID NO: 82. H and V comprising the amino acid sequence shown in SEQ ID NO: 83 L In certain embodiments, the extracellular antigen binding domain comprises a V comprising the amino acid sequence shown in SEQ ID NO: 76 or a conservative modification thereof. H CDR1, comprising the amino acid sequence shown in SEQ ID NO: 77 or a conservative modification thereof H CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 78 or a conservative modification thereof H In certain embodiments, the extracellular antigen binding domain comprises a VDR3 comprising the amino acid sequence shown in SEQ ID NO: 76. H CDR1, V comprising the amino acid sequence shown in SEQ ID NO: 77 H CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 78 H In certain embodiments, the extracellular antigen binding domain comprises a VDR3 comprising an amino acid sequence as shown in SEQ ID NO: 79 or a conservative modification thereof. L CDR1, comprising the amino acid sequence shown in SEQ ID NO: 80 or a conservative modification thereof L CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 81 or a conservative modification thereof LIn certain embodiments, the extracellular antigen binding domain comprises a VDR3 comprising the amino acid sequence shown in SEQ ID NO: 79. L CDR1, V comprising the amino acid sequence shown in SEQ ID NO: 80 L CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 81 L In certain embodiments, the extracellular antigen binding domain comprises a VDR3 comprising an amino acid sequence as shown in SEQ ID NO: 76 or a conservative modification thereof. H CDR1, comprising the amino acid sequence shown in SEQ ID NO: 77 or a conservative modification thereof H CDR2, comprising the amino acid sequence shown in SEQ ID NO: 78 or a conservative modification thereof H CDR3, comprising the amino acid sequence shown in SEQ ID NO: 79 or a conservative modification thereof L CDR1, comprising the amino acid sequence shown in SEQ ID NO: 80 or a conservative modification thereof L CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 81 or a conservative modification thereof L In certain embodiments, the extracellular antigen binding domain comprises a VDR3 comprising the amino acid sequence shown in SEQ ID NO: 76. H CDR1, V comprising the amino acid sequence shown in SEQ ID NO: 77 H CDR2, comprising the amino acid sequence of SEQ ID NO: 78 H CDR3, comprising the amino acid sequence of SEQ ID NO: 79 L CDR1, V comprising the amino acid sequence shown in SEQ ID NO: 80 L CDR2 and V comprising the amino acid sequence shown in SEQ ID NO: 81 L CDR3.

[0139] Table 1

[0140]

[0141] As used herein, the term "conservative sequence modification" refers to an amino acid modification that does not significantly affect or change the binding characteristics of the CAR (e.g., the extracellular antigen binding domain of CAR) comprising an amino acid sequence disclosed herein. Conservative modifications may include amino acid substitutions, additions, and deletions. Modifications may be introduced into the human scFv of the CAR disclosed herein by standard techniques known in the art (e.g., site-directed mutagenesis and PCR-mediated mutagenesis). Amino acids can be divided into several groups according to their physicochemical properties (e.g., charge and polarity). Conservative amino acid substitutions are amino acid substitutions in which amino acid residues are replaced by amino acids in the same group. For example, amino acids can be classified by charge: positively charged amino acids include lysine, arginine, histidine, negatively charged amino acids include aspartic acid, glutamic acid, neutrally charged amino acids include alanine, asparagine, cysteine, glutamine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. In addition, amino acids can be classified by polarity: polar amino acids include arginine (basic polarity), asparagine, aspartic acid (acidic polarity), glutamic acid (acidic polarity), glutamine, histidine (basic polarity), lysine (basic polarity), serine, threonine and tyrosine; non-polar amino acids include alanine, cysteine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan and valine. Therefore, one or more amino acid residues in the CDR region can be replaced by other amino acid residues from the same group, and the retained function of the altered antibody (i.e., the functions listed in (c) to (l) above) can be tested using the functional assays described herein. In certain embodiments, no more than one, no more than two, no more than three, no more than four, no more than five residues are changed in a specified sequence or CDR region.

[0142] Relative to a specified sequence, a V sequence having at least about 80%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% (e.g., about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%) homology or identity to a specified sequence (e.g., SEQ ID NOs: 82 and 83). H and / or V LThe amino acid sequence may contain substitutions (e.g., conservative substitutions), insertions or deletions, but retains the ability to bind to the target antigen (e.g., CD19). In certain embodiments, in a given sequence (e.g., SEQ ID NOs: 82 and 83), a total of 1 to 10 amino acids are substituted, inserted and / or deleted. In certain embodiments, substitutions, insertions or deletions occur in regions outside the CDRs of the extracellular antigen-binding domain (e.g., in the FRs). In certain embodiments, the extracellular antigen-binding domain comprises a V selected from SEQ ID NOs: 82 and 83 (including post-translational modifications of the sequences (SEQ ID NOs: 82 and 83)). H and / or V L sequence.

[0143] As used herein, the homology percentage between two amino acid sequences is equivalent to the identity percentage between the two sequences. The identity percentage between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % homology = number of identical positions # / total number of positions #×100), wherein the number of spaces and the length of each space are taken into account, and these spaces need to be introduced to achieve the best comparison of the two sequences. The comparison of sequences and the determination of the identity percentage between the two sequences can be completed using a mathematical algorithm.

[0144] The percent homology between two amino acid sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4: 11-17 (1988)), which has been incorporated into the ALIGN program (version 2.0), using the PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent homology between two amino acid sequences can be determined using the Needleman and Wunsch (J. Mol. Biol. 48: 444-453 (1970)) algorithm, which has been incorporated into the GAP program in the GCG software package (available from www.gcg.com), using a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4, and a length weight of 1, 2, 3, 4, 5, or 6.

[0145] Additionally or alternatively, the amino acid sequences of the disclosed subject matter can be further used as "query sequences" to search public databases to, for example, identify related sequences. Such searches can be performed using the XBLAST program (version 2.0) of Altschul et al. ((1990) J. Mol. Biol. 215: 403-10). BLAST protein searches can be performed using the XBLAST program, score = 50, word length = 3, to obtain amino acid sequences homologous to the specified sequences disclosed herein (e.g., heavy and light chain variable region sequences of scFv m903, m904, m905, m906, and m900). In order to obtain gapped alignments for comparison purposes, Gapped BLAST can be used as described in Altschul et al., (1997) Nucleic Acids Res. 25 (17): 3389-3402. When using BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0146] 2.2.2. Transmembrane domain of CAR

[0147] In certain non-limiting embodiments, the transmembrane domain of CAR includes a hydrophobic alpha helix of at least a portion of the transmembrane. Different transmembrane domains lead to different receptor stability. After antigen recognition, receptors aggregate and signals are delivered to cells. According to the subject matter of the present disclosure, the transmembrane domain of CAR may include CD8 polypeptides, CD28 polypeptides, CD3 ζ polypeptides, CD40 polypeptides, 4-1BB polypeptides, OX40 polypeptides, CD84 polypeptides, CD166 polypeptides, CD8a polypeptides, CD8b polypeptides, ICOS polypeptides, ICAM-1 polypeptides, CTLA-4 polypeptides, CD27 polypeptides, CD40 / My88 peptides, NKGD2 peptides, synthetic peptides (not based on proteins associated with immune responses) or a combination thereof of natural or modified transmembrane domains.

[0148] CD8

[0149] In certain embodiments, the transmembrane domain comprises a CD8 polypeptide. In certain embodiments, the CD8 polypeptide comprises or contains an amino acid sequence or a fragment of the sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity (homology herein can be determined using standard software, such as BLAST or FASTA), and / or may optionally contain at most one or at most two or at most three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 86, which is at least 20 or at least 30 or at least 40 or at least 50 and at most 235 amino acids in length. Alternatively or additionally, in various non-limiting embodiments, the CD8 polypeptide comprises or has an amino acid sequence of amino acids 1 to 235, 1 to 50, 50 to 100, 100 to 150, 150 to 200, or 200 to 235 of SEQ ID NO: 86. In certain embodiments, the CAR of the present disclosure comprises a transmembrane domain comprising a CD8 polypeptide comprising or has an amino acid sequence of amino acids 137 to 209 of SEQ ID NO: 86.

[0150]

[0151] In certain embodiments, the CD8 polypeptide comprises or contains an amino acid sequence or fragment thereof having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% homology or identity (homology herein can be determined using standard software, such as BLAST or FASTA) to a sequence containing NCBI reference number AAA92533.1 (SEQ ID NO: 87) as provided below, and / or may optionally contain up to one, up to two, or up to three conservative amino acid substitutions. In certain embodiments, the CD8 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 87 that is at least 20, or at least 30, or at least 40, or at least 50, or at least 60, or at least 70, or at least 100, or at least 200 and up to 247 amino acids in length. Alternatively or additionally, in various non-limiting embodiments, the CD8 polypeptide comprises or has an amino acid sequence of amino acids 1 to 247, 1 to 50, 50 to 100, 100 to 150, 150 to 200, 151 to 219, or 200 to 247 of SEQ ID NO: 87. In certain embodiments, the CAR of the present disclosure comprises a transmembrane domain comprising a CD8 polypeptide comprising or has an amino acid sequence of amino acids 151 to 219 of SEQ ID NO: 87.

[0152]

[0153] In certain embodiments, the CD8 polypeptide comprises or has the amino acid sequence as shown in SEQ ID NO: 88, which is provided as follows:

[0154]

[0155] According to the presently disclosed subject matter, a "CD8 nucleic acid molecule" refers to a polynucleotide encoding a CD8 polypeptide.

[0156] In certain embodiments, the CD8 nucleic acid molecule encoding a CD8 polypeptide having an amino acid sequence as shown in SEQ ID NO: 88 comprises or has a nucleic acid having a sequence as shown in SEQ ID NO: 89 as provided below.

[0157]

[0158] CD28

[0159] In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a CD28 polypeptide. The CD28 polypeptide comprises or contains an amino acid sequence or a fragment of the sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence containing NCBI reference number P10747 or NP_006130 (SEQ ID NO: 90) provided below, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence as a continuous portion of SEQ ID NO: 90, which is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids in length. Alternatively or additionally, in various non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 90. In certain embodiments, the CD28 polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 153 to 179 of SEQ ID NO: 90.

[0160] SEQ ID NO:90 is provided as follows:

[0161]

[0162] According to the subject matter of the present disclosure, "CD28 nucleic acid molecule" refers to a polynucleotide encoding a CD28 polypeptide. In certain embodiments, a CD28 nucleic acid molecule encoding a CD28 polypeptide having amino acids 153 to 179 of SEQ ID NO: 90 comprises or has a nucleic acid having a sequence as shown in SEQ ID NO: 91 as provided below.

[0163]

[0164] In certain embodiments, the intracellular signaling domain of the CAR comprises a human CD28 transmembrane domain. The human CD28 transmembrane domain may comprise or have an amino acid sequence or fragment thereof having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with SEQ ID NO: 92, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 92 is provided as follows:

[0165]

[0166] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:92 is set forth in SEQ ID NO:93, which is provided below:

[0167]

[0168] CD84

[0169] In certain embodiments, the transmembrane domain of the CAR of the present disclosure comprises a natural or modified transmembrane domain of a CD84 polypeptide. The CD84 polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_001171808.1 (SEQ ID No: 1), or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD84 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 1, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CD84 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 1. In certain embodiments, the CD84 polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 226 to 250 of SEQ ID NO: 1.

[0170] SEQ ID NO: 1 is provided as follows:

[0171]

[0172] According to the subject matter of the present disclosure, "CD84 nucleic acid molecule" refers to a polynucleotide encoding a CD84 polypeptide. In certain embodiments, a CD84 nucleic acid molecule encoding a CD84 polypeptide having amino acids 226 to 250 of SEQ ID NO: 1 comprises or has a nucleic acid having a sequence as shown in SEQ ID NO: 2 as provided below.

[0173]

[0174] CD166

[0175] In certain embodiments, the transmembrane domain of CAR of the present disclosure includes a natural or modified transmembrane domain of CD166 polypeptide.CD166 polypeptides may have an amino acid sequence with at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence with NCBI reference number NP_001618.2 (SEQ ID NO: 3), or a fragment thereof, and / or may optionally include at most one or at most two or at most three conservative amino acid substitutions.In non-limiting certain embodiments, CD166 polypeptides include or have an amino acid sequence as a continuous portion of SEQ ID NO: 3, having a length of at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in non-limiting various embodiments, the CD166 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 3. In certain embodiments, the CD166 polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 528 to 553 of SEQ ID NO: 3. In certain embodiments, the CD166 polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 528 to 549 of SEQ ID NO: 3.

[0176] SEQ ID NO:3 is provided as follows:

[0177]

[0178] According to the subject of the present disclosure, "CD166 nucleic acid molecules" refers to the polynucleotides encoding CD166 polypeptides. In certain embodiments, the CD166 nucleic acid molecules encoding the CD166 polypeptides of amino acids 528 to 553 of SEQ ID NO:3 include or have the nucleic acid containing the sequence shown in SEQ ID NO:4 provided below.

[0179]

[0180] CD8a

[0181] In certain embodiments, the transmembrane domain of the CAR of the present disclosure includes a natural or modified transmembrane domain of a CD8a polypeptide. The CD8a polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_001139345.1 (SEQ ID NO: 5), or a fragment thereof, and / or may optionally include at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD8a polypeptide includes or has an amino acid sequence that is a continuous portion of SEQ ID NO: 5, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CD8a polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 5. In certain embodiments, the CD8a polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 183 to 207 of SEQ ID NO: 5.

[0182] SEQ ID NO:5 is provided as follows:

[0183]

[0184] According to the subject matter of the present disclosure, "CD8a nucleic acid molecule" refers to a polynucleotide encoding a CD8a polypeptide. In certain embodiments, a CD8a nucleic acid molecule encoding a CD8a polypeptide having amino acids 183 to 207 of SEQ ID NO: 5 comprises or has a nucleic acid having a sequence as shown in SEQ ID NO: 6 provided below.

[0185]

[0186] CD8b

[0187] In certain embodiments, the transmembrane domain of the CAR of the present disclosure includes a natural or modified transmembrane domain of a CD8b polypeptide. The CD8b polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_742099.1 (SEQ ID NO: 7), or a fragment thereof, and / or may optionally include at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD8b polypeptide includes or has an amino acid sequence that is a continuous portion of SEQ ID NO: 7, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CD8b polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 7. In certain embodiments, the CD8b polypeptide contained in the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence of amino acids 171 to 195 of SEQ ID NO: 7.

[0188] SEQ ID NO:7 is provided as follows:

[0189]

[0190] According to the subject matter of the present disclosure, "CD8b nucleic acid molecule" refers to a polynucleotide encoding a CD8b polypeptide. In certain embodiments, a CD8b nucleic acid molecule encoding a CD8b polypeptide having amino acids 171 to 195 of SEQ ID NO: 7 comprises or has a nucleic acid containing a sequence as shown in SEQ ID NO: 8 provided below.

[0191]

[0192] ICOS

[0193] In certain embodiments, the transmembrane domain of the CAR of the present disclosure includes a natural or modified transmembrane domain of an ICOS polypeptide. The ICOS polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_036224.1 (SEQ ID NO: 9), or a fragment thereof, and / or may optionally include at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the ICOS polypeptide includes or has an amino acid sequence that is a continuous portion of SEQ ID NO: 9, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the ICOS polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 9. In certain embodiments, the ICOS polypeptide comprised in the transmembrane domain of a CAR of the present disclosure comprises or has an amino acid sequence of amino acids 141 to 165 of SEQ ID NO: 9.

[0194] SEQ ID NO:9 is provided as follows:

[0195]

[0196] According to the subject matter of the present disclosure, "ICOS nucleic acid molecule" refers to a polynucleotide encoding an ICOS polypeptide. In certain embodiments, an ICOS nucleic acid molecule encoding an ICOS polypeptide having amino acids 141 to 165 of SEQ ID NO: 9 comprises or has a nucleic acid having a sequence as set forth in SEQ ID NO: 10, provided below.

[0197]

[0198] CTLA-4

[0199] In certain embodiments, the transmembrane domain of the CAR of the present disclosure includes a natural or modified transmembrane domain of a CTLA-4 polypeptide. The CTLA-4 polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_005205.2 (SEQ ID NO: 11), or a fragment thereof, and / or may optionally contain at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CTLA-4 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 11, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CTLA-4 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 11. In certain embodiments, the CTLA-4 polypeptide contained in the transmembrane domain of a CAR of the present disclosure comprises or has an amino acid sequence of amino acids 162 to 186 of SEQ ID NO: 11.

[0200] SEQ ID NO: 11 is provided as follows:

[0201]

[0202] According to the presently disclosed subject matter, a "CTLA-4 nucleic acid molecule" refers to a polynucleotide encoding a CTLA-4 polypeptide. In certain embodiments, a CTLA-4 nucleic acid molecule encoding a CTLA-4 polypeptide having amino acids 162 to 186 of SEQ ID NO: 11 comprises or has a nucleic acid containing the sequence set forth in SEQ ID NO: 12 as provided below.

[0203]

[0204] ICAM-1

[0205] In certain embodiments, the transmembrane domain of the CAR of the present disclosure includes a natural or modified transmembrane domain of an ICAM-1 polypeptide. The ICAM-1 polypeptide may have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% or at least about 100% homology or identity with a sequence having NCBI reference number NP_000192.2 (SEQ ID NO: 13), or a fragment thereof, and / or may optionally contain at most one or at most two or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the ICAM-1 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 13, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the ICAM-1 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 13. In certain embodiments, the ICAM-1 polypeptide comprised in the transmembrane domain of a CAR of the present disclosure comprises or has an amino acid sequence of amino acids 481 to 507 of SEQ ID NO: 13.

[0206] SEQ ID NO: 13 is provided as follows:

[0207]

[0208] According to the subject matter of the present disclosure, "ICAM-1 nucleic acid molecule" refers to a polynucleotide encoding an ICAM-1 polypeptide. In certain embodiments, an ICAM-1 nucleic acid molecule encoding an ICAM-1 polypeptide having amino acids 481 to 507 of SEQ ID NO: 13 comprises or has a nucleic acid having a sequence as set forth in SEQ ID NO: 14, provided below.

[0209]

[0210] 2.2.3. Hinge / spacer region

[0211] In some non-limiting embodiments, CAR can also include a hinge / spacer for connecting the extracellular antigen-binding domain to a transmembrane domain. Hinge / spacer can be flexible enough to allow antigen-binding domains to be oriented in different directions to promote antigen recognition. In some non-limiting embodiments, the hinge / spacer of CAR can include CD8 polypeptides, CD28 polypeptides, CD3 ζ polypeptides, CD40 polypeptides, 4-1BB polypeptides, OX40 polypeptides, CD84 polypeptides, CD166 polypeptides, CD8a polypeptides, CD8b polypeptides, ICOS polypeptides, ICAM-1 polypeptides, CTLA-4 polypeptides, CD27 polypeptides, CD40 / My88 peptides, NKGD2 peptides, synthetic polypeptides (not based on proteins associated with immune responses) or a combination thereof Natural or modified hinge region. The hinge / spacer region can be a hinge region from IgG1, or a portion of the CH2CH3 region and CD3 of an immunoglobulin, a portion of a CD28 polypeptide (e.g., a portion of SEQ ID NO: 90), a portion of a CD8 polypeptide (e.g., a portion of SEQ ID NO: 86 or a portion of SEQ ID NO: 87), a variant having at least about 80%, at least about 85%, at least about 90%, at least about 95% or at least about 100% homology or identity with any of the foregoing, or a synthetic spacer sequence.

[0212] CD28

[0213] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of a CD28 polypeptide described herein. In certain embodiments, the CD28 polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has an amino acid sequence of amino acids 114 to 152 of SEQ ID NO: 90. In certain embodiments, the CD28 nucleic acid encoding the CD28 polypeptide having amino acids 114 to 152 of SEQ ID NO: 90 comprises or has a nucleic acid containing a sequence as shown in SEQ ID NO: 15 provided below.

[0214]

[0215] CD84

[0216] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of a CD84 polypeptide described herein. In certain embodiments, the CD84 polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has an amino acid sequence of amino acids 187 to 225 of SEQ ID NO: 1. In certain embodiments, the CD84 nucleic acid encoding the CD84 polypeptide having amino acids 187 to 225 of SEQ ID NO: 1 comprises or has a nucleic acid containing a sequence as shown in SEQ ID NO: 16 provided below.

[0217]

[0218] CD166

[0219] In certain embodiments, the hinge / spacer of CAR disclosed herein comprises a natural or modified hinge region of CD166 polypeptides as described herein. In certain embodiments, the CD166 polypeptides included in the hinge / spacer of CAR disclosed herein include or have SEQ ID NO:3 amino acids 489 to 527. In certain embodiments, the CD166 nucleic acid encoding the CD166 polypeptides with SEQ ID NO:3 amino acids 489 to 527 includes or has a nucleic acid containing a sequence as shown in SEQ ID NO:17 provided below.

[0220]

[0221] In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region of the CAR of the present disclosure comprises or has amino acids 484 to 527 of SEQ ID NO: 3. In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region of the CAR of the present disclosure comprises or has amino acids 506 to 527 of SEQ ID NO: 3. In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region of the CAR of the present disclosure comprises or has amino acids 517 to 527 of SEQ ID NO: 3. In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region of the CAR of the present disclosure comprises or has an amino acid sequence shown in SEQ ID NO: 109 or SEQ ID NO: 110.

[0222]

[0223] In certain embodiments, the CD166 polypeptide contained in the hinge / spacer region and the transmembrane domain of the CAR of the present disclosure comprises or has an amino acid sequence shown in SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116 or SEQ ID NO: 117.

[0224]

[0225] CD8a

[0226] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of a CD8a polypeptide described herein. In certain embodiments, the CD8a polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has amino acids 137 to 182 of SEQ ID NO: 5. In certain embodiments, the CD8a nucleic acid encoding the CD8a polypeptide having amino acids 137 to 182 of SEQ ID NO: 5 comprises or has a nucleic acid containing a sequence as shown in SEQ ID NO: 18 provided below.

[0227]

[0228] CD8b

[0229] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of a CD8b polypeptide described herein. In certain embodiments, the CD8b polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has amino acids 132 to 170 of SEQ ID NO: 7. In certain embodiments, the CD8b nucleic acid encoding the CD8b polypeptide having amino acids 132 to 170 of SEQ ID NO: 7 comprises or has a nucleic acid containing a sequence as shown in SEQ ID NO: 19 provided below.

[0230]

[0231] ICOS

[0232] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of an ICOS polypeptide described herein. In certain embodiments, the ICOS polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has amino acids 102 to 140 of SEQ ID NO: 9. In certain embodiments, the ICOS nucleic acid encoding the ICOS polypeptide having amino acids 102 to 140 of SEQ ID NO: 9 comprises or has a nucleic acid containing the sequence set forth in SEQ ID NO: 20 as provided below.

[0233]

[0234] CTLA-4

[0235] In certain embodiments, the hinge / spacer region of a CAR disclosed herein comprises a native or modified hinge region of a CTLA-4 polypeptide described herein. In certain embodiments, the CTLA-4 polypeptide contained in the hinge / spacer region of a CAR disclosed herein comprises or has amino acids 123 to 161 of SEQ ID NO: 11. In certain embodiments, a CTLA-4 nucleic acid encoding a CTLA-4 polypeptide having amino acids 123 to 161 of SEQ ID NO: 11 comprises or has a nucleic acid containing a sequence as set forth in SEQ ID NO: 21 as provided below.

[0236]

[0237] ICAM-1

[0238] In certain embodiments, the hinge / spacer region of the CAR disclosed herein comprises a native or modified hinge region of an ICAM-1 polypeptide described herein. In certain embodiments, the ICAM-1 polypeptide contained in the hinge / spacer region of the CAR disclosed herein comprises or has amino acids 442 to 480 of SEQ ID NO: 13. In certain embodiments, the ICAM-1 nucleic acid encoding an ICAM-1 polypeptide having amino acids 442 to 480 of SEQ ID NO: 13 comprises or has a nucleic acid containing a sequence as set forth in SEQ ID NO: 22 as provided below.

[0239]

[0240] In some embodiments, CAR of the present disclosure includes hinge / spacer.In some embodiments, hinge / spacer is located between extracellular antigen binding domain and transmembrane domain.In some embodiments, hinge / spacer includes CD8 polypeptide, CD28 polypeptide, CD3ζ polypeptide, CD4 polypeptide, 4-1BB polypeptide, OX40 polypeptide, CD166 polypeptide, CD8a polypeptide, CD8b polypeptide, ICOS polypeptide, ICAM-1 polypeptide, CTLA-4 polypeptide, CD27 polypeptide, CD40 / My88 peptide, NKGD2 peptide, synthetic polypeptide (not based on protein associated with immune response) or its combination. In certain embodiments, the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, a NKGD2 peptide, a synthetic polypeptide (not based on a protein associated with an immune response), or a combination thereof.

[0241] In certain embodiments, the transmembrane domain and hinge / spacer are derived from the same molecule. In certain embodiments, the transmembrane domain and hinge / spacer are derived from different molecules. In certain embodiments, the hinge / spacer of CAR comprises a CD28 polypeptide and the transmembrane domain of CAR comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer of CAR comprises a CD28 polypeptide, and the transmembrane domain of CAR comprises a CD28 polypeptide. In certain embodiments, the hinge / spacer of CAR comprises a CD84 polypeptide, and the transmembrane domain of CAR comprises a CD84 polypeptide. In certain embodiments, the hinge / spacer of CAR comprises a CD166 polypeptide, and the transmembrane domain of CAR comprises a CD166 polypeptide. In certain embodiments, the hinge / spacer of CAR comprises a CD8a polypeptide, and the transmembrane domain of CAR comprises a CD8a polypeptide. In certain embodiments, the hinge / spacer of CAR comprises a CD8b polypeptide, and the transmembrane domain of CAR comprises a CD8b polypeptide. In certain embodiments, the hinge / spacer region of the CAR comprises a CD28 polypeptide and the transmembrane domain of the CAR comprises an ICOS polypeptide.

[0242] 2.2.4. Intracellular signaling domain of CAR

[0243] In certain non-limiting embodiments, the intracellular signaling domain of CAR includes a CD3 ζ polypeptide that can activate or stimulate cells (e.g., cells of lymphoid lineage, such as T cells). Wild-type ("natural") CD3 ζ includes three immunoreceptor tyrosine-based activation motifs ("ITAM") (e.g., ITAM1, ITAM2, and ITAM3), three basic-rich extension (BRS) regions (BRS1, BRS2, ​​and BRS3), and after antigen binding, the activation signal is delivered to cells (e.g., cells of lymphoid lineage, such as T cells). The intracellular signaling domain of the natural CD3 ζ chain is the main sender of signals from endogenous TCR. As used in the embodiments herein, CD3 ζ is not natural CD3 ζ, but modified CD3 ζ. In certain embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the sequence having NCBI Reference Number: NP_932170 (SEQ ID No: 94), or a fragment thereof. In certain non-limiting embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 94, which is at least 20, or at least 30, or at least 40, or at least 50, or at least 100, or at least 110, or at least 113, and at most 163 amino acids in length. Alternatively or additionally, in various non-limiting embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence of amino acids 1 to 50, 50 to 100, 100 to 150, 50 to 164, 55 to 164, or 150 to 164 of SEQ ID NO: 94. In certain embodiments, the modified CD3 zeta polypeptide comprises or has an amino acid sequence of amino acids 52 to 164 of SEQ ID NO: 94.

[0244] SEQ ID NO:94 is provided as follows:

[0245]

[0246] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified human CD3 zeta polypeptide. The modified human CD3 zeta polypeptide may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to SEQ ID NO: 95, or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 95 is provided as follows:

[0247]

[0248] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:95 is set forth in SEQ ID NO:96 provided below.

[0249]

[0250] Immunoreceptor tyrosine-based activation motif (ITAM)

[0251] In certain non-limiting embodiments, the intracellular signaling domain of CAR comprises a modified CD3 zeta polypeptide comprising one, two or three ITAMs. In certain embodiments, the modified CD3 zeta polypeptide comprises a native ITAM1 comprising an amino acid sequence shown in SEQ ID NO: 23.

[0252]

[0253] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 23 is set forth in SEQ ID NO: 24, which is provided below.

[0254]

[0255] In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM1 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3ζ polypeptide has an ITAM1 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM1. In certain embodiments, the ITAM1 variant consisting of two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 25, which is provided below.

[0256]

[0257] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 25 is set forth in SEQ ID NO: 26 provided below.

[0258]

[0259] In certain embodiments, the modified CD3zeta polypeptide comprises a native ITAM2 comprising the amino acid sequence set forth in SEQ ID NO: 27, which is provided below.

[0260]

[0261] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 27 is set forth in SEQ ID NO: 28 provided below.

[0262]

[0263] In certain embodiments, the modified CD3ζ polypeptide comprises an ITAM2 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3ζ polypeptide has an ITAM2 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM2. In certain embodiments, the ITAM2 variant consisting of two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 29, which is provided below.

[0264]

[0265] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 29 is set forth in SEQ ID NO: 30 provided below.

[0266]

[0267] In certain embodiments, the modified CD3zeta polypeptide comprises a native ITAM3 comprising the amino acid sequence set forth in SEQ ID NO:31 provided below.

[0268]

[0269] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 131 is set forth in SEQ ID NO: 32 provided below.

[0270]

[0271] In certain embodiments, the modified CD3 zeta polypeptide comprises an ITAM3 variant comprising one or more loss-of-function mutations. In certain embodiments, the modified CD3 zeta polypeptide has an ITAM3 variant comprising two loss-of-function mutations. In certain embodiments, the loss-of-function mutation comprises a mutation of a tyrosine residue in ITAM3. In certain embodiments, the ITAM3 variant consisting of two loss-of-function mutations comprises the amino acid sequence set forth in SEQ ID NO: 33, which is provided below.

[0272]

[0273] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 33 is set forth in SEQ ID NO: 34 provided below.

[0274]

[0275] In certain embodiments, the intracellular signaling domain of CAR comprises a modified CD3 zeta polypeptide, which comprises or consists essentially of or consists of an ITAM1 variant comprising one or more loss-of-function mutations, an ITAM2 variant comprising one or more loss-of-function mutations, an ITAM3 variant comprising one or more loss-of-function mutations, or a combination thereof. In certain embodiments, the intracellular signaling domain of CAR comprises a modified CD3 zeta polypeptide, which comprises an ITAM2 variant comprising one or more (e.g., two) loss-of-function mutations and an ITAM3 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of CAR comprises a modified CD3 zeta polypeptide, which comprises a native ITAM1, an ITAM2 variant comprising two loss-of-function mutations, and an ITAM3 variant comprising two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1 having the amino acid sequence shown in SEQ ID NO: 23, an ITAM2 variant having the amino acid sequence shown in SEQ ID NO: 29, and an ITAM3 variant having the amino acid sequence shown in SEQ ID NO: 33 (e.g., a construct designated as "1XX").

[0276] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having one or more (e.g., two) loss-of-function mutations and an ITAM3 variant having one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having two loss-of-function mutations, a native ITAM2, and an ITAM3 variant having two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having an amino acid sequence as shown in SEQ ID NO: 25, a native ITAM2 having an amino acid sequence as shown in SEQ ID NO: 27, and an ITAM3 variant having an amino acid sequence as shown in SEQ ID NO: 33 (e.g., a construct designated as "X2X").

[0277] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having one or more (e.g., two) loss-of-function mutations and an ITAM2 variant having one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having two loss-of-function mutations, an ITAM2 variant having two loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having an amino acid sequence as shown in SEQ ID NO: 25, an ITAM2 variant having an amino acid sequence as shown in SEQ ID NO: 29, and a native ITAM3 having an amino acid sequence as shown in SEQ ID NO: 31 (e.g., a construct designated as "XX3").

[0278] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having two loss-of-function mutations, a native ITAM2 and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising an ITAM1 variant having an amino acid sequence as shown in SEQ ID NO: 27, a native ITAM2 having an amino acid sequence as shown in SEQ ID NO: 29, and a native ITAM3 having an amino acid sequence as shown in SEQ ID NO: 31 (e.g., a construct designated as "X23").

[0279] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1, a native ITAM2, and an ITAM3 variant comprising one or more (e.g., two) loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1, a native ITAM2, and an ITAM1 variant comprising two loss-of-function mutations. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1 having an amino acid sequence as shown in SEQ ID NO: 23, a native ITAM2 having an amino acid sequence as shown in SEQ ID NO: 27, and an ITAM3 variant having an amino acid sequence as shown in SEQ ID NO: 33 (e.g., a construct designated as "12X").

[0280] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1, an ITAM2 variant comprising one or more (e.g., two) loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1, an ITAM2 variant comprising two loss-of-function mutations, and a native ITAM3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native ITAM1 having an amino acid sequence as shown in SEQ ID NO: 23, an ITAM2 variant having an amino acid sequence as shown in SEQ ID NO: 29, and a native ITAM3 variant having an amino acid sequence as shown in SEQ ID NO: 31 (e.g., a construct designated as "1X3").

[0281] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a deletion of one or two ITAMs. In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM1 and ITAM2, for example, the modified CD3 zeta polypeptide comprises a natural ITAM3 or ITAM3 variant, but does not comprise ITAM1 or ITAM2. In certain embodiments, the modified CD3 zeta polypeptide comprises a natural ITAM3 having an amino acid sequence as shown in SEQ ID NO: 31, but does not comprise ITAM1 (natural or modified) or ITAM2 (natural or modified) (e.g., D12).

[0282] In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM2 and ITAM3, for example, the modified CD3 zeta polypeptide comprises a native ITAM1 or ITAM1 variant, but does not comprise ITAM2 or ITAM3. In certain embodiments, the modified CD3 zeta polypeptide comprises a native ITAM1 having an amino acid sequence as shown in SEQ ID NO: 23, but does not comprise ITAM2 (native or modified) or ITAM3 (native or modified) (e.g., D23).

[0283] In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM1 and ITAM3, for example, the modified CD3 zeta polypeptide comprises a native ITAM2 or ITAM2 variant, but does not comprise ITAM1 or ITAM3. In certain embodiments, the modified CD3 zeta polypeptide comprises a native ITAM2 having an amino acid sequence as shown in SEQ ID NO: 27, but does not comprise ITAM1 (native or modified) or ITAM3 (native or modified) (e.g., D13).

[0284] In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM1, for example, the modified CD3 zeta polypeptide comprises native ITAM2 or an ITAM2 variant and native ITAM3 or an ITAM3 variant, but does not comprise ITAM1 (native or modified).

[0285] In certain embodiments, the modified CD3 zeta polypeptide comprises a deletion of ITAM2, for example, the modified CD3 zeta polypeptide comprises native ITAM1 or an ITAM1 variant and native ITAM3 or an ITAM3 variant, but does not comprise ITAM2 (native or modified).

[0286] In certain embodiments, the modified CD3zeta polypeptide comprises a deletion of ITAM3, for example, the modified CD3zeta polypeptide comprises native ITAM1 or an ITAM1 variant and native ITAM2 or an ITAM2 variant, but does not comprise ITAM3 (native or modified).

[0287] Base Rich Stretching (BRS) Zone

[0288] In certain non-limiting embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising one, two or three BRS regions (i.e., BRS1, BRS2, ​​and BRS3). The BRS region can be a natural BRS or a modified BRS (e.g., a BRS variant). In certain embodiments, the modified CD3ζ polypeptide comprises a natural BRS1 region comprising an amino acid sequence shown in SEQ ID NO: 35, which is provided below.

[0289]

[0290] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 35 is set forth in SEQ ID NO: 36 provided below.

[0291]

[0292] In certain embodiments, the modified CD3zeta polypeptide comprises a BRS1 variant comprising one or more loss-of-function mutations.

[0293] In certain embodiments, the modified CD3ζ polypeptide comprises a native BRS2 comprising the amino acid sequence set forth in SEQ ID NO:37.

[0294]

[0295] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 37 is set forth in SEQ ID NO: 38 provided below.

[0296]

[0297] In certain embodiments, the modified CD3zeta polypeptide comprises a BRS2 variant having one or more loss-of-function mutations.

[0298] In certain embodiments, the modified CD3ζ polypeptide comprises a native BRS3 comprising the amino acid sequence set forth in SEQ ID NO:39.

[0299]

[0300] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:39 is set forth in SEQ ID NO:40 provided below.

[0301]

[0302] In certain embodiments, the modified CD3zeta polypeptide comprises a BRS3 variant having one or more loss-of-function mutations.

[0303] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising all three BRS regions, i.e., BRS1, BRS2, ​​and BRS3 regions. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native BRS1, a native BRS2, ​​and a native BRS3. In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3 zeta polypeptide comprising a native BRS1 having an amino acid sequence as shown in SEQ ID NO: 35, a native BRS2 having an amino acid sequence as shown in SEQ ID NO: 37, and a native BRS3 having an amino acid sequence as shown in SEQ ID NO: 39, for example, a modified CD3 zeta polypeptide contained in construct 1XX.

[0304] In certain embodiments, the intracellular signaling domain of the CAR comprises a modified CD3ζ polypeptide comprising one or two but not all three BRS regions. In certain embodiments, the modified CD3ζ polypeptide comprises a BRS1 region and a BRS2 region, but does not comprise a BRS3 region. In certain embodiments, the modified CD3ζ polypeptide comprises a BRS1 region and a BRS3 region, but does not comprise a BRS2 region. In certain embodiments, the modified CD3ζ polypeptide comprises a BRS2 region and a BRS3 region, but does not comprise a BRS1 region.

[0305] In certain embodiments, the modified CD3ζ polypeptide comprises a BRS1 region, but does not comprise a BRS2 region or a BRS3 region. In certain embodiments, the modified CD3ζ polypeptide comprises a native BRS1 having an amino acid sequence as shown in SEQ ID NO: 35, but does not comprise a BRS2 region or a BRS3 region, such as a modified CD3ζ polypeptide contained in construct D23. In certain embodiments, the modified CD3ζ polypeptide comprises a BRS2 region, but does not comprise a BRS1 region or a BRS3 region. In certain embodiments, the modified CD3ζ polypeptide comprises a BRS3 region, but does not comprise a BRS1 region or a BRS2 region.

[0306] In certain embodiments, the modified CD3ζ polypeptide does not comprise a BRS region (native or modified BRS1, BRS2 or BRS3), for example, all three BRS are deleted, for example, the modified CD3ζ polypeptide contained in construct D12.

[0307] In certain non-limiting embodiments, CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or part of an immunoreceptor tyrosine-based activation motif (ITAM), wherein ITAM is ITAM1, ITAM2, and ITAM3. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide also lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof. In certain embodiments, the modified CD3ζ polypeptide lacks all or part of a basic stretch (BRS) region, wherein the BRS region is BRS1, BRS2, ​​and BRS3. In certain embodiments, the modified CD3ζ polypeptide lacks BRS2 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide further lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide lacks BRS1 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide further lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide lacks BRS3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof. In certain embodiments, the modified CD3 zeta polypeptide lacks ITAM2, ITAM3, BRS2, ​​and BRS3. In certain embodiments, the CAR comprises the amino acid sequence shown in SEQ ID NO: 45 or SEQ ID NO: 47. In certain embodiments, the CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide lacks all or part of a basic-rich stretch (BRS) region, wherein the BRS region is BRS1, BRS2, ​​and BRS3. In certain embodiments, the CAR comprises an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, wherein the BRS variant comprises one or more loss-of-function mutations.

[0308] Costimulatory signaling region

[0309] In certain non-limiting embodiments, the intracellular signaling domain of CAR further comprises at least one co-stimulatory signaling region. In certain embodiments, the co-stimulatory signaling region comprises at least one co-stimulatory molecule that can provide optimal lymphocyte activation.

[0310] As used herein, "costimulatory molecules" refer to cell surface molecules other than antigen receptors or their ligands required for the effective response of lymphocytes to antigens. The at least one co-stimulatory signaling region may include CD28 polypeptide, 4-1BB polypeptide, OX40 polypeptide, ICOS polypeptide, DAP-10 polypeptide, CD27 peptide, CD40 / My88 peptide, NKGD2 peptide or a combination thereof. Costimulatory molecules can be combined with co-stimulatory ligands, which are proteins expressed on the cell surface, and co-stimulatory responses can be produced after binding to receptors, that is, the intracellular responses of the stimulations produced when the antigen is combined with its CAR molecules are affected. Co-stimulatory ligands include but are not limited to CD80, CD86, CD70, OX40L and 4-1BBL. As an example, 4-1BB ligands (i.e., 4-1BBL) can be combined with 4-1BB (also referred to as "CD137") to provide intracellular signals that induce CAR together with CAR signals. + Effector cell function of T cells. In U.S. Pat. No. 7,446,190 (incorporated herein by reference in its entirety), a CAR comprising an intracellular signaling domain comprising a co-stimulatory signaling region having 4-1BB, ICOS or DAP-10 is disclosed.

[0311] In certain embodiments, the intracellular signaling domain of the CAR comprises a co-stimulatory signaling region having a CD28 polypeptide. The CD28 polypeptide may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with a sequence having NCBI reference number: P10747 or NP_006130 (SEQ ID NO: 90), or a fragment thereof, and / or may optionally comprise at most one, at most two, or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is a continuous portion of SEQ ID NO: 90, and its length is at least 20, or at least 30, or at least 40, or at least 50 and at most 220 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence of amino acids 1 to 220, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, or 200 to 220 of SEQ ID NO: 90. In certain embodiments, the intracellular signaling domain of the CAR comprises a costimulatory signaling region comprising a CD28 polypeptide comprising or having an amino acid sequence of amino acids 180 to 220 of SEQ ID NO: 90.

[0312] In certain embodiments, the CD28 polypeptide comprises or has an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the sequence having NCBI reference number NP_031668.3 (SEQ ID NO: 97), or a fragment thereof, and / or may optionally comprise at most one, at most two, or at most three conservative amino acid substitutions. In certain non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence that is a contiguous portion of SEQ ID NO: 97, having a length of at least about 20, or at least about 30, or at least about 40, or at least about 50 and at most 218 amino acids. Alternatively or additionally, in various non-limiting embodiments, the CD28 polypeptide comprises or has an amino acid sequence of amino acids 1 to 218, 1 to 50, 50 to 100, 100 to 150, 114 to 220, 150 to 200, 178 to 218, or 200 to 220 of SEQ ID NO: 97. In certain embodiments, the costimulatory signaling region of the CAR of the present disclosure comprises a CD28 polypeptide comprising or having amino acids 178 to 218 of SEQ ID NO: 97.

[0313] SEQ ID NO:97 is provided as follows:

[0314]

[0315] According to the subject matter of the present disclosure, "CD28 nucleic acid molecule" refers to a polynucleotide encoding a CD28 polypeptide. In certain embodiments, the CD28 nucleic acid molecule encoding the CD28 polypeptide (e.g., SEQ ID NO: 97 amino acids 178 to 218) contained in the co-stimulatory signaling region of the CAR of the present disclosure comprises or has a nucleotide sequence shown in SEQ ID NO: 98, which is provided below.

[0316]

[0317] In certain embodiments, the intracellular signaling domain of the CAR comprises the murine intracellular signaling domain of CD28. The murine intracellular signaling domain of CD28 may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to SEQ ID NO: 99, or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 99 is provided as follows:

[0318]

[0319] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:99 is set forth in SEQ ID NO:100, which is provided below.

[0320]

[0321] In certain embodiments, the intracellular signaling domain of the CAR comprises the human intracellular signaling domain of CD28. The human intracellular signaling domain of CD28 may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with SEQ ID NO: 101, or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 101 is provided as follows:

[0322]

[0323] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:70 is set forth in SEQ ID NO:102, which is provided below.

[0324]

[0325] In certain embodiments, the intracellular signaling domain of the CAR comprises a deimmunized human intracellular signaling domain of CD28. The deimmunized human intracellular signaling domain of CD28 may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with SEQ ID NO: 108, or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 108 is provided as follows:

[0326]

[0327] In certain embodiments, the intracellular signaling domain of the CAR comprises a costimulatory signaling region comprising two costimulatory molecules, such as the costimulatory signaling region of CD28 and 4-1BB or the costimulatory signaling region of CD28 and OX40.

[0328] 4-1BB can act as a tumor necrosis factor (TNF) ligand and has stimulatory activity. The 4-1BB polypeptide may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with a sequence having NCBI reference number: P41273 or NP_001552 (SEQ ID NO: 103), or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions.

[0329] SEQ ID NO: 103 is provided as follows:

[0330]

[0331] According to the presently disclosed subject matter, a "4-1BB nucleic acid molecule" refers to a polynucleotide encoding a 4-1BB polypeptide.

[0332] In certain embodiments, the intracellular signaling domain of the CAR comprises the intracellular signaling domain of 4-1BB. The intracellular signaling domain of 4-1BB may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with SEQ ID NO: 104, or a fragment thereof, and / or may optionally comprise at most one or at most two or at most three conservative amino acid substitutions. SEQ ID NO: 104 is provided as follows:

[0333]

[0334] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 104 is set forth in SEQ ID NO: 105 provided below.

[0335]

[0336] The OX40 polypeptide may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the sequence having NCBI Reference Number: P43489 or NP_003318 (SEQ ID NO: 106), or a fragment thereof, and / or may optionally comprise up to one or up to two or up to three conservative amino acid substitutions.

[0337] SEQ ID NO: 106 is provided as follows:

[0338]

[0339] According to the presently disclosed subject matter, an "OX40 nucleic acid molecule" refers to a polynucleotide encoding an OX40 polypeptide.

[0340] The ICOS polypeptide may comprise or have an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the sequence having NCBI Reference Number: NP_036224 (SEQ ID NO: 65), or a fragment thereof, and / or may optionally comprise at most one, or at most two, or at most three conservative amino acid substitutions.

[0341] SEQ ID NO:65 is provided as follows:

[0342]

[0343] According to the presently disclosed subject matter, an "ICOS nucleic acid molecule" refers to a polynucleotide encoding an ICOS polypeptide.

[0344] In certain embodiments, the CAR of the present disclosure further comprises an inducible promoter for expressing nucleic acid sequences in human cells. The promoter for expressing the CAR gene can be a constitutive promoter, such as ubiquitin protein C (UbiC) promoter.

[0345] In certain embodiments, mutation sites and / or junctions between domains / motifs / regions of CARs from different proteins are deimmunized. The immunogenicity of the junctions between different CAR parts can be predicted using NetMHC 4.0Server. For each peptide containing at least one amino acid from the next part, the binding affinity to all alleles to HLA A, B, and C can be predicted. An immunogenicity score for each peptide can be assigned to each peptide. The immunogenicity score can be calculated using the formula: Immunogenicity score = [(50-binding affinity) * HLA frequency] n . n is the number of predictions per peptide.

[0346] 1928z WT construct

[0347] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising native ITAM1, native ITAM2, native ITAM3, native BRS1, native BRS2, ​​and native BRS3. In certain embodiments, the CAR is designated as "1928z WT". In certain embodiments, the CAR (e.g., 1928z WT) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with the amino acid sequence shown in SEQ ID NO: 41 (which is provided below). SEQ ID NO: 41 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0348]

[0349] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:41 is set forth in SEQ ID NO:42 provided below.

[0350]

[0351] 1XX construct

[0352] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising a native ITAM1, a native BRS1, a native BRS2, ​​a native BRS3, an ITAM2 variant with two loss-of-function mutations, and an ITAM3 variant with two loss-of-function mutations. In certain embodiments, the CAR is named "1XX". In certain embodiments, the CAR (e.g., 1XX) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the amino acid sequence shown in SEQ ID NO: 43 (which is provided below). SEQ ID NO: 43 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0353]

[0354] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:43 is set forth in SEQ ID NO:44 provided below.

[0355]

[0356] D12 construct

[0357] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain, a transmembrane domain and a hinge / spacer region derived from a CD28 polypeptide that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), an intracellular signaling domain comprising a modified CD3 ζ polypeptide (e.g., a modified human CD3 ζ polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3 ζ polypeptide comprises a native ITAM3 and does not comprise ITAM1 (native or modified), ITAM2 (native or modified), BRS1 (native or modified), BRS2 (native or modified) or BRS3 (native or modified). In certain embodiments, CAR is named "D12". In certain embodiments, the CAR (e.g., D12) comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology to the amino acid sequence set forth in SEQ ID NO: 45 (which is provided below). SEQ ID NO: 45 comprises a CD8 leader sequence at amino acids 1 to 18 and is capable of binding to CD19 (e.g., human CD19).

[0358]

[0359] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:45 is set forth in SEQ ID NO:46 provided below.

[0360]

[0361] D23 construct

[0362] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain, a transmembrane domain and a hinge / spacer region derived from a CD28 polypeptide that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), an intracellular signaling domain comprising a modified CD3 ζ polypeptide (e.g., a modified human CD3 ζ polypeptide) with ITAM1, BRS1 and ITAM2, ITAM3, BRS2 and BRS3 deletions and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., human CD28), wherein the modified CD3 ζ polypeptide comprises a natural ITAM1 and a natural BRS1, and does not comprise ITAM2 (natural or modified), ITAM3 (natural or modified), BRS2 (natural or modified) or BRS3 (natural or modified). In certain embodiments, CAR is named "D23". In certain embodiments, the CAR (e.g., D23) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the amino acid sequence shown in SEQ ID NO: 47 provided below. SEQ ID NO: 47 comprises a CD8 leader sequence at amino acids 1 to 18 and is capable of binding to CD19 (e.g., human CD19).

[0363]

[0364] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:47 is set forth in SEQ ID NO:48 provided below.

[0365]

[0366] XX3 construct

[0367] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising a native ITAM3, a native BRS1, a native BRS2, ​​a native BRS3, an ITAM1 variant with two loss-of-function mutations, and an ITAM2 variant with two loss-of-function mutations. In certain embodiments, the CAR is named "XX3". In certain embodiments, the CAR (e.g., XX3) comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology to the amino acid sequence shown in SEQ ID NO: 49 provided below. SEQ ID NO: 49 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0368]

[0369]

[0370] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:49 is set forth in SEQ ID NO:50, which is provided below.

[0371]

[0372] X23 construct

[0373] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising a native ITAM2, a native ITAM3, a native BRS1, a native BRS2, ​​a native BRS3, and an ITAM1 variant having two loss-of-function mutations. In certain embodiments, the CAR is named "X23". In certain embodiments, the CAR (e.g., X23) comprises an amino acid sequence having at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology to the amino acid sequence shown in SEQ ID NO: 51 provided below. SEQ ID NO: 51 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0374]

[0375] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:51 is set forth in SEQ ID NO:52 provided below.

[0376]

[0377] X2X Construct

[0378] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising a native ITAM2, a native BRS1, a native BRS2, ​​a native BRS3, an ITAM1 variant with two loss-of-function mutations, and an ITAM3 variant with two loss-of-function mutations. In certain embodiments, the CAR is named "X2X". In certain embodiments, the CAR (e.g., X2X) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with the amino acid sequence shown in SEQ ID NO: 53 provided below. SEQ ID NO: 53 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0379]

[0380] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:53 is set forth in SEQ ID NO:54 provided below.

[0381]

[0382]

[0383] 12X construct

[0384] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), a transmembrane domain, and a hinge / spacer region derived from a CD28 polypeptide, an intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified human CD3 zeta polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), the modified CD3 zeta polypeptide comprising a native ITAM1, a native ITAM2, a native BRS1, a native BRS2, ​​a native BRS3, and an ITAM3 variant having two loss-of-function mutations. In certain embodiments, the CAR is named "12X". In certain embodiments, the CAR (e.g., 12X) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with the amino acid sequence shown in SEQ ID NO: 55 provided below. SEQ ID NO: 55 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0385]

[0386] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:55 is set forth in SEQ ID NO:56 provided below.

[0387]

[0388] D3 Construct

[0389] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain, a transmembrane domain and a hinge / spacer region derived from a CD28 polypeptide that binds to a CD19 polypeptide (e.g., a human CD19 polypeptide), an intracellular signaling domain comprising a modified CD3 ζ polypeptide (e.g., a modified human CD3 ζ polypeptide) with ITAM1, ITAM2, BRS1, BRS2 and a portion of ITAM3 and BRS3 missing, and a co-stimulatory signaling region comprising a CD28 polypeptide (e.g., a human CD28 polypeptide), wherein the modified CD3 ζ polypeptide comprises a natural ITAM1, a natural ITAM2, a natural BRS1 and a natural BRS2, ​​and does not comprise ITAM3 (natural or modified) or a natural BRS3. In certain embodiments, CAR is named "D3". In certain embodiments, the CAR (e.g., D3) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the amino acid sequence set forth in SEQ ID NO: 57 provided below. SEQ ID NO: 57 comprises a CD8 leader sequence at amino acids 1 to 18 and is capable of binding to CD19 (e.g., human CD19).

[0390]

[0391] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:57 is set forth in SEQ ID NO:58 provided below.

[0392]

[0393] [SEQ ID NO: 58]

[0394] 19-166-28z construct

[0395] In certain embodiments, the CAR of the present disclosure comprises an extracellular antigen binding domain, a transmembrane domain and a hinge / spacer region derived from a CD166 polypeptide bound to a CD19 polypeptide (eg, a human CD19 polypeptide), an intracellular signaling domain comprising a modified CD3 ζ polypeptide (eg, a modified human CD3 ζ polypeptide) and a co-stimulatory signaling region comprising a CD28 polypeptide (eg, a human CD28 polypeptide), the modified CD3 ζ polypeptide comprising a natural ITAM1, a natural ITAM2, a natural ITAM3, a natural BRS1, a natural BRS2 and a natural BRS3. In certain embodiments, CAR is named "19-166-28z". In certain embodiments, CAR (eg, 19-166-28z) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity with the amino acid sequence shown in SEQ ID NO: 59 provided below. SEQ ID NO: 59 comprises the CD8 leader sequence at amino acids 1 to 18 and is capable of binding CD19 (eg, human CD19).

[0396]

[0397] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:59 is set forth in SEQ ID NO:60 provided below.

[0398]

[0399] 19-166-28z 1XX construct

[0400] In certain embodiments, CAR of the present disclosure includes the extracellular antigen binding domain, membrane spaning domain and hinge / spacer derived from CD166 polypeptide combined with CD19 polypeptide (such as human CD19 polypeptide), the intracellular signaling domain of CD3 ζ polypeptide (such as modified human CD3 ζ polypeptide) and the co-stimulatory signaling region including CD28 polypeptide (such as human CD28 polypeptide), the modified CD3 ζ polypeptide includes natural ITAM1, natural BRS1, natural BRS2, ​​natural BRS3, ITAM2 variants with two loss-of-function mutations and ITAM3 variants with two loss-of-function mutations. In certain embodiments, CAR is named "19-166-28z 1XX". In certain embodiments, the CAR (e.g., 19-166-28z1XX) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the amino acid sequence set forth in SEQ ID NO: 61 provided below. SEQ ID NO: 61 comprises a CD8 leader sequence at amino acids 1 to 18 and is capable of binding to CD19 (e.g., human CD19).

[0401]

[0402] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO:61 is set forth in SEQ ID NO:62 provided below.

[0403]

[0404]

[0405] 19-166-28z D23 construct

[0406] In certain embodiments, CAR of the present disclosure includes an extracellular antigen binding domain, a membrane spaning domain and a hinge / spacer derived from CD166 polypeptides combined with CD19 polypeptides (e.g., human CD19 polypeptides), including an intracellular signaling domain of the modified CD3 ζ polypeptides (e.g., modified human CD3 ζ polypeptides) with ITAM1, BRS1 and missing ITAM2, ITAM3, BRS2 and BRS3 and a co-stimulatory signaling region comprising CD28 polypeptides (e.g., human CD28 polypeptides), wherein the modified CD3 ζ polypeptides include natural ITAM1 and natural BRS1, and do not include ITAM2 (natural or modified), ITAM3 (natural or modified), BRS2 (natural or modified) or BRS3 (natural or modified). In certain embodiments, CAR is named "19-166-28z D23". In certain embodiments, the CAR (e.g., 19-166-28z D23) comprises an amino acid sequence having at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%, at least about 100% homology or identity to the amino acid sequence set forth in SEQ ID NO: 63 provided below. SEQ ID NO: 63 comprises a CD8 leader sequence at amino acids 1 to 18 and is capable of binding to CD19 (e.g., human CD19).

[0407]

[0408] An exemplary nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 63 is set forth in SEQ ID NO: 64 provided below.

[0409]

[0410] 3. Immune response cells

[0411] The subject matter of the present disclosure provides immune response cells comprising one or more CAR disclosed herein. In certain embodiments, CAR can activate immune response cells. In certain embodiments, CAR is expressed by endogenous locus (e.g., TRAC).

[0412] In certain embodiments, compared with control cells, immune response cells comprising one or more CARs of the present disclosure show improved therapeutic efficacy. In certain embodiments, compared with control cells, immune response cells comprising one or more CARs of the present disclosure show similar cytolytic effects. In certain embodiments, compared with control cells, when administered to a subject, immune response cells comprising one or more CARs of the present disclosure show increased cell accumulation. In certain embodiments, compared with control cells, when administered to a subject, immune response cells comprising one or more CARs of the present disclosure show reduced cell exhaustion. Immune response cell exhaustion markers include but are not limited to TIM3, LAG3 and PD1. In certain embodiments, compared with control cells, when administered to a subject, immune response cells comprising CARs of the present disclosure maintain a higher population of memory immune cells. Memory immune cell markers include but are not limited to CD62L and CD45RA. In certain embodiments, compared with control cells, immune response cells comprising one or more CARs of the present disclosure secrete similar levels of cytokines. In certain embodiments, cytokines secreted by immune response cells include but are not limited to TNFα, IFNγ and IL2. In certain embodiments, the control cell comprises a CAR comprising an intracellular signaling domain having a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide comprises all native ITAM1-3 and all native BRS1-3.

[0413] 3.1 Immune response cells containing two or more CARs

[0414] In some embodiments, the immune response cell comprises two or more CARs. In some embodiments, at least one of the two or more CARs is a CAR disclosed herein. In some embodiments, the immune response cell comprises two CARs. In some embodiments, the immune response cell comprises three CARs.

[0415] In certain embodiments, the immune response cell comprises: a) a first CAR comprising a first extracellular antigen binding domain that binds to a first antigen, a first transmembrane domain, and a first intracellular signaling domain comprising a modified CD3 zeta polypeptide (e.g., a modified CD3 zeta polypeptide disclosed herein); b) a second CAR comprising a second extracellular antigen binding domain that binds to a second antigen, a second transmembrane domain, and a second intracellular signaling domain. In certain embodiments, the first CAR further comprises a first hinge / spacer. In certain embodiments, the second CAR further comprises a second hinge / spacer.

[0416] In certain embodiments, the second intracellular signaling domain comprises a modified CD3 zeta polypeptide (e.g., a modified CD3 zeta polypeptide disclosed herein). In certain embodiments, the second intracellular signaling domain comprises a native CD3 zeta polypeptide. In certain embodiments, the modified CD3 zeta polypeptide contained in the second intracellular signaling domain is the same as the modified CD3 zeta polypeptide contained in the first intracellular signaling domain. In certain embodiments, the modified CD3 zeta polypeptide contained in the second intracellular signaling domain is different from the modified CD3 zeta polypeptide contained in the first intracellular signaling domain. In certain embodiments, the modified CD3ζ polypeptide is selected from: a CD3ζ polypeptide comprising one native ITAM, a CD3ζ polypeptide comprising two native ITAMs, a CD3ζ polypeptide comprising three native ITAMs, a CD3ζ polypeptide comprising an ITAM variant disclosed herein, a CD3ζ polypeptide comprising two ITAM variants disclosed herein, a CD3ζ polypeptide comprising a native BRS region, a CD3ζ polypeptide comprising two native BRS regions, a CD3ζ polypeptide comprising three native BRS regions, a CD3ζ polypeptide lacking all or part of ITAM1, ITAM2, ITAM3 and / or any part thereof, and any combination thereof.

[0417] In some embodiments, two or more CARs included in immune response cells are different (e.g., the first CAR is different from the second CAR). In some embodiments, two or more CARs included in immune response cells are the same (e.g., the first CAR is the same as the second CAR).

[0418] In certain embodiments, the two or more CARs bind different antigens (e.g., the first antigen is different from the second antigen).

[0419] In certain embodiments, two or more CARs comprise different intracellular signaling domains (e.g., the first intracellular signaling domain is different from the second intracellular signaling domain). In certain embodiments, two or more CARs comprise the same intracellular signaling domain (e.g., the first intracellular signaling domain is the same as the second intracellular signaling domain).

[0420] In some embodiments, the intracellular signaling domains of two or more CARs include different costimulatory signaling regions. In some embodiments, the costimulatory signaling region is selected from CD28 polypeptide, 4-1BB polypeptide, OX40 polypeptide, ICOS polypeptide, DAP-10 polypeptide, CD27 peptide, CD40 / My88 peptide, NKGD2 peptide and a combination thereof. In some embodiments, the intracellular signaling domains of two or more CARs include the same costimulatory signaling region.

[0421] In certain embodiments, the immune response cell comprises two, three or more CARs of the present disclosure. In certain embodiments, each intracellular signaling domain of the CAR is independently selected from the intracellular signaling domains of 1928ζ, 19ζ, 1XX, X2X, XX3, X23, 12X, D3, D12 and D23.

[0422] The choice of CAR included in the cell can depend on the density of the antigen targeted by the CAR, the total number of all ITAMs, the distance between each ITAM, the transmembrane domain of the CAR and / or the co-stimulatory signaling domain of the CAR, as described above, which can determine the strength of the activation signal generated by each CAR.

[0423] In certain embodiments, the immune response cell comprises two CARs, wherein the first CAR comprises a first intracellular signaling domain and the second CAR comprises a second intracellular signaling domain. In certain embodiments, each of the first and second intracellular signaling domains is selected from the intracellular signaling domains of 1928ζ, 19ζ, 1XX, X2X, XX3, 12X, X23, D3, D12 and D23.

[0424] In certain embodiments, the first intracellular signaling domain is the same as the second intracellular signaling domain. In certain embodiments, each of the first and second intracellular signaling domains is an intracellular signaling domain of 1XX. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are an intracellular signaling domain of 1XX and an intracellular signaling domain of D23. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are an intracellular signaling domain of 1XX and an intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are an intracellular signaling domain of D23 and an intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are an intracellular signaling domain of 1XX and an intracellular signaling domain of X2X. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are an intracellular signaling domain of 1XX and an intracellular signaling domain of D12. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are the intracellular signaling domain of 1XX and the intracellular signaling domain of 12X. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are the intracellular signaling domain of 1XX and the intracellular signaling domain of D3. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are the intracellular signaling domain of X2X and the intracellular signaling domain of X2X. In certain embodiments, the first intracellular signaling domain and the second intracellular signaling domain are the intracellular signaling domain of 1928ζ and the intracellular signaling domain of 1XX.

[0425] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof. In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0426] In certain embodiments, the total number of native ITAMs contained in two CARs does not exceed about five, does not exceed about four, does not exceed about three, or does not exceed about two.

[0427] In certain embodiments, the immune response cell comprises three CARs, wherein the first CAR comprises a first intracellular signaling domain, the second CAR comprises a second intracellular signaling domain, and the third CAR comprises a third intracellular signaling domain. In certain embodiments, each of the first, second, and third intracellular signaling domains is independently selected from the intracellular signaling domains of 1928ζ, 19ζ, 1XX, X2X, XX3, X23, 12X, D3, D12, and D23.

[0428] In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of D23, and the intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of D23, the intracellular signaling domain of D23, and the intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of D23, the intracellular signaling domain of XX3, and the intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of XX3, the intracellular signaling domain of XX3, and the intracellular signaling domain of XX3. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of 1XX. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of X2X, and the intracellular signaling domain of X2X. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of X2X. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of D12. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of D23. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of 12X.In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of 1XX, the intracellular signaling domain of 1XX, and the intracellular signaling domain of D3. In certain embodiments, the first intracellular signaling domain, the second intracellular signaling domain, and the third intracellular signaling domain are the intracellular signaling domain of X2X, the intracellular signaling domain of X2X, and the intracellular signaling domain of X2X.

[0429] In certain embodiments, the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant. In certain embodiments, the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

[0430] In certain embodiments, the total number of native ITAMs contained in the three CARs does not exceed about five, does not exceed about four, does not exceed about three.

[0431] In certain embodiments, the targets of the CARs are different from each other.

[0432] 3.1 Types of immune response cells

[0433] The immune response cells of the subject matter of the present disclosure can be cells of the lymphoid lineage. The lymphoid lineages including B, T and natural killer (NK) cells provide the production of antibodies, the regulation of the cellular immune system, the detection of exogenous agents in the blood, the detection of host exogenous cells, etc. Non-limiting examples of immune response cells of the lymphoid lineage include T cells, natural killer (NK) cells, embryonic stem cells and pluripotent stem cells (for example, those that can be differentiated into lymphoid cells therefrom). T cells can be lymphocytes that mature in the thymus and are primarily responsible for cell-mediated immunity. T cells participate in the adaptive immune system. The T cells of the subject matter of the present disclosure can be any type of T cells, including but not limited to helper T cells, cytotoxic T cells, memory T cells (including central memory T cells, stem cell-like memory T cells (or stem-like memory T cells), and two effector memory T cells: for example, T EM Cells and T EMRA Cells), regulatory T cells (also called suppressor T cells), natural killer T cells, mucosal-associated invariant T cells, and γδ T cells. Cytotoxic T cells (CTLs or killer T cells) are a subset of T lymphocytes that can induce the death of infected somatic cells or tumor cells. The patient's own T cells can be genetically modified to target specific antigens through the introduction of CAR. In certain embodiments, the immune response cell is a T cell. The T cell can be a CD4 + T cells or CD8 + In some embodiments, the T cells are CD8 + T cells.

[0434] Natural killer (NK) cells can be lymphocytes that are part of cell-mediated immunity and play a role in the innate immune response. NK cells do not require prior activation to perform cytotoxic effects on target cells.

[0435] Types of human lymphocytes of the disclosed subject matter include, but are not limited to, peripheral donor lymphocytes, such as those described in Sadelain, M. et al., 2003, Nat Rev Cancer 3:35-45 (disclosing peripheral donor lymphocytes genetically modified to express CAR), in Morgan, RA et al., 2006 Science 314:126-129 (disclosing peripheral donor lymphocytes genetically modified to express a full-length tumor antigen recognizing T cell receptor complex comprising α and β heterodimers), in Panelli, MC, et al. 2000 J Immunol 164:495-504; Panelli, MC, et al. 2000 J Immunol 164:4382-4392 (disclosing lymphocyte cultures derived from tumor infiltrating lymphocytes (TILs) in tumor biopsies) and in Dupont, J., et al. 2005 Cancer Res65:5417-5427; Papanicolaou, GA, et al. 2003 Blood 102:2498-2505 (selectively disclosing antigen-specific peripheral blood leukocytes expanded in vitro using artificial antigen presenting cells (AAPC) or pulsed dendritic cells). Immune response cells (e.g., T cells) can be autologous, non-autologous (e.g., allogeneic), or derived in vitro from engineered progenitor cells or stem cells.

[0436] The immune response cells disclosed herein are capable of modulating the tumor microenvironment. Tumors have a microenvironment that is hostile to the host immune response, which involves a series of mechanisms by which malignant cells protect themselves from immune recognition and elimination. This "hostile tumor microenvironment" contains a variety of immunosuppressive factors, including infiltrating regulatory CD4 + Expression of T cells (Tregs), myeloid-derived suppressor cells (MDSC), tumor-associated macrophages (TAMs), immunosuppressive cytokines including TGF-b, and ligands targeting immunosuppressive receptors (CTLA-4 and PD-1) expressed by activated T cells. These immunosuppressive mechanisms play a role in maintaining tolerance and suppressing inappropriate immune responses, but within the tumor microenvironment, these mechanisms prevent effective anti-tumor immune responses. These immunosuppressive factors can jointly induce significant anergy or apoptosis of adoptively transferred CAR-modified T cells after encountering target tumor cells.

[0437] The unpurified CTL source can be any source known in the art, such as bone marrow, fetus, newborn or adult or other hematopoietic cell sources, such as fetal liver, peripheral blood or umbilical cord blood. Various techniques can be used to separate cells. For example, negative selection can initially remove non-CTL. mAbs are particularly useful for identifying markers associated with specific cell lineages and / or differentiation stages of positive and negative selection.

[0438] Most of the terminally differentiated cells can be removed initially by relatively crude separation. For example, magnetic bead separation can be used initially to remove a large number of irrelevant cells. In certain embodiments, at least about 80%, typically at least 70%, of the total hematopoietic cells will be removed prior to separation of the cells.

[0439] Separation procedures include, but are not limited to, density gradient centrifugation; reconstitution; coupling to particles that alter cell density; magnetic separation using antibody-coated magnetic beads; affinity chromatography; cytotoxic agents conjugated to or used in conjunction with mAbs, including but not limited to complement and cytotoxins; and panning with antibodies attached to a solid matrix (e.g., plates, chips, elutriation) or any other convenient technique.

[0440] Techniques for separation and analysis include, but are not limited to, flow cytometry, which can have varying degrees of sophistication, such as multiple color channels, low-angle and obtuse-angle light scatter detection channels, impedance channels.

[0441] Cells can be selected for dead cells by using a dye associated with dead cells, such as propidium iodide (PI).In certain embodiments, cells are collected in medium containing 2% fetal calf serum (FCS) or 0.2% bovine serum albumin (BSA) or any other suitable, eg, sterile, isotonic medium.

[0442] 4. Carrier

[0443] Genetic modification of immune response cells (e.g., T cells or NK cells) can be accomplished by transducing substantially homogeneous cell compositions with recombinant DNA constructs. In certain embodiments, retroviral vectors (γ-retrovirus or slow virus) are used to introduce DNA constructs into cells. For example, the polynucleotide encoding CAR can be cloned into a retroviral vector, and expression can be driven from its endogenous promoter, retroviral long terminal repeats, or promoters specific to the target cell type of interest. Non-viral vectors can also be used.

[0444] For the initial genetic modification of immune response cells to include CAR, retroviral vectors are generally used for transduction, but any other suitable viral vectors or non-viral delivery systems can be used.CAR can be constructed with auxiliary molecules (such as cytokines) in a single polycistronic expression cassette, multiple expression cassettes of a single vector or multiple vectors.The example of the element producing a polycistronic expression cassette includes but is not limited to various viruses and non-viral internal ribosome entry sites (IRES, for example, FGF-1IRES, FGF-2IRES, VEGF IRES, IGF-II IRES, NF-κB IRES, RUNX1 IRES, p53 IRES, hepatitis A IRES, hepatitis C IRES, pestivirus IRES, no baculovirus IRES, picornavirus IRES, poliovirus IRES and encephalomyocarditis virus IRES) and cleavable joints (such as 2A peptides, such as P2A, T2A, E2A and F2A peptides). In certain embodiments, any vector or CAR disclosed herein may comprise a P2A peptide comprising the amino acid sequence of GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 107). A combination of a retroviral vector and a suitable packaging system is also suitable, wherein the capsid protein will have the function of infecting human cells. Various cell lines that produce amphoteric viruses are known, including but not limited to PA12 (Miller et al., (1985) Mol. Cell. Biol. 5: 431-437); PA317 (Miller et al., (1986) Mol. Cell. Biol. 6: 2895-2902); and CRIP (Danos et al., (1988) Proc. Acad. Sci. USA 85: 6460-6464). Non-amphoteric particles are also suitable, for example, particles with VSVG, RD114 or GALV envelopes and any other pseudotypes known in the art.

[0445] Possible transduction methods also include direct co-cultivation of cells with producer cells, for example by the method of Bregni et al. (1992) Blood 80:1418-1422, or cultivation with viral supernatant alone or concentrated vector stocks with or without appropriate growth factors and polycations, for example by the method of Xu, et al. (1994) Exp. Hemat. 22:223-230; and Hughes, et al. (1992) J. Clin. Invest. 89:1817.

[0446] Other transduction virus vectors can be used to modify immune response cells. In certain embodiments, the selected vectors show high infection efficiency and stable integration and expression (see, e.g., Cayouette et al., Human Gene Therapy 8:423-430, 1997; Kido et al., Current Eye Research 15:833-844, 1996; Bloomer et al., Journal of Virology 71:6641-6649, 1997; Naldini et al., Science 272:263-267, 1996; and Miyoshi et al., Proc. Natl. Acad. Sci. USA 94:10319, 1997). Other viral vectors that can be used include, for example, adenovirus, lentivirus and adeno-associated viral vectors, vaccinia virus, bovine papilloma virus or herpes virus, such as Epstein-Barr virus (see also, for example, Miller, Human Gene Therapy 15-14, 1990; Friedman, Science 244:1275-1281, 1989; Eglitis et al., BioTechniques 6:608-614, 1988; Tolstoshev et al., Current Opinion in Biotechnology 1:55-61, 1990; Sharp, The Lancet 337:1277-1278, 1991; Cornetta et al., Nucleic Acid Research and Molecular Biology 36:311-322, 1987; Anderson, Science 226:401-409, 1984; Moen, Blood Cells 23:411-429, 1985). 17:407-416, 1991; Miller et al., Biotechnology 7:980-990, 1989; LeGal La Salle et al., Science 259:988-990, 1993; and Johnson, Chest 107:77S-83S, 1995). Retroviral vectors are particularly well developed and have been used clinically (Rosenberg et al., N. Engl. J. Med 323:370, 1990; Anderson et al., US Pat. No. 5,399,346).

[0447] Non-viral methods can also be used for genetic modification of immune response cells. For example, nucleic acid molecules can be introduced into immune response cells by administering the nucleic acid in the context of lipofection (Feigner et al., Proc. Natl. Acad. Sci. USA 84:7413, 1987; Ono et al., Neuroscience Letters 17:259, 1990; Brigham et al., Am. J. Med. Sci. 298:278, 1989; Staubinger et al., Methods in Enzymology 101:512, 1983), asialomucoid-polylysine conjugation (Wu et al., Journal of Biological Chemistry 263:14621, 1988; Wu et al., Journal of Biological Chemistry 264:16985, 1989), or microinjection under surgical conditions (Wolff et al., Science 247:1465, 1990). Other non-viral gene transfer methods include in vitro transfection using calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes may also be useful for delivering DNA to cells. It is also possible to complete the transplantation of normal genes into the affected tissue of the subject by transferring normal nucleic acids to a cell type (e.g., autologous or heterologous primary cells or their offspring) that can be cultured in vitro, after which the cells (or their offspring) are injected into the target tissue or injected systemically. Recombinant receptors can also be derived or obtained using transposases or targeted nucleases (e.g., zinc finger nucleases, meganucleases or TALE nucleases, CRISPR). Transient expression can be obtained by RNA electroporation.

[0448] The clustered regularly interspaced short palindromic repeats (CRISPR) system is a genome editing tool found in prokaryotic cells. When used for genome editing, the system includes Cas9 (a protein that is able to modify DNA using crRNA as its guide), CRISPR RNA (crRNA, containing RNA that Cas9 uses to guide it to the correct segment of host DNA, and a region that binds to tracrRNA (usually in the form of a hairpin loop), forming an active complex with Cas9), trans-activating crRNA (tracrRNA, which binds to crRNA and forms an active complex with Cas9), and an optional segment of DNA repair template (DNA that can guide the cell's repair process to allow the insertion of a specific DNA sequence). CRISPR / Cas9 is usually transfected into target cells using a plasmid. The crRNA needs to be designed for each application because this is the sequence that Cas9 uses to recognize and directly bind to the target DNA in the cell. The repair template carrying the CAR expression cassette also needs to be designed for each application because it must overlap with the sequences on both sides of the incision and encode for the insertion sequence. Multiple crRNAs and tracrRNAs can be packaged together to form a single guide RNA (sgRNA). The sgRNA can be linked to the Cas9 gene and made into a plasmid so that it can be transfected into cells.

[0449] Zinc finger nuclease (ZFN) is an artificial restriction enzyme produced by combining a zinc finger DNA binding domain with a DNA cleavage domain. Zinc finger domains can be engineered to target specific DNA sequences, which allows zinc finger nucleases to target desired sequences within the genome. The DNA binding domain of each ZFN typically contains multiple independent zinc finger repeats, and each can recognize multiple base pairs. The most common way to generate new zinc finger domains is to combine smaller zinc finger "modules" of known specificity. The most common cleavage domain in ZFN is the non-specific cleavage domain from the type II restriction endonuclease FokI. Using endogenous homologous recombination (HR) machinery and a homologous DNA template with a CAR expression cassette, ZFN can be used to insert the CAR expression cassette into the genome. After the target sequence is cleaved by the ZFN enzyme, the HR machine searches for homology between the damaged chromosome and the homologous DNA template, and then copies the sequence of the template between the two broken ends of the chromosome, thereby integrating the homologous DNA template into the genome.

[0450] Transcription activator-like effector nucleases (TALENs) are restriction enzymes that can be engineered to cut specific sequences of DNA. The TALEN system works almost identically to ZFNs. They are created by combining a transcription activator-like effector DNA binding domain with a DNA cleavage domain.

[0451] Transcription activator-like effectors (TALEs) consist of 33-34 amino acid repeating motifs with two variable positions that have strong recognition for specific nucleotides. By assembling arrays of these TALEs, the TALE DNA binding domain can be modified to bind to the desired DNA sequence, thereby directing the nuclease to cut a specific position in the genome. The cDNA expression for polynucleotide therapy can be directed from any suitable promoter (e.g., human cytomegalovirus (CMV), simian virus 40 (SV40), or metallothionein promoter) and regulated by any appropriate mammalian regulatory element or intron (e.g., elongation factor 1a enhancer / promoter / intron structure). For example, if necessary, enhancers known to preferentially direct gene expression in a specific cell type can be used to direct the expression of nucleic acids. The enhancers used may include, but are not limited to, those characterized as tissue or cell-specific enhancers. Alternatively, if a genomic clone is used as a therapeutic construct, regulation may be mediated by a homologous regulatory sequence or, if necessary, by a heterologous regulatory sequence derived from any of the above-mentioned promoters or regulatory elements.

[0452] The resulting cells can be grown under conditions similar to unmodified cells, and thus the modified cells can be expanded and used for a variety of purposes.

[0453] 5. Genome Editing Methods

[0454] Any targeted genome editing method can be used to place the CAR of the present disclosure in one or more endogenous gene sites of immune response cells of the present disclosure. In certain embodiments, the CRISPR system is used to deliver the CAR of the present disclosure to one or more endogenous gene sites of immune response cells of the present disclosure. In certain embodiments, zinc finger nucleases are used to deliver the CAR of the present disclosure to one or more endogenous gene sites of immune response cells of the present disclosure. In certain embodiments, the TALEN system is used to deliver the CAR of the present disclosure to one or more endogenous gene sites of immune response cells of the present disclosure.

[0455] The method for delivering genome editing agents / systems can be varied as needed. In some embodiments, the components of the selected genome editing method are delivered as DNA constructs in one or more plasmids. In some embodiments, components are delivered by viral vectors. Common delivery methods include but are not limited to electroporation, microinjection, gene guns, puncture (impalefection), hydrostatic pressure, continuous infusion, ultrasonic treatment, magnetic transfection, adeno-associated viruses, envelope protein pseudotypes of viral vectors, replicable vector cis and trans elements, herpes simplex viruses and chemical media (e.g., oligonucleotides, lipid complexes, polymer bodies, polycomplexes, dendrimers, inorganic nanoparticles and peptides that penetrate cells).

[0456] The CAR of the present disclosure can be placed at any endogenous locus. In certain embodiments, the endogenous gene locus is a TRAC locus, a TRBC locus, or a TRGC locus. In certain embodiments, the endogenous locus is a TRAC locus. In certain embodiments, the placement of the CAR destroys or eliminates the endogenous expression of the TCR.

[0457] 6. Peptides and analogs

[0458] When expressed in immune response cells, CD19, CD8, CD28, CD3ζ, CD40, 4-1BB, OX40, CD84, CD166, CD8a, CD8b, ICOS, ICAM-1, CD27, MY88, NKGD2 and CTLA-4 polypeptides or fragments thereof modified in a manner that enhances their anti-tumor activity are also included in the subject matter of the present disclosure. The subject matter of the present disclosure provides a method for optimizing an amino acid sequence or a nucleic acid sequence by producing a sequence change. Such changes may include certain mutations, deletions, insertions or post-translational modifications. The subject matter of the present disclosure also includes analogs of any naturally occurring polypeptide disclosed herein (including but not limited to CD19, CD8, CD28, CD3ζ, CD40, 4-1BB, OX40, CD27, CD40 / My88, NKGD2, CD84, CD166, CD8a, CD8b, ICOS, ICAM-1 and CTLA-4). Analogs may differ from naturally occurring polypeptides disclosed herein by amino acid sequence differences, by post-translational modifications or by both. Analogs may exhibit at least about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more homology to all or part of a naturally occurring amino acid sequence of the disclosed subject matter. The length of the sequence differences is at least 5, 10, 15 or 20 amino acid residues, such as at least 25, 50 or 75 amino acid residues, or more than 100 amino acid residues. Likewise, in an exemplary method of determining the degree of identity, the BLAST program may be used, with a probability score in the range of e -3 and e -100, indicating closely related sequences. Modifications include in vivo and in vitro chemical derivatization of polypeptides, such as acetylation, carboxylation, phosphorylation or glycosylation; such modifications may occur during polypeptide synthesis or processing or after treatment with a separate modifying enzyme. Analogs may also differ from naturally occurring polypeptides by changes in the native sequence. These include natural and induced genetic variations (e.g., as described in Sambrook, Fritsch and Maniatis, "Molecular Cloning: A Laboratory Manual" (2nd Edition), CSH Press, 1989, or Ausubel et al., supra, due to random mutagenesis by radiation or exposure to ethane methylsulfate or by site-specific mutagenesis). Also included are cyclized peptides, molecules and analogs containing residues other than L-amino acids, such as D-amino acids or non-naturally occurring or synthetic amino acids, such as β or γ amino acids.

[0459] In addition to full-length polypeptides, the disclosed subject matter also provides fragments of any polypeptide or peptide domain disclosed herein. As used herein, the term "fragment" refers to at least 5, 10, 13 or 15 amino acids. In some embodiments, the fragment comprises at least 20 continuous amino acids, at least 30 continuous amino acids or at least 50 continuous amino acids. In some embodiments, the fragment comprises at least 60 to 80, 100, 200, 300 or more continuous amino acids. The fragment can be produced by methods known to those skilled in the art, or can be produced by normal protein processing (for example, removing amino acids that are not needed for biological activity from nascent polypeptides, or removing amino acids by alternative mRNA splicing or alternative protein processing events)).

[0460] Non-protein analogs have a chemical structure designed to mimic the functional activity of the proteins disclosed herein. Such analogs may exceed the physiological activity of the original polypeptide. The method of analog design is well known in the art, and the synthesis of analogs can be carried out by modifying the chemical structure according to such a method so that the resulting analogs increase the anti-tumor activity of the original polypeptide when expressed in immune response cells. These chemical modifications include but are not limited to replacing the R group of the substitution and changing the saturation at the specific carbon atom of the reference polypeptide. In some embodiments, protein analogs are relatively resistant to degradation in vivo, thereby resulting in a longer therapeutic effect after administration. The assays for measuring functional activity include but are not limited to those described in the following examples.

[0461] 7. Drug Administration

[0462] The composition comprising the immune response cells of the present disclosure can be provided to the subject systematically or directly to induce and / or enhance the immune response to the antigen and / or treat and / or prevent tumors, pathogen infection or infectious diseases. In certain embodiments, the immune response cells of the present disclosure or the composition comprising it are directly injected into the organ of interest (e.g., an organ affected by neoplasia). Alternatively, the immune response cells of the present disclosure or the composition comprising it are indirectly provided to the organ of interest, such as by administration to the circulatory system (e.g., tumor vasculature). Amplification and differentiation agents can be provided before, during or after the administration of cells or compositions to increase the production of T cells, NK cells or CTL cells in vitro or in vivo.

[0463] The immune response cells of the present disclosure may be administered intravascularly in any physiologically acceptable carrier, however they may also be introduced into the bone or other convenient site where the cells can find a suitable site for regeneration and differentiation (e.g., the thymus). Typically, at least about 1×10 5 cells, eventually reaching about 1×10 10 More than one or more. The immune response cells of the present disclosure may include purified cell populations. Those skilled in the art may use various well-known methods, such as fluorescence activated cell sorting (FACS), to easily determine the percentage of immune response cells of the present disclosure in a population. In a population comprising immune response cells of the present disclosure, the suitable range of purity is about 50% to about 55%, about 5% to about 60%, and about 65% to about 70%. In certain embodiments, the purity is about 70% to about 75%, about 75% to about 80%, or about 80% to about 85%. In certain embodiments, the purity is about 85% to about 90%, about 90% to about 95%, and about 95% to about 100%. Dosage can be easily adjusted by those skilled in the art (for example, purity reduction may require increased dosage). Cells may be introduced by injection, catheter, etc.

[0464] Compositions of the present disclosure can be pharmaceutical compositions comprising immune response cells of the present disclosure or their progenitor cells and a pharmaceutically acceptable carrier. Administration can be autologous or allogenic. For example, immune response cells or progenitor cells can be obtained from a subject and applied to the same subject or different compatible subjects. Immune response cells or their progenitor cells derived from peripheral blood (for example, in vivo, ex vivo or in vitro sources) can be applied by local injection, including catheter administration, systemic injection, local injection, intravenous injection or parenteral administration. When the therapeutic composition of the subject of the present disclosure (for example, a pharmaceutical composition comprising immune response cells of the present disclosure) is applied, it can be formulated into a unit dose injectable form (solution, suspension, emulsion).

[0465] 8. Dosage form

[0466] Compositions comprising immune response cells of the present disclosure can be conveniently provided in the form of sterile liquid preparations, such as isotonic aqueous solutions, suspensions, emulsions, dispersants or viscous compositions, which can be buffered to selected pH. Liquid preparations are generally easier to prepare than gels, other viscous compositions and solid compositions. In addition, liquid compositions are more convenient to use to a certain extent, especially by injection. On the other hand, viscous compositions can be prepared within a suitable viscosity range to provide a longer contact time with a particular tissue. Liquid or viscous compositions can include a carrier, which can be a solvent or a dispersion medium, which includes, for example, water, saline, phosphate buffered saline, polyols (such as glycerol, propylene glycol, liquid polyethylene glycol, etc.) and suitable mixtures thereof.

[0467] Can be by genetically modified immune response cell is mixed in the suitable solvent of required amount, and mix other components of different amount as required to prepare sterile injection solution.Such composition can be mixed with suitable carrier, diluent or excipient such as sterile water, saline, glucose, dextrose etc.Composition can also be lyophilized.Described composition can include auxiliary substance, such as wetting agent, dispersant or emulsifier (for example, methylcellulose), pH buffer, gelling agent or tackifier, preservative, flavoring agent, pigment etc., this depends on route of administration and required preparation.Can refer to standard text, such as " REMINGTON ' S PHARMACEUTICAL SCIENCE ", the 17th edition in 1985, is incorporated herein by reference, to prepare suitable preparation, without too much experiment.

[0468] Various additives that enhance the stability and sterility of the composition can be added, including antimicrobial preservatives, antioxidants, chelating agents and buffers. Various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc., can be used to ensure that the effects of microorganisms are prevented. The absorption of the injectable drug form can be extended by using reagents that delay absorption, such as aluminum monostearate and gelatin. However, according to the subject matter of the present disclosure, any vehicle, diluent or additive used must be compatible with the immune response cells or their progenitor cells of genetic modification.

[0469] The compositions may be isotonic, i.e., they may have the same osmotic pressure as blood and tears. The desired isotonicity of the composition may be achieved using sodium chloride or other pharmaceutically acceptable agents such as glucose, boric acid, sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride may be particularly suitable for use as a buffer containing sodium ions.

[0470] If necessary, pharmaceutically acceptable thickening agents can be used to maintain the viscosity of the composition at a selected level. For example, methylcellulose is easily and economically available and easy to use. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, etc. The concentration of the thickening agent can depend on the reagent selected. It is important to use an amount that can reach the selected viscosity. Obviously, the selection of suitable carriers and other additives will depend on the property of definite route of administration and specific dosage form, such as liquid dosage form (for example, whether the composition is formulated into solution, suspension, gel or other liquid form, such as timed release form or liquid filled form).

[0471] The number of cells to be administered will vary depending on the subject being treated. In one embodiment, about 10 immune response cells of the present disclosure are administered to a human subject. 4 to about 10 10 Between, about 10 5 to about 10 9 Between or about 10 6 to about 10 8 More effective cells may be administered in smaller quantities. In certain embodiments, the immune response cells of the present disclosure administered to a human subject are at least about 1×10 8 , about 2×10 8 , about 3×10 8 , about 4×10 8 or about 5×10 8 In certain embodiments, about 1×10 7 Up to 5×10 8 The immune response cells of the present disclosure are administered to human subjects. The precise determination of the effective dose can be determined based on individual factors of each subject, including their size, age, sex, weight and the condition of the specific subject. Those skilled in the art can easily determine the dosage from this disclosure and knowledge in the art.

[0472] Those skilled in the art can easily determine the amount of cells and optional additives, vehicles and / or carriers used in the composition and in the method. Typically, any additive (except one or more active cells and / or one or more agents) is present in phosphate buffered saline in an amount of 0.001% to 50% (weight) solution, and the active ingredient is present in the order of micrograms to milligrams, such as about 0.0001wt% to about 5wt%, about 0.0001wt% to about 1wt%, about 0.0001wt% to about 0.05wt% or about 0.001wt% to about 20wt%, about 0.01wt% to about 10wt% or about 0.05wt% to about 5wt%. For any composition to be applied to an animal or human, the following results can be determined: toxicity, for example, by determining the lethal dose (LD) and LD50 in a suitable animal model, such as a rodent such as a mouse; the dose of the composition, the concentration of the components therein and the time of applying the composition, causing a suitable response. According to the knowledge of the technician, the disclosure and the literature cited herein, this determination does not require excessive experiments. Furthermore, the duration of continuous administration can be determined without undue experimentation.

[0473] 9. Treatment Methods

[0474] The subject matter of the present disclosure provides a method for inducing and / or increasing an immune response in a subject in need thereof. The immune response cells disclosed herein and compositions comprising them can be used to treat and / or prevent tumors in subjects. The immune response cells disclosed herein and compositions comprising them can be used to prolong the survival of subjects with tumors. The immune response cells disclosed herein and compositions comprising them can also be used to treat and / or prevent pathogen infection or other infectious diseases in human subjects such as immunocompromised subjects. In certain embodiments, immune response cells comprising CAR disclosed herein can be used to treat subjects with recurrent disease, wherein the subject has received treatment resulting in residual tumor cells. In certain embodiments, the residual tumor cells have a low density of target molecules on the surface of tumor cells. In certain embodiments, the target molecule with low density on the cell surface has less than about 10,000 molecules per cell, less than about 8,000 molecules per cell, less than about 6,000 molecules per cell, less than about 4,000 molecules per cell, less than about 2,000 molecules per cell, less than about 1,000 molecules per cell, less than about 500 molecules per cell, less than about 200 molecules per cell, or less than about 100 molecules per cell. In certain embodiments, the target molecule with low density on the cell surface has about 4,000 to about 2,000 molecules per cell or about 2,000 to about 1,000 molecules per cell. In certain embodiments, the immune response cell comprising a CAR disclosed herein can be used to treat a subject with a recurrence of the disease, wherein the subject has received an immune response cell (e.g., T cell) comprising a CAR, the CAR comprising an intracellular signaling domain comprising a co-stimulatory signaling domain (e.g., 4-1BBz CAR) containing a 4-1BB polypeptide. In certain embodiments, the tumor cells have a low density of tumor-specific antigens on the tumor cell surface. In certain embodiments, the disease is CD19 + ALL. In certain embodiments, the tumor cells have a low density of CD19 on the tumor cells. Such methods include administering an effective amount of the immune response cells of the present disclosure or a composition (e.g., a pharmaceutical composition) comprising the same to achieve the desired effect, alleviate an existing condition, or prevent recurrence. For treatment, the amount administered is an amount effective to produce the desired effect. The effective amount may be provided in one or more administrations. The effective amount may be provided in large doses or by continuous infusion.

[0475] An "effective amount" (or "therapeutically effective amount") is an amount sufficient to produce a beneficial or desired clinical outcome following treatment. The effective amount may be administered to a subject in one or more doses. For treatment, an effective amount is an amount sufficient to alleviate, improve, stabilize, reverse or slow the progression of a disease or otherwise reduce the pathological consequences of the disease. The effective amount is typically determined by a physician based on the specific circumstances and is within the capabilities of those skilled in the art. When determining an appropriate dosage to achieve an effective amount, several factors are typically considered. These factors include the age, sex, and weight of the subject, the disease being treated, the severity of the disease, and the form and effective concentration of the immune response cells being administered.

[0476] For adoptive immunotherapy using antigen-specific T cells, approximately 10 6 -10 10 (e.g. about 10 9 ) range. After the cells of the present disclosure are administered to a host and subsequently differentiated, T cells specific for a particular antigen are induced. The immune response cells can be administered by any method known in the art, including but not limited to intravenous, subcutaneous, intranodal, intratumoral, intrathecal, intrapleural, intraperitoneal, and direct administration to the thymus.

[0477] The subject matter of the present disclosure provides a method for treating and / or preventing a tumor in a subject. The method may include administering an effective amount of the immune response cells of the present disclosure or a composition comprising the same to a subject having a tumor.

[0478] Non-limiting examples of neoplasia include blood cancers (e.g., leukemias, lymphomas, and myelomas), ovarian cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, laryngeal cancer, melanoma, neuroblastoma, adenocarcinoma, glioma, soft tissue sarcomas, and various carcinomas (including prostate cancer and small cell lung cancer). Suitable cancers also include any cancer known in the art of oncology, including, but not limited to, astrocytomas, fibrosarcomas, myxosarcoma, liposarcoma, oligodendroglioma, ependymomas, medulloblastomas, primitive neuroectodermal tumors (PNET), chondrosarcomas, osteogenic sarcomas, pancreatic ductal adenocarcinomas, small cell and large cell lung adenocarcinomas, chordomas, angiosarcomas, endotheliosarcomas, squamous cell carcinomas, bronchoalveolar carcinomas, epithelial adenocarcinomas and their liver metastases, lymphangiosarcomas, lymphangioendotheliosarcomas, hepatocarcinomas, bile duct carcinomas, synovioma, mesothelioma, Ewing's tumor, rhabdomyosarcoma, colon carcinoma, basal cell carcinoma, sweat gland carcinoma, papillary carcinoma, sebaceous gland carcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, ulcerative colitis ... ductal carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, testicular tumors, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, leukemia, multiple myeloma, Waldenstrom's macroglobulinemia and heavy chain disease, breast tumors such as ductal and lobular adenocarcinoma, squamous and adenocarcinoma of the cervix, epithelial carcinoma of the uterus and ovary, adenocarcinoma of the prostate, transitional squamous cell carcinoma of the bladder, B and T cell lymphomas (nodular and diffuse) plasmacytomas, acute and chronic leukemias, malignant melanoma, soft tissue sarcomas and leiomyosarcomas. In certain embodiments, the neoplasia is selected from blood cancer (e.g., leukemia, lymphoma, and myeloma), ovarian cancer, prostate cancer, breast cancer, bladder cancer, brain cancer, colon cancer, intestinal cancer, liver cancer, lung cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, glioblastoma, and laryngeal cancer. In certain embodiments, the immune response cells of the present disclosure and compositions comprising the same can be used to treat and / or prevent blood cancer (e.g., leukemia, lymphoma, and myeloma) or ovarian cancer for which conventional therapeutic measures are not suitable.

[0479] The subject may have an advanced form of the disease, in which case the goal of treatment may include slowing or reversing disease progression and / or alleviating side effects. The subject may have a history of disease for which treatment has already been performed, in which case the goal of treatment typically includes reducing or delaying the risk of relapse.

[0480] Suitable human subjects for treatment generally include two treatment groups that can be distinguished by clinical criteria. Subjects suffering from "advanced disease" or "high tumor burden" are subjects carrying clinically measurable tumors. A clinically measurable tumor is a tumor that can be detected based on the tumor mass (e.g., by palpation, CAT scan, ultrasonography, mammogram or X-ray; positive biochemical or histopathological markers alone are not enough to identify the population). Pharmaceutical compositions are administered to these subjects to induce an anti-tumor response to alleviate their condition. Ideally, the result is a reduction in tumor mass, but any clinical improvement can bring benefits. Clinical improvement includes reducing risk or progression rate or reducing tumor pathological consequences.

[0481] The second group of suitable subjects is referred to in the art as the "adjuvant group". These are individuals with a history of neoplasia but who have responded to another treatment modality. Previous therapies may include, but are not limited to, surgical resection, radiation therapy, and traditional chemotherapy. As a result, these individuals do not have clinically measurable tumors. However, they are suspected of being at risk for disease progression near the primary tumor site or metastasis. This group can be further divided into high-risk and low-risk individuals. The subdivisions are based on features observed before or after initial treatment. These features are known in the clinical field and are appropriately defined for each different tumor. The typical characteristics of the high-risk subgroup are tumor invasion of adjacent tissues or lymph node involvement.

[0482] Another group has a genetic predisposition to tumors but has not yet demonstrated clinical signs of tumors. For example, a woman who tests positive for a genetic mutation associated with breast cancer but is still of childbearing age may wish to receive prophylactic treatment with one or more of the immune response cells described herein to prevent the development of tumors until preventive surgery is appropriate.

[0483] In addition, the subject matter of the present disclosure provides a method for treating and / or preventing pathogen infection (e.g., viral infection, bacterial infection, fungal infection, parasitic infection, or protozoan infection) in, for example, an immunocompromised subject. The method may include administering an effective amount of an immune response cell of the present disclosure or a composition comprising the same to a subject suffering from a pathogen infection. Exemplary viral infections that are susceptible to treatment include, but are not limited to, cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and influenza virus infection.

[0484] The immune response cells (e.g., T cells) of the present disclosure may be further modified to avoid or minimize immune complications (referred to as "malignant T cell transformation"), such as graft-versus-host disease (GvHD), or when healthy tissues express the same target antigen as tumor cells, the risk of a result similar to GvHD may result. A potential solution to this problem is to engineer suicide genes into immune response cells of the present disclosure. Suitable suicide genes include, but are not limited to, herpes simplex virus thymidine kinase (hsv-tk), inducible Caspase 9 suicide gene (iCasp-9), and truncated human epidermal growth factor receptor (EGFRt) polypeptides. In certain embodiments, the suicide gene is an EGFRt polypeptide. The EGFRt polypeptide can eliminate T cells by administering an anti-EGFR monoclonal antibody (e.g., cetuximab). EGFRt may be covalently linked to the upstream of the CAR of the present disclosure. The suicide gene may be contained in a vector comprising a nucleic acid encoding the CAR of the present disclosure. In this way, administration of a prodrug designed to activate a suicide gene (e.g., a prodrug (e.g., AP1903 that can activate iCasp-9)) during malignant T cell transformation (e.g., GVHD) can trigger apoptosis of CAR-expressing T cells activated by the suicide gene. Incorporating a suicide gene into the CAR of the present disclosure can improve safety and enable elimination of most CAR T cells in a very short period of time. Immune response cells (e.g., T cells) of the present disclosure that incorporate a suicide gene can be preemptively eliminated at a given time point after CAR T cell infusion, or eliminated at the earliest sign of toxicity.

[0485] 10. Test kit

[0486] The subject matter of the present disclosure provides a kit for inducing and / or enhancing an immune response and / or treating and / or preventing a tumor or pathogen infection in a subject. In certain embodiments, the kit comprises an effective amount of immune response cells of the present disclosure or a pharmaceutical composition comprising the same. In certain embodiments, the kit comprises a sterile container; such a container may be a box, an ampoule, a bottle, a vial, a tube, a bag, a pouch, a blister pack, or other suitable container forms known in the art. Such a container may be made of plastic, glass, laminated paper, metal foil, or other materials suitable for containing drugs. In certain non-limiting embodiments, the kit comprises an isolated nucleic acid molecule encoding a CAR of the present disclosure, which is directed to a target antigen in an expressible form and may be optionally contained in one or more vectors.

[0487] If desired, the immune response cells and / or nucleic acid molecules are provided together with instructions for administering the cells or nucleic acid molecules to a subject having a neoplasia or pathogen or immune disease or at risk of developing a neoplasia or pathogen or immune disease. The instructions typically include information about the use of the composition for treating and / or preventing a tumor or pathogen infection. In certain embodiments, the instructions include at least one of the following: a description of the therapeutic agent; a dosage table and administration for treating or preventing a neoplasia, pathogen infection or immune disease or symptoms thereof; precautions; warnings; indications; contraindications; medication information; adverse reactions; animal pharmacology; clinical studies; and / or references. These instructions can be printed directly on the container (if any), or as a label affixed to the container, or provided in or with the container as a separate sheet, brochure, card or folder.

[0488] Example

[0489] Unless otherwise indicated, the practice of the present disclosure employs conventional techniques of molecular biology, microbiology, cell biology, biochemistry and immunology (including recombinant techniques), which are within the capabilities of the skilled person. These techniques are fully explained in such books as "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook, 1989); "Oligonucleotide Synthesis" (Gait, 1984); "Animal Cell Culture" (Freshney, 1987); "Enzymatic Methods" "Handbook of Experimental Immunology" (Weir, 1996); "Gene Transfer Vectors for Mammalian Cells" (Miller and Calos, 1987); "Current Methods in Molecular Biology" (Ausubel, 1987); "PCR: Polymerase Chain Reaction", (Mullis, 1994); "Current Methods in Immunology" (Coligan, 1991). These techniques are applicable to the production of polynucleotides and polypeptides disclosed herein, and therefore can be considered in the preparation and implementation of the subject matter of the present disclosure. Particularly useful techniques for specific embodiments will be discussed in the following sections.

[0490] The following examples are put forth to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the cells and compositions of the present disclosure and are not intended to limit the scope of what the inventors regard as their invention.

[0491] Example 1

[0492] Introduction

[0493] It has been proposed that multiple ITAMs in the CD3ζ and TCR complex amplify TCR signals (PMID: 20516133). At the same time, CD28 provides quantitative support for TCR signaling (PMID: 14647476). Therefore, the number and type of signaling domains are important in TCR signaling. In human T cells, CD28 and TCR / CD3ζ are expressed at ~6×10 per cell. 4 and ~2×10 4 The 1928z CAR is a CAR that is expressed by three molecules (PMID: 14647476). Therefore, three molecules of CD28 can provide signal transduction support for one molecule of TCR / CD3ζ with three ITAMs. However, the second-generation CAR 1928z has a design with fused CD28 and CD3ζ cytoplasmic domains (fixing their stoichiometric ratio to 1). The 1928z CAR, which has excellent killing and proliferation capabilities, can quickly eliminate cells with CD19 in vitro, in mouse models, and in patients. However, in order to overcome certain problems in clinical trials, it is necessary to improve the current 1928zCAR. One problem is cytokine release syndrome (CRS), which is characterized by a large number of synchronized T cell activation and the release of a large number of cytokines. Although the mechanism of CRS remains elusive, it may be related to excessive signal transduction of 1928z CAR T cells. Another problem is the exhaustion and persistence of CAR T cells. Weeks or months after infusion, 1928zCAR T cells were found to be present in small numbers and / or in a dysfunctional state expressing exhaustion markers (e.g., PD-1), which may account for some relapses. Exhaustion is hypothesized to be associated with overactivation (PMID: 26331345), which may be due to properties inherent to the design of the 1928z CAR.

[0494] Comparing 1928z CAR signaling to TCR signaling, some major differences due to the fusion of two cytoplasmic domains are apparent. First, in the CAR, the CD28 signaling domain is arranged in cis with the CD3ζ signaling domain, while CD28 is recruited to the synapse and co-localizes with CD3ζ in trans. Second, CD28 activation occurs simultaneously with CD3ζ activation in the CAR, while CD28 co-stimulation is seconds after TCR ligation. Third, three CD28 molecules assist one TCR, while the ratio in the CAR is one to one. The first two differences are not easily modified under the current CAR design, but the third difference can be addressed by balancing the co-stimulatory and activation signals, which may help address existing overstimulation issues. Due to the fusion design, the CD28 / CD3ζ ratio cannot be directly changed, but the number of ITAMs in CD3ζ can be mutated to mimic the ratio in TCR signaling. The three ITAMs in CD3ζ differ in their primary amino acid sequence and their position relative to the plasma membrane (i.e., ITAM1, ITAM2, ITAM3 from proximal to distal), and therefore differ in their ability to be phosphorylated by Lck or to bind to ZAP70 after phosphorylation (PMID: 23555234). Previous studies on ErbB2 CARs based on CD28 with only one ITAM in the second position showed reduced apoptosis in vitro (PMID: 19843940), but further CAR characterization and in vivo studies were still lacking. Therefore, a new CAR based on the 1928z CAR design was designed, which introduced a limited number and position of ITAMs to evaluate its function, especially with respect to the above-mentioned issues, including its impact on T cell persistence, differentiation, exhaustion, and anti-tumor activity. It was analyzed how each ITAM coupled to CD28 signaling in the context of the 1928zCAR affects overall CAR function in vitro and in vivo. ITAM1 coupled to CD28 is not only better than ITAM2 or ITAM3 coupled to CD28, but more importantly also better than the original 1928z CAR in terms of in vivo anti-tumor efficacy, making it an ideal candidate for clinical application. All studies were performed in human peripheral blood T cells.

[0495] result

[0496] The 3ζITAM domain in the 1928ζCAR exerts qualitatively different CAR T cell functions

[0497] The first step was to explore whether each CD3ζ ITAM in the second generation 1928z-CAR construct contributed to a qualitatively unique function or whether the individual ITAMs displayed overlapping and functionally redundant properties. To assess the contribution of each individual ITAM to 1928zCAR function, 1928z CARs with only a single functional ITAM domain were generated (1XX, X2X, and XX3, see Figure 1A ). Signaling of the remaining two ITAMs was interrupted by the insertion of a point mutation that converted two tyrosines (Y) to phenylalanines (F), thereby abrogating phosphorylation and subsequent recruitment of ZAP70 for full activation of downstream signaling pathways. T cells were efficiently transduced using the SFG retroviral vector, with comparable transduction rates between the different constructs ( Figure 1B ).

[0498] To compare the therapeutic potential of the generated 1928z mutant, a suboptimal CAR T cell dose of 5 × 10 4 CAR + T cells and compared the efficacy with that of treatment with 1928z wild-type (1928z WT) mice ( Figure 2 ).

[0499] We found progressive differences in tumor eradication and survival of mice related to the relevant functional ITAMs: unmodified ITAM1 (1XX) or ITAM2 (X2X) in their original 1928z CAR position showed improved anti-tumor activity compared to the 3 functional ITAMs in the original 1928z wild type (WT). In contrast, ITAM3 performed poorly as the only functional ITAM (XX3) in combination with dysfunctional ITAMs 1 and 2, with reduced tumor eradication and decreased survival of mice (Figure 3).

[0500] Thus, while maintaining the original position in the 1928z structure of the second generation, the individual ITAMs in the 1928z CAR exert qualitatively different functions. As the distal position of each functional ITAM increases, the efficacy of tumor elimination gradually decreases: 1XX consistently shows rapid tumor eradication and achieves long-term complete remission, while treatment with X2X delays tumor progression, superior to 1928zWT, but ultimately relapses. The unmutated (natural) ITAM of XX3 is located at the most distal end and cannot achieve tumor control, resulting in rapid tumor progression and reduced survival (Figure 3). In summary, 1928z CARs with 1 or 2 ITAMs at the second or third ITAM positions (XX3, X2X, X23) have low activity or no therapeutic activity relative to the 1928z wild type (in vivo).

[0501] A single functional CD3ζ ITAM in the correct location is sufficient for potent antitumor activity

[0502] The next problem to be solved was the combination of two functional ITAMs at the distal position, ITAM2 and ITAM3 (X23, Figure 1A ) (assuming that they have lower affinity for ZAP70 than ITAM1) could collectively improve the efficacy of their related single ITAM 1928ζ mutants (X2X / XX3). In vivo analysis showed that mice treated with X23 had poor tumor clearance and survival, comparable to the results of mice treated with XX3 (Figures 2 and 3). In contrast, 1928z mutant CARs with only a single functional ITAM at the first (1XX) or second (X2X) position outperformed 1928z CARs with two (X23) or three (WT) functional ITAMs, as reflected in the progression of tumor burden and survival. 1XX consistently proved to be the most potent 1928z mutant, capable of rapid and durable tumor eradication even at very low therapeutic doses. Thus, the results suggest that a single ITAM is sufficient for effective killing, but also show significant differences in the therapeutic capacity of CAR T cells depending on which ITAM in CD3ζ is functional.

[0503] Next, it was analyzed whether the reduced CAR function in XX3 was attributed to the individual specificity of ITAM3 or was related to the more distal position of ITAM3 compared to its natural position in the context of the second-generation CAR. Therefore, a 1928z mutant CAR with ITAM1 or ITAM3 with exactly the same proximal CAR position (D12 and D23) was constructed, and the remaining CD3ζ chain was deleted, so that the two ITAMs could be directly compared in the context of 1928-CAR (Figure 1). The results showed that ITAM3 (D12) in a more proximal position was sufficient for rapid and effective long-term tumor clearance (Figures 2 and 3), showing results comparable to D23. Despite sharing the same ITAM (ITAM3), D12 clearly outperformed XX3 and achieved effective anti-tumor efficacy. Therefore, the significant difference in therapeutic efficacy between D12 and XX3 demonstrated the influence of ITAM position in the second-generation CAR. In conclusion, 1928z CARs with a single ITAM at the first ITAM position (ITAM1 in 1XX and D23 or ITAM3 in D12) were more therapeutically active (in vivo) than the 1928z wild type.

[0504] Although D23 and 1XX share ITAM1 as the only functional ITAM, 1XX displayed improved functional properties compared with D23, leading to higher T cell proliferation and favorable T cell phenotypes ( Figure 4and 5). This supports the possibility that the basic-rich stretch (BRS) within the CD3ζ chain (which has previously been shown to mediate membrane association and regulate signaling) may contribute to the functional properties of the 1928z CAR ( Figure 1B ).

[0505] Therefore, additional mutations were inserted into the 1XX CAR construct, disrupting BRS-2 and -3 (= 1XX BRS 阴性 The results show that the BRS region is essential for the function of 1XX, because the 1XX BRS 阴性 We thus demonstrated the functional importance of the BRS region in 1XX by showing reduced proliferation and killing functions both in vitro and in vivo.

[0506] CD3ζ ITAM mutations allow enhanced T cell proliferation and limit T cell differentiation and exhaustion in the 1928ζCAR

[0507] In vivo studies showed enhanced CAR T cell accumulation for all CAR groups with one functional ITAM and two mutated ITAM regions: after 17 days, the number of cells of XX3, X2X, and 1XX was significantly higher in the tumor site compared with 1928ζWT ( Figure 4 ). T cells expressing mutant 1928z CARs containing a single ITAM (XX3, X2X, 1XX) accumulated at higher levels in vivo than T cells expressing wild-type 28z CARs. CARs containing 2 or more ITAMs (1928z and X23) showed reduced accumulation relative to T cells expressing a single ITAM CAR (XX3, X2X, 1XX, D23, and D12).

[0508] Higher T cell accumulation was associated with less T cell differentiation, as shown in CD4 + and CD8 + Central memory in CAR T cells (CD62L+CD45RA-) CM ) and effector (CD62L-CD45RA+) (T EFF ) cells: 1XX showed significantly higher T CM (T cell phenotype associated with improved in vivo proliferative potential) percentages—as well as significantly lower terminally differentiated T EFF In addition, on day 17 after CAR infusion, 1XX T cells were expressed in the bone marrow of treated mice. CM In addition, from day 10 to day 17 after CAR administration, both T cell populations showed significant increases ( Figure 6). Overall, 1XX elicited the largest proportion of memory T cells, while D23 ranked second in long-term in vitro assays. Delayed differentiation and increased IL7R-expressing CAR T cells were also observed in vitro after repeated exposure to antigen (data not shown).

[0509] Furthermore, the 1928z mutants differed in the extent of T cell exhaustion, as determined by co-expression of inhibitory molecules PD1, TIM3, and LAG3, which are associated with reduced antitumor activity. The group of 1928z mutants with a single functional ITAM and two other ITAM deletions (D12 and D23) showed significantly lower expression of exhaustion markers ( Figure 7 ).

[0510] XX3 has more CAR at the tumor site than 1928z WT ( Figure 4 ) and showed high T CM percentage, but these cells were unable to prevent tumor progression. XX3-treated mice showed an initial treatment response but relapsed a short time later. In vitro functional analysis showed that XX3 had reduced killing activity and reduced secretion of Th1 cytokines and granzyme B (GrB) (Figures 8 and 9). Figure 8 shows that in a standard in vitro cytotoxicity assay, all CARs lysed tumor cells similarly, with the exception of XX3, which had reduced cytolytic activity. Although all constructs showed similar and potent cytotoxic activity after initial T cell transduction, differences emerged after CAR expansion with repeated Ag exposure (Figure 8). Figure 9 shows that standard in vitro cytokine assays do not correlate with in vivo functional properties, but 1XX and D23 show good characteristics (IL2 and anti-tumor cytokines such as IFNg and TNFa)

[0511] These findings suggest an uncoupling of effector and proliferative functions in XX3 and indicate that the expansion and persistence of CAR T cells are insufficient for effective tumor eradication. In contrast, 1928z WT exerted high cytotoxic activity but differentiated early into effector cells and increased upregulation of inhibitory molecules, which led to the exhaustion and reduced persistence of 1928z CAR.

[0512] in conclusion

[0513] In the second generation 1928z CAR, due to the combination of CD3ζ activation and CD28 co-stimulation, functional redundancy and enhanced signaling may lead to early T cell differentiation and exhaustion, thereby reducing antitumor activity. Therefore, the contribution of a single ITAM to CAR function was analyzed. Differences in the position, affinity, and number of ITAMs in the CD3ζ chain affect the functional properties of 1928z CAR T cells. Overall, 1928z CARs containing a single ITAM can guide excellent T cell accumulation, memory formation, and reduced exhaustion ( Figure 4-7), but a single ITAM must be placed in the first position to provide the highest therapeutic (anti-tumor) activity (Figure 2-3). 1XX includes the most favorable characteristics of both effector cells and memory cells, thereby balancing activation and differentiation. 1XX regulates the strong activation of combined CD3ζ signaling and CD28 co-stimulation and fine-tunes the intensity to the appropriate intracellular signal, thereby regulating CAR-mediated signaling, resulting in long-term superior tumor eradication.

[0514] Example 2: Alternative hinge / spacer and transmembrane domains of CAR

[0515] Alternative hinge / spacer regions and transmembrane domains were tested in the CAR constructs. Schematic diagram of 1XX CARs with different hinge (H) and transmembrane domains (TM) is shown in Fig.10 As shown. All hinge and transmembrane domains tested belong to the immunoglobulin superfamily (IgSF) and are capable of forming cell surface homodimers. All constructs were cloned into the P2A bicistronic oncoretroviral vector (SFG) encoding CAR and LNGFR. Flow cytometric analysis showed CAR and LNGFR expression using goat IgG anti-mouse IgG (F(ab′)2) fragments and anti-LNGFR, respectively. T cells were obtained from PBMCs (peripheral blood mononuclear cells) of healthy donors, stably transduced 48 hours after activation, and CAR expression was analyzed at multiple time points. The 1928z-LNGFR CAR containing the CD28 / CD28 H / TM region was used as a control.

[0516] Replacing CD28 / CD28(H / TM) with ICOS / ICOS(H / TM), CTLA-4 / CTLA-4(H / TM), or ICAM-1 / ICAM-1(H / TM) hinges abolished cell surface expression of CAR. However, CAR expression was rescued when the CD28 hinge was fused to the ICOS transmembrane (CD28 / ICOS; H / TM). However, CAR expression could not be rescued in the CD28 / CTLA-4(H / TM) configuration. These findings suggest that it is not obvious to find an H / TM combination that can effectively express CAR. In summary, 1XX CARs with CD84 / CD84, CD166 / CD166, CD8a / CD8a, CD8b / CD8b, or CD28 / ICOS(H / TM) regions were similarly expressed on the T cell surface, and three of them were unable to form dimers with CD28: CD166-28z, CD8a-28z, and CD8b-28z.

[0517] From 10 6 Cells / ml CAR T cells were used to start, and the accumulated CAR T cells after weekly stimulation were counted as Fig.11As shown. The proliferation of CAR T cells induced by weekly exposure to CD19 was first evaluated in vitro over 21 days. CAR T cells were then incubated with irradiated CD19 + NIH 3T3 co-culture. 6 cells / ml CAR + T cells were added to irradiated and fresh CD19 + NIH 3T3. 1928z-1XX-LNGFR CAR with CD28 / CD28(H / TM) was used as a reference. The in vitro proliferation of 19-CD166-28z was similar to that of 1928z wild type.

[0518] Data are organized based on CAR T cell surface assays. T cells transduced with CARs containing ICOS / ICOS(H / TM), CTLA-4 / CTLA-4(H / TM), ICAM-1 / ICAM-1 (or CD28 / CTLA-4(H:TM)) failed to accumulate after co-culture with CD19+ NIH 3T3 cells. CAR T cells with CD84 / CD84 and CD8b / CD8b(H / TM) accumulated after two rounds of stimulation. However, these cells lost their ability to accumulate after the third round of stimulation. CAR T cells with CD166(H / TM), CD8a(H / TM) domains, and CD28 / ICOS(H / TM) accumulated as effectively as control 1928z-1XX CAR T cells.

[0519] Use 4 hours at the end of the third stimulation (D21) 51 The Cr release assay measured the cytotoxic activity of CAR T cells, and the results were Fig.12 As shown. T cells and EL-4-CD19+ target cells were used at different effector: target ratios (E:T). EL-4-PSMA cells were used as controls. As expected, the in vitro cytotoxic potential of all well-expressed H / TM CD28 / CD3ζ variants was similar. The cytotoxic capacity of CAR T cells with CD166 (H / TM), CD8a (H / TM) domains and CD28 / ICOS (H / TM) was comparable to that of CAR T cells with CD28 / CD28 (H / TM).

[0520] In vivo antitumor efficacy of different H / TM CART cells using NOD.Cg PrkdcscidIl2rgtmlWjl / SzJ (immunodeficient NSG) mice Fig.13 As shown. 5×10 5FFLuc-GFP NALM6 cells (former BALL cell line), followed by injection of 2 × 10 5 CAR T cells. Bioluminescent signal was quantified weekly after tumor burden. All selected constructs for in vivo studies, CD166 / CD166(H / TM), CD8a / CD8a(H / TM), and CD28 / ICOS(H / TM), were able to completely eradicate tumor cells. No significant differences in tumor burden or survival were observed in any case compared to the control 1928z CAR T cells.

[0521] Example 3 - Deimmunization Strategy

[0522] The juxtaposition of human sequences or their mutations has the risk of generating new antigens. Therefore, the mutations in the new CD166 junction and 1XX are deimmunized. The immunogenicity of the junction between different CAR parts can be predicted using NetMHC 4.0Server. A total of 26 amino acids (13 amino acids in the first part and 13 amino acids in the second part) were selected. For each peptide produced (14, 13, 12, 11, 10, 9 and 8 polymers), which contains at least 1 amino acid from the next part, the binding affinity of all alleles to HLA A, B and C is predicted. Each peptide is assigned an immunogenicity score for each peptide. The immunogenicity score is calculated using the formula immunogenicity score = [(50-binding affinity) * HLA frequency] n. 50nm is used as a cutoff value for strong binding affinity. The HLA frequency of the Caucasian population is used. n = the predicted number of each peptide. HLA frequencies below 1% in the total population are excluded. For junction deimmunization, shuffling of the two amino acids that form the junction or deletion of amino acids from both sides of the junction was tested. The immunogenicity prediction strategy described previously was used for each newly generated peptide. The junction with the minimum immunogenicity score was used to construct a deimmunized CAR. An exemplary deimmunization strategy is shown in FIG. Fig.14 shown.

[0523] Example 4: Rescue of relapse of CD19 low ALL after treatment with 4-1BBz CAR T cells

[0524] Introduction

[0525] Adoptive immunotherapy using chimeric antigen receptors (CARs) has shown significant clinical results in the treatment of leukemia and lymphoma, and is a promising immunotherapy that can be applied to a variety of cancers in principle. Two promising CAR designs have been successfully introduced clinically, one using the cytoplasmic domain of CD28 as a co-stimulatory component and the other using the cytoplasmic domain of 4-1BB. In both cases, T cell activation is initiated by the fusion cytoplasmic domain of the CD3ζ chain. Although both designs have achieved remarkable results, the shortcomings of these CAR structures limit clinical results. T cells expressing CD28-based CARs are effective but short-lived, while T cells expressing 4-1BB-based CARs have a longer lifespan, but can allow antigen escape of tumor cells expressing low levels of target antigens. Therefore, a new CAR design is needed that extends the persistence of T cells without compromising function.

[0526] result

[0527] The CD28z CAR T cells of the present disclosure can rescue relapses of CD19 low ALL after treatment with 4-lBBz CAR T cells. This may be the main rescue pathway for many relapses that occur after treatment with 4-lBBz CAR T cells (except those CD19 negative stable cells).

[0528] NSG mice were injected with 5 × 10 5 FFLuc-GFP NALM6 cells (pre-B ALL cell line), followed by injection of 2 × 10 5 Ten days after the first injection of T cells (an ineffective dose that only delayed tumor progression), mice were injected with 19BBz CAR T cells again, or with 1928z or (5×10 5 / mice). Various survival curves are shown in Fig.15 Only fresh injection of I928z-based CAR T cells (second injection) was able to rescue relapse in mice treated with NALM-6. No significant improvement in survival was observed after injection of fresh 19BBz CAR T cells.

[0529] In summary, CD28z CAR T cells can rescue the failure of 4-lBBz CAR T cells. In view of the above embodiments, the modified CD28z CAR T cells disclosed herein, such as 1XX, D23 and D12 CAR T cells (having various hinge / TM domains, such as CD166 hinge / TM domains) can be even more effective than 1928zCAR T in the rescue failure of 4-lBBz CAR T cells.

[0530] Example 5

[0531] This embodiment is an update and further study of some aspects of Example 1.

[0532] Chimeric antigen receptors (CARs) are synthetic receptors that target and reprogram T cells to acquire enhanced anti-tumor properties. 1 CD19-specific CAR containing CD28 and CD3ζ signaling motifs 2 Refractory leukemia 3-5 and lymphoma 6 The drug has induced significant responses in patients with 7 Although they confer T cells 3-6,8 Limited persistence, but these CARs mediated effective tumor eradication 4,8 High-performance effector function. Prolonging their functional persistence without compromising their potency should improve current CAR therapies. Strong T cell activation drives exhaustion 9,10 This may be due to the redundancy of CD28 and CD3ζ signaling. 11,12 And the second generation CAR 2 The spatiotemporal constraints imposed by the structure of are exacerbated by the . Therefore, it is hypothesized that calibrating the activation potential of CD28-based CARs will differentially reprogram T cell function and differentiation. Here, CARs encoding a single immunoreceptor tyrosine-based activation motif direct T cells to distinct fates by balancing effector and memory programs, resulting in a CAR design with enhanced therapeutic properties.

[0533] Redundancy of CD28 and CD3 signaling in the design of chimeric antigen receptors (CARs) assuming inclusion of all three CD3 immunoreceptor tyrosine-based activation motifs (ITAMs) 11,13 May promote counterproductive T cell differentiation and exhaustion 9,10 Therefore, ITAM activity is calibrated by mutating tyrosine residues to prevent their phosphorylation and downstream signaling. 14-17 To investigate the contribution of three CD3 ITAMs to the function, differentiation, and therapeutic potential of 1928Z-engineered T cells, 1928Z mutants containing single ITAMs were generated, termed 1XX, X2X, and XX3 ( Fig.16A In another mutant, called X23, the two distal ITAMs (ITAM2 and ITAM3) were retained, and both ITAMs showed a similar expression relative to ITAM1. 13,18 Lower binding affinity for the tyrosine protein kinase ZAP-70. All mutant CARs were similarly expressed in retrovirally transduced human peripheral blood T cells ( Fig. 16B ); they are found in 4-hour chromium 51 ( 51Cr) release assay and had indistinguishable cytotoxicity and proliferation effects after three weekly stimulations with CD19 antigen ( Figures 20A-20B ).

[0534] It is noteworthy that in the well-established Nalm6 mouse model of pre-B acute lymphoblastic leukemia 8,19,20 In the CAR stress test, the therapeutic effects of CAR T cells expressing these mutant CARs were significantly different. 8 As described in the literature, CAR T cell doses were intentionally reduced to better compare T cell potency. Relative to the parental 1928, XX3 showed significantly reduced antitumor efficacy, achieving only transient reductions in tumor burden, whereas 1XX surpassed 1928z, inducing long-term remissions in all mice ( Fig. 16C and Fig. 20C Compared with 1928, treatment with X2X and X23 did not significantly change the survival rate (1928 vs. X2X: P = 0.6942; 1928 vs. X23: P = 0.1085).

[0535] Thus, while the presence of one (1XX, X2X, XX3), two (X23), or three (1928z) functional ITAMs did not significantly alter short-term in vitro functionality, CARs containing a single ITAM outperformed CARs containing three and two ITAMs in vivo. The efficacy of tumor eradication gradually decreased with increasing distal localization of functional ITAMs. The 1XX CAR consistently demonstrated the ability to rapidly eradicate tumors and was the only CAR design to achieve durable and complete remissions at the lowest T cell dose. Treatment with X2X slightly delayed tumor progression compared to wild-type 1928z, but ultimately resulted in relapse. The XX3 CAR did not achieve any tumor control, resulting in rapid tumor progression and significantly reduced survival ( Fig. 16C and Fig. 20C ).

[0536] To investigate the functional basis for these major differences in antitumor efficacy, the responses conferred by these CARs were further investigated. In extended (18 h) cytotoxicity assays at lower effector-to-target ratios, XX3 was less active than 1928z and other mutants ( Fig.21A ). CD19 + Reduced expression of granzyme B (GrB) after target stimulation ( Fig. 21B ) and single and multifunctional type 1 T helper cells (T H 1) Decreased cytokine secretion ( Fig. 21C) further confirmed that XX3 has reduced effector function. As determined by CD62L / CD45RA expression, the inclusion of a single ITAM (ITAM1, 2, or 3) can restrict T cell differentiation in response to CD19 + Repeated in vitro stimulation of the target resulted in an increase in the central memory CAR T cell fraction and a decrease in the proportion of effector cells ( Fig.20D ).

[0537] These findings were extended in vivo, as CAR T cells with two inactive CD3 ITAM domains exhibited increased persistence ( Fig.16D ) and delayed T cell differentiation ( Fig.16E ). 1XX, X2X, and XX3 CAR T cells all showed a high percentage of CD62L + CD45RA - Central memory T cells (TCM) and terminal differentiation CD62L - CD45RA + Effector cells (TEFF) The score decreases ( Fig.16E and Fig.20E ). CD4 + and CD8 + The reduction in effector differentiation in CAR T cells was associated with increased accumulation of two T cell subsets at tumor sites ( Fig.16D ), established the benefit of reducing CD3 signaling in second-generation CD28-based CARs.

[0538] We next investigated whether the lower potency of XX3 was intrinsic to ITAM3 or due to its distal position. Therefore, we generated 1928ζ mutant CARs with ITAM1 or ITAM3 at the same proximal CAR position by deleting the remaining CD3ζ chain (D12 and D23, Figures 17A-17B ). In vitro studies showed that all constructs had equivalent cytolytic activity, undiminished cytokine and GrB secretion, and comparable proliferation potential between D12, D23, and 1928ζ in both 4-hour and 18-hour assays (Figures 21 and 22). However, both D12 and D23 performed better in vivo than 1928ζ, completely eradicating tumors ( Fig. 17C and Fig.22D ). Both CAR constructs modestly reduced T cell differentiation and promoted higher CAR T cell accumulation at tumor sites relative to 1928ζ ( Figures 17D-17E). These findings demonstrate the importance of ITAM dosage and position in 1928ζCAR. A single functional ITAM is sufficient to achieve effective anti-tumor efficacy and is superior to the efficacy provided by the wild-type CD3ζ chain containing three ITAMs. In addition, in their respective natural positions (XX3 for 1XX), the therapeutic efficacy conferred by ITAM3 is smaller than that of ITAM1, but comparable in the same proximal position (D12 vs. D23). Despite sharing the same ITAM sequence, D12 can still eradicate tumors better than XX3, which demonstrates the importance of ITAM positioning in second-generation CARs.

[0539] To exclude potential confounding effects due to different CAR expression levels, CAR complementary DNA (cDNA) was targeted to the TRAC locus. 19 , thereby normalizing transgene regulation and copy number while removing endogenous T cell receptors (TCR; Fig.24A ). Under these conditions, 1XX CAR T cells again outperformed those expressing 1928z or XX3 (Figure 3a). TRAC-1XX T cells achieved complete remission within 21 days, whereas TRAC-XX3 T cells only delayed tumor progression and were unable to achieve tumor control ( Fig.18A ). Analysis of recovered CAR T cells and tumor cells 17 days after CAR infusion showed that CD4 + and CD8 + In the subset, the accumulation of TRAC-1XX and TRAC-XX3 CAR T cells was higher than that of TRAC-1928z ( Fig.18C and Fig. 24B and 24E ). Increased persistence of CAR T cells is associated with TCM Higher percentage and interleukin 7 receptor (IL7R) + CAR T cell counts Fig.24C and 24D ), reinforcing the finding of delayed T cell differentiation in the 19280 mutants. Similar to retrovirally engineered T cells, TRAC-XX3 T cells lost their cytolytic potential over time compared to TRAC-1928z and TRAC-1XX cells ( Fig.24F ). Compared with TRAC-1928z, the expression of exhaustion markers was reduced in the 1928z mutant and was enhanced by isolating CAR from treated mice and ex vivo re-exposure to T cells after Nalm6 cells. H 1. Decreased cytokine secretion and GrB / CD107a expression confirmed functional depletion of TRAC-1928z ( Fig.18D25 ). TRAC-1XX retained high cytolytic function and the ability to co-produce multiple cytokines, whereas TRAC-1928z exhibited a progressive inability to secrete T cells associated with increased expression of exhaustion markers. H 1Cytokine.

[0540] Two different T cell doses (5×10 5 and 1×10 5 CAR + Long-term follow-up studies after 5 × 10 T cells have clearly demonstrated the therapeutic advantage of TRAC-1XX. Although tumor-related deaths occurred in less than 60 days (using 5 × 10 5 CAR + T cell therapy) or less than 40 days (with 1×10 5 CAR + T cell therapy), when mice treated with TRAC-1XX showed complete tumor eradication and improved survival throughout the observation period ( Fig.18B and Figure 29).

[0541] When the sorted naive T cells were used for in vivo therapy, the enhanced ability of 1XX to develop into powerful, long-lived memory cells was further demonstrated. TRAC-1XX showed that over time, TCM The population and cells expressing IL7R (associated with enhanced persistence of highly effective CAR T cells) will increase ( Figures 26A-26C Importantly, TRAC-1XX CAR was able to elicit an effective recall response, achieving complete tumor control after tumor rechallenge ( Fig.18E ). Persistent 1XX CAR T cells contain increased numbers of TCM, TEFF, and IL7R + CAR( Fig.18F and 18G as well as Figures 26D-26F In contrast, TRAC-1928z was more likely to acquire an exhausted phenotype, which was accompanied by reduced persistence of CAR T cells without memory formation and an inability to control tumor re-attack.

[0542] To further characterize these different phenotypes and functional patterns, we compared the genome-wide transcriptional profiles of 1928z, 1XX, and XX3 after CD19 antigen stimulation of TRAC-edited naive T cells. Principal component analysis showed that CAR T cells had distinct clustering properties dependent on their CD3z mutations ( Fig.27A ). Consistent with the functional studies, major differences emerged in transcriptome profiles associated with T cell function, differentiation, and exhaustion. Gene set enrichment analysis (GSEA) revealed downregulation of naive / memory-related genes and enrichment of T cell activation and effector-related genes in 1928z relative to XX3 and 1XX ( Fig.19A and Fig.27B As expected, 1928z CAR T cells showed the greatest upregulation of T cell differentiation, exhaustion, and apoptosis gene expression profiles ( Fig.19B and 19C as well as Fig.28A ). Gene Ontology and GSEA analysis found that gene sets related to inflammation, cytokine and chemokine activity were significantly upregulated in 1928z compared with XX3 and in 1XX compared with XX3 ( Fig.19C , Fig.28B and 28C ). These gene sets are also enriched in 1928z relative to 1XX, albeit to a lesser extent, consistent with an intermediate state of 1XX relative to 1928z and XX3 ( Fig.19B and 19C as well as Fig.28B and 28C To compare TRAC-edited CAR T cells with non-genetically modified CD8 + Effector and memory characteristics of T cell subsets. Naive (T N ), stem cell memory (T SCM two or more) and T EFF , as their characteristic transcriptional profiles have been previously determined 21 ( Fig.27C ). Differentially expressed genes associated with effector versus naive / memory T cell fate (adjusted P < 0.05) distinguished these CAR constructs ( Fig.19B Interestingly, TRAC-1928z and TRAC-XX3 T cells (respectively T EFF and T N TRAC-1XX cells are more similar to TSCM cells ( Fig.19B ).

[0543] Upregulation of key regulators of effector differentiation such as T-bet (and T-bet:Eomes ratio), PR domain zinc finger protein 1 (PRDM1), and inhibitor of DNA binding protein ID-2 (refs. 22–24), along with loss of naive / memory-associated markers such as CCR7, CD27, and IL7R 21 ) confirmed the rapid acquisition of the effector state seen in 1928z ( Fig.19B and Fig.28C and 28DIn contrast, modulated signaling intensity in 1XX resulted in slower T cell differentiation and preserved expression of important memory-related transcription factors such as transcription factor 7 (TCF7), B-cell lymphoma 6 protein (BCL6), lymphoid enhancer binding factor 1 (LEF1), and Kriippel-like factor 2 (KLF2). 23-26 ( Fig.19B ), which is further reflected in the upregulation of KLF2-regulated genes such as CCR7, CD62L, ITGB7, and S1PR1 (Ref. 27 ,28 )( Fig.19B and Fig.28D While 1XX T cells showed only a partial transition toward a less differentiated T cell state, XX3 revealed high levels of naive / memory-related genes, as well as systemic repression of genes encoding major transcription factors for T cell differentiation and effector function ( Figures 19B-19D These findings highlight the critical role of ITAM dosage and location in conferring distinct T cell fates. They further support a model of memory formation that places cell fate under the control of signaling intensity. 24,29 .

[0544] Recent reports support the notion that less differentiated T cell subsets and memory signatures are associated with increased antitumor efficacy and persistence of adoptively transferred T cells. 30,31 These results extend these findings, demonstrating that T cell differentiation status can be intrinsically controlled by mutations in the CD3z chain of CAR T cells. The CD28 and CD3z signaling domains are confined within the CAR in a 1:1 stoichiometric ratio. 2 , which is different from its natural space-time relationship 11 Previous studies of CD3ζ mutations have been limited to in vitro comparisons that did not reveal major effects. 32-34 , in contrast to the key results found in vivo (Figure 16). In vivo studies have shown that balancing T cell differentiation and acquisition of effector function is critical for optimizing the therapeutic efficacy of CAR T cells based on the comparison of different signaling motifs expressed from constant genomic loci (Figures 18 and 19). This experimental setup is believed to be optimal for quantitative CAR and TCR comparisons 19 .

[0545] In summary, under stress test conditions, 1XX induced robust effector functions without shutting down the memory program and outperformed 1928ζ. Further reduction of T cell activation potential by XX3 resulted in highly persistent T cells, but with modest antitumor activity due to insufficient stimulation of effector functions. Notably, the modified ITAM configuration in 1XX favors the persistence of a powerful CAR, balancing the replicative capacity of long-lived memory cells and the acquisition of potent antitumor function. Preparations for clinical studies using the 1XX CAR design are ongoing.

[0546] method

[0547] Cell lines and culture conditions. As previously described 8,20 , Nalm6 cells were transduced to express firefly luciferase (FFLuc)-green fluorescent protein (GFP), and murine thymoma EL4 cells and NIH / 3T3 cells were transduced to express human CD 19. Cells were regularly tested for mycoplasma using the MycoAlert Mycoplasma Detection Kit (Lonza) and the results were negative.

[0548] Isolation and expansion of human T cells. Buffy coats from anonymous healthy donors were purchased from the New York Blood Center (Institutional Review Board exempt), and peripheral blood was obtained from healthy volunteers. All blood samples were handled in accordance with required ethical and safety procedures. Peripheral blood mononuclear cells were isolated by density gradient centrifugation and treated with phytohemagglutinin (2 μg ml -1 ) for experiments using retroviral vectors, or T cells were purified using the Pan T cell isolation kit (MiltenyiBiotec) and purified as previously described. 19 The cells were stimulated with CD3 / CD28 T cell activator Dynabeads (Invitrogen) and cultured in X-VIVO 15 serum-free hematopoietic cell medium (Lonza) supplemented with 5% human serum (Gemini Bio-Products), 5 ng ml -1 Interleukin-7 (IL7) and 5 ng ml -1 IL15 (BioLegend) was used for gene targeting experiments. The culture medium was changed every 2 days and the cells were cultured at 10 6 Cells were plated.

[0549] For some experiments, naive (TCR + CD62L + CCR7 + CD45RA + CD95 - ), TSCM(TCR + CD62L +CCR7 + CD45RA + CD95 + ) and T EFF Cells (TCR + CD62L - CCR7 - CD45RA + CD95 + ) were sorted by flow cytometry. CAR cDNA was then targeted to the TRAC locus of sorted naive T cells, followed by in vitro culture and TCR negative purification as described below. Seven days after gene targeting, T cells were stimulated with 3T3-CD19 for 24 hours for further analysis or injected into tumor-bearing mice.

[0550] Genetic modification of T cells was performed using previously described 20 Preparation of retroviral vector encoding SFGγ using standard molecular biology techniques 35 Vesicular stomatitis virus glycoprotein G (VSV-G) pseudotyped retroviral supernatant from transduced gpg29 fibroblasts (H29) was used to construct a stable retroviral producing cell line 36 .

[0551] The synthesis of SFG-1928ζ has been described previously. 2,20,37 ; It contains a single-chain variable fragment specific for human CD19, preceded by a CD8a leader peptide, followed by a CD28 hinge transmembrane intracellular region, and CD3ζ or ITAM-mutated / deleted CD3ζ intracellular domain linked to a P2A sequence to induce co-expression of a truncated low-affinity nerve growth factor receptor (LNGFR). 1928ζ mutants were constructed using standard molecular biology techniques. A point mutation from tyrosine to phenylalanine in the ITAM of the CD3ζ chain was introduced to generate 1928ζCARs with one or two functional ITAMs. For deletion mutations, the membrane-proximal ITAM sequence (ITAM1) was retained or replaced with a membrane-distal ITAM (ITAM3) sequence, and the remaining CD3ζ domain was deleted. 48 hours after T cell activation was initiated, T cells were transduced with retroviral supernatant by centrifugation on RetroNectin-coated plates (Takara) as described above. The transduction efficiency was determined by flow cytometry 4 days later, and the CAR was injected into tumor-bearing mice or used for in vitro experiments.

[0552] As previously mentioned 19 Gene targeting experiments were performed. Briefly, a modified guide RNA (gRNA) targeting the first exon of the invariant chain of the TRA gene was synthesized by TriLink Biotechnology. 19and Cas9 messenger RNA (mRNA). pAAV-TRAC-1928ζ was cloned based on the pAAV-GFP backbone (Cell Biolabs). pAAV-TRAC-1928ζ contains 1.9 kb genomic TRAC flanked by the gRNA targeting sequence, a self-cleaving P2A peptide and the first exon of TRAC, followed by 1928ζ or 1928ζ mutant CAR as described previously. Following the CAR cDNA is the bovine growth hormone polyA signal.

[0553] CD3 / CD28 beads were magnetically removed 48 h after initiation of T cell activation. T cells were transfected by electrotransfer of Cas9 mRNA and gRNA using the AgilePulse MAX system (BTX) and as previously described. 19 Recombinant AAV6 donor vector (manufactured by SignaGen Laboratories) was added to the culture after electroporation. To obtain TCR-negative T cells, TCR-positive T cells were removed from the culture using magnetic biotin anti-TCRαβ, anti-biotin microbeads and LS columns (Miltenyi Biotec).

[0554] Cytotoxicity assay. 51 Cr release assay and luciferase-based assay were used to determine the cytotoxicity of T cells transduced with CAR. 51 Cr release assay, as previously described 38 , EL4 expressing CD19 was used as target cells. For luciferase-based assays, Nalm6 expressing FFLuc-GFP was used as target cells. Effector and tumor target cells were co-cultured in triplicate at the indicated effector / target ratios using black-walled 96-well plates with 5 × 10 cells / well in a total volume of 100 μl of Nalm6 medium. 4 Target cells were plated only at the same cell density to determine the maximum luciferase expression (relative light units (RLU)); 18 hours later, 100 μl of luciferase substrate (Bright-Glo; Promega) was added directly to each well. Luminescence was detected in a luminescence plate reader. Lysis was determined as (1-(RLUsample) / (RLUmax))×100.

[0555] Antigen stimulation and proliferation assay. Four days after transduction, CAR T cells were fused with irradiated CD19 + NIH / 3T3 were cultured in 24-well tissue culture plates at 10 6 CAR +Co-culture. The same stimulation was performed weekly in fresh medium. Total cells were counted and CAR expression was determined weekly by flow cytometry. Subsequently, CAR T cells were restimulated under the same conditions.

[0556] Mouse systemic tumor model. NOD / SCID / IL-2Rγ null male mice (Jackson Laboratory) aged 6 to 12 weeks were used according to protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center (MSKCC). All relevant animal use guidelines and ethical regulations were followed. Mice were inoculated with 0.5 × 10 6 FFLuc-GFP NALM6 cells were injected 4 days later, and then 5 × 10 4 , 1×10 5 or 5×10 5 CAR T cells were administered intravenously at 0.5 × 10 cells / mL at designated time points at 7–10 day intervals. 6 , 1×10 6 or 2×10 6 Tumor rechallenge experiments were performed with FFLuc-GFP Nalm6 cells. Nalm6 produces a very uniform tumor burden, and no mice were excluded prior to treatment. No randomization or blinding was used. Bioluminescence imaging was performed using the IVIS imaging system (PerkinElmer) and Living Image software (PerkinElmer) to acquire imaging datasets. Tumor burden was assessed as previously described. 39 .

[0557] RNA extraction, transcriptome sequencing, and RNA-seq analysis. Seven days after gene targeting of sorted naive T cells, TRAC-1928ζ, TRAC-XX3, and TRAC-1XX were stimulated with irradiated 3T3-CD19 for 24 h, followed by magnetic separation of CD8 +cells (Miltenyi Biotec). Washed T cells were resuspended in 250 μl PBS and placed in 750 μl TRIzol LS Reagent (Thermo Fisher Scientific). RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the instructions provided by the manufacturer. After quantification and quality control of RiboGreen RNA using an Agilent Bioanalyzer, 500 ng of total RNA was subjected to polyA selection and TruSeq RNA library preparation using 8 PCR cycles according to the instructions provided by the manufacturer (TruSeq Stranded mRNA LT Kit; Illumina). Samples were barcoded using the HiSeq 3000 / 4000 SBS Kit (Illumina) and run on the HiSeq 4000 (Illumina) with 50 base pairs (bp) / 50 bp paired ends. An average of 30.6 million paired reads were generated per sample. Ribosomal reads accounted for a maximum of 4.69% of the total reads generated; the percentage of mRNA bases averaged 69.3%.

[0558] The STAR RNA-seq aligner (version 2.5.0a; two-pass method) was used. 40 The output FASTQ data were mapped to the target genome, resolving reads that spanned junctions. The first mapping pass used Ensemble’s list of known annotated junctions (https: / / www.ensembl.org / index.html). The junctions found in the first pass were then added to the known junctions, and a second mapping pass was done using the RemoveNoncanonical flag. After mapping, the output SAM files (SAMtools, version 0.1.19) were processed using the PICARD tool (version 1.124; https: / / broadinstitute.github.io / picard / ) to add read groups and AddOrReplaceReadGroups, and the files were also sorted and converted to a compressed BAM format. Expression count matrices were then calculated from the mapped reads using HTSeq (version 0.5.3; https: / / htseq.readthedocs.io / en / release_0.10.0 / ) and one of several possible gene model databases. The R (version 3.2.0) package DESeq (https: / / www.huber.embl.de / users / anders / DESeq / ) was used both to normalize the entire dataset and to analyze differential expression between sample groups.

[0559] From Gattinoni et al. 21 T cell subsets (T N , T CM , T SCM , T EFF Cells) differentially expressed genes. GSEA is performed using a pre-sorted file that uses log2 (fold change) on a selected pathway gene set from the Broad Institute Molecular Signature Database (http: / / www.broadinstitute.org / gsea / msigdb / ). The displayed gene signatures are from immune signature C7, Reactome, KEGG, and gene ontology (BiologicalProcess) gene sets. GSE41867 is used for GSEA of naive / memory CD8 T cells that are exhausted, and is used to manage the signature of 200 genes that are upregulated in exhausted CD8 T cells (30 days after lymphocytic choriomeningitis virus infection) relative to memory and naive cells. Using the R package richR (http: / / amp.pharm.mssm.edu / Enrichr / ), genes identified as differentially expressed between experimental conditions (adjusted P value <0.05 and absolute log2 (fold change)>1) are used for gene ontology analysis.

[0560] Antibodies and intracellular staining. The following antibodies conjugated to fluorophores were used. From BD Biosciences: APC-Cy7 mouse anti-human CD8; APC-Cy7 mouse anti-human CD45; BUV395 mouse anti-human CD4; PE mouse anti-human CD4; BB515 mouse anti-human CD4; BV421 mouse anti-human CD62L; BV650 mouse anti-human CD45RA; BV421 mouse anti-human CD45RA; BV480 mouse anti-human CD279 (PD-1); BV650 mouse anti-human CD279 (PD-1); BUV737 mouse anti-human CD19; BV421 mouse anti-human TIM3 (CD366); BB515 mouse anti-human CD95; APC-H7 mouse anti-human CD27; PE mouse anti-human CD271 (LNGFR). From BioLegend: APC anti-human CD8a; APC / Cy7 anti-human CD62L; FITC anti-human CD45RA; Brillian Violet 785 anti-human CD366 (Tim-3); PE anti-human CD127 (IL-7Rα); Alexa Fluor 488 anti-human CD127 (IL-7Rα); PerCP / Cyanine5.5 anti-human CD197 (CCR7); Brillian Violet 650 anti-human CD28. From Invitrogen: CD8a monoclonal antibody (RPA-T8), PE-cyanine 7; CD223 (LAG-3) monoclonal antibody (3DS223H) PerCP-eFluor 710; CD223 (LAG-3) monoclonal antibody (3DS223H), APC; Invitrogen TCRα / β monoclonal antibody (IP26), PE-cyanine 7. From Miltenyi Biotec: Human monoclonal anti-TCR α / β-PE. 7-AAD (BD Biosciences) and LIVE / DEAD Fixed Violet Dead Cell Stain Kit (Invitrogen) were used as viability dyes.

[0561] For CAR staining, Alexa Fluor 647AffmiPure F(ab')2 fragment goat anti-mouse IgG, a F(ab')2 fragment-specific antibody (Jackson ImmunoResearch) was used. For cell counting, CountBright Absolute Counting Beads (Invitrogen) were added according to the manufacturer's instructions. For in vivo experiments, Fc receptors were blocked using mouse FcR blocker (Miltenyi Biotec).

[0562] For intracellular cytokine secretion assays, T cells were co-cultured with 3T3-CD19 or Nalm6 in the presence of a Golgi plug transport inhibitor (BD Biosciences) for the last 4 hours. For CD107a staining, BrilliantViolet 650 anti-human CD107a (LAMP-1) antibody (BioLegend) was added to the co-culture. For in vitro cytokine analysis, CAR T cells were obtained from the bone marrow and spleen of treated mice and purified using a mouse cell depletion kit (Miltenyi Biotec). The samples were treated or merged in biological triplicates (d16) (due to low cell numbers in mice treated with 1928ζ), and three technical replicates (d36) were performed. Myristic acid-phorbol-acetate (PMA) / ionomycin (Invitrogen) stimulation was used as a positive control. T cells were then washed, stained for cell surface markers, fixed, and permeabilized using the Cytofix / Cytoperm Fixation / Permeabilization Solution Kit (BD Biosciences) according to the manufacturer's instructions. Intracellular cytokine staining was performed using BV421 rat anti-human IL2, BV650 mouse anti-human TNF, BUV395 mouse anti-human TNF, BUV395 mouse anti-human IFN-γ, or FITC mouse anti-human IFN-γ (all from BD Biosciences), and APC or PE granzyme B monoclonal antibodies (GB12, both from Invitrogen).

[0563] Flow cytometry was performed on an LSR II or LSRFortessa instrument (BD Biosciences), and cell sorting was performed using a FACSAria sorter (BD Biosciences). Data were analyzed using FlowJo software v.10.1 (FlowJo LLC).

[0564] Statistical analysis. All statistical analyses were performed using Prism 7 (GraphPad) software. No statistical methods were used to predetermine sample size. Statistical comparisons between the two groups were performed by two-tailed parametric or nonparametric (Mann-Whitney U test) t-test to determine unpaired data or by two-tailed paired Student's t-test to determine matched samples. For in vivo experiments, overall survival was presented as Kaplan-Meier curves, and the log-rank test was used to compare survival differences between groups. P values ​​< 0.05 were considered statistically significant. The statistical tests used for each figure are described in the corresponding legend.

[0565] Summary of report. For more information on the study design, see the Nature study summary of report linked to this article.

[0566] Data availability

[0567] The RNA-seq data have been deposited in Gene Expression Omnibus and are available under accession number GSE121226. The raw data for the figures in the manuscript will be provided to the corresponding author upon request.

[0568] References

[0569] 1. Sadelain, M., Rivière, I. & Riddell, S. Therapeutic T cellengineering. Nature 545, 423-431 (2017).

[0570] 2. Maher, J., Brentjens, RJ, Gunset, G., Rivière, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta / CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002).

[0571] 3. Brentjens, RJ et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblasticleukemia. Sci. Transl. Med. 5, 177ra38 (2013).

[0572] 4. Lee, DWet al. T cells expressing CD19chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).

[0573] 5.Park,J.H.et al.Long-term follow-up of CD19 CAR therapy in acutelymphoblastic leukemia.N.Engl.J.Med.378,449-459(2018).

[0574] 6.Neelapu,S.S.et al.Axicabtagene Ciloleucel CAR T-cell therapy inrefractory large B-cell lymphoma.N.Engl.J.Med.377,2531-2544(2017).

[0575] 7.Sadelain,M.CD19 CAR T cells.Cell 171,1471(2017).

[0576] 8.Zhao,Z.et al.Structural design of engineered costimulationdetermines tumor rejection kinetics and persistence of CAR T cells.CancerCell 28,415-428(2015).

[0577] 9.Youngblood,B.,Davis,C.W.&Ahmed,R.Making memories that last alifetime:heritable functions of self-renewing memory CD8 Tcells.Int.Immunol.22,797-803(2010).

[0578] 10.Wherry,E.J.&Kurachi,M.Molecular and cellular insights into T cellexhaustion.Nat.Rev.Immunol.15,486-499(2015).

[0579] 11.Acuto,O.&Michel,F.CD28-mediated co-stimulation:a quantitativesupport for TCR signalling.Nat.Rev.Immunol.3,939-951(2003).

[0580] 12.Smith-Garvin,J.E.,Koretzky,G.A.&Jordan,M.S.T cellactivation.Annu.Rev.Immunol.27,591-619(2009).

[0581] 13.Love,P.E.&Hayes,S.M.ITAM-mediated signaling by the T-cell antigenreceptor.Cold Spring Harb.Perspect.Biol.2,a002485(2010).

[0582] 14.Kersh,E.N.,Shaw,A.S.&Allen,P.M.Fidelity of T cell activationthrough multistep T cell receptor zeta phosphorylation.Science 281,572-575(1998).

[0583] 15.Isakov,N.et al.ZAP-70 binding specificity to T cell receptortyrosine-based activation motifs:the tandem SH2 domains of ZAP-70binddistinct tyrosine-based activation motifs with varyingaffinity.J.Exp.Med.181,375-380(1995).

[0584] 16.van Oers,N.S.et al.The 21-and 23-kD forms of TCR zeta aregenerated by specific ITAM phosphorylations.Nat.Immunol.1,322-328(2000).

[0585] 17.Chae,W.J.et al.Qualitatively differential regulation of T cellactivation and apoptosis by T cell receptor zeta chain ITAMs and theirtyrosine residues.Int.Immunol.16,1225-1236(2004).

[0586] 18.Mukhopadhyay,H.,Cordoba,S.P.,Maini,P.K.,van der Merwe,P.A.&Dushek,O.Systems model of T cell receptor proximal signaling reveals emergentultrasensitivity.PLoS Comput.Biol.9,e1003004(2013).

[0587] 19.Eyquem,J.et al.Targeting a CAR to the TRAC locus with CRISPR / Cas9enhances tumour rejection.Nature 543,113-117(2017).

[0588] 20.Brentjens,R.J.et al.Eradication of systemic B-cell tumors bygenetically targeted human T lymphocytes co-stimulated by CD80 andinterleukin-15.Nat.Med.9,279-286(2003).

[0589] 21.Gattinoni,L.et al.A human memory T cell subset with stem cell-likeproperties.Nat.Med.17,1290-1297(2011).

[0590] 22.Chang,J.T.,Wherry,E.J.&Goldrath,A.W.Molecular regulation ofeffector and memory T cell differentiation.Nat.Immunol.15,1104-1115(2014).

[0591] 23.Yu,B.et al.Epigenetic landscapes reveal transcription factors thatregulate CD8 + T cell differentiation.Nat.Immunol.18,573-582(2017).

[0592] 24.Kaech,S.M.&Cui,W.Transcriptional control of effector and memoryCD8 + T cell differentiation.Nat.Rev.Immunol.12,749-761(2012).

[0593] 25.Ichii,H.et al.Role for Bcl-6in the generation and maintenance ofmemory CD8 + T calls.Nat.Immunol.3,558-563(2002).

[0594] 26.Zhou,X.&Xue,H.H.Cutting edge:generation of memory pracursors andfunctional memory CD8 + T cells depends on T cell factor-1 and lymphoidenhancer-binding factor-1.J.Immunol.189,2722-2726(2012).

[0595] 27.Carlson,C.M.et al.Kruppel-like factor 2 regulates thymocyte and T-cell migration.Nat...

Claims

1. A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or part of an immunoreceptor tyrosine-based activation motif (ITAM), wherein the ITAM is ITAM1, ITAM2 and ITAM3.

2. The CAR of claim 1, wherein the modified CD3ζ polypeptide lacks ITAM2 or a portion thereof.

3. The CAR according to claim 2, wherein the modified CD3ζ polypeptide also lacks ITAM3 or a portion thereof.

4. The CAR according to claim 2, wherein the modified CD3ζ polypeptide also lacks ITAM1 or a portion thereof.

5. The CAR of claim 1, wherein the modified CD3ζ polypeptide lacks ITAM1 or a portion thereof.

6. The CAR of claim 5, wherein the modified CD3ζ polypeptide further lacks ITAM3 or a portion thereof.

7. The CAR of claim 1, wherein the modified CD3ζ polypeptide lacks ITAM3 or a portion thereof.

8. The CAR of claim 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM2 or a portion thereof.

9. The CAR of claim 8, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM3 or a portion thereof.

10. The CAR of claim 8, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM1 or a portion thereof.

11. The CAR of claim 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM1 or a portion thereof.

12. The CAR of claim 11, wherein the modified CD3ζ polypeptide further comprises a deletion of ITAM3 or a portion thereof.

13. The CAR of claim 1, wherein the modified CD3ζ polypeptide comprises a deletion of ITAM3 or a portion thereof.

14. A CAR according to any one of claims 1-13, wherein the modified CD3ζ polypeptide lacks all or part of the basic-rich stretch (BRS) region, wherein the BRS region is BRS1, BRS2 and BRS3.

15. The CAR of claim 14, wherein the modified CD3ζ polypeptide lacks BRS2 or a portion thereof.

16. The CAR of claim 15, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof.

17. The CAR of claim 16, wherein the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof.

18. The CAR of claim 14, wherein the modified CD3ζ polypeptide lacks BRS1 or a portion thereof.

19. The CAR of claim 18, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof.

20. The CAR of claim 14, wherein the modified CD3ζ polypeptide lacks BRS3 or a portion thereof.

21. The CAR of claim 14, wherein the modified CD3zeta polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof.

22. The CAR of claim 1, wherein the modified CD3ζ polypeptide lacks ITAM2, ITAM3, BRS2 and BRS3.

23. The CAR of claim 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS2 or a portion thereof.

24. The CAR of claim 23, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof.

25. The CAR of claim 24, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS1 or a portion thereof.

26. The CAR of claim 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS1 or a portion thereof.

27. The CAR of claim 26, wherein the modified CD3ζ polypeptide further comprises a deletion of BRS3 or a portion thereof.

28. The CAR of claim 14, wherein the modified CD3ζ polypeptide comprises a deletion of BRS3 or a portion thereof.

29. The CAR of claim 14, wherein the modified CD3ζ polypeptide comprises a deletion of: BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof.

30. The CAR of claim 1, wherein the modified CD3zeta polypeptide comprises a deletion of: ITAM2, ITAM3, BRS2, ​​and BRS3.

31. The CAR of claim 1, wherein the CAR comprises the amino acid sequence shown in SEQ ID NO: 45 or SEQ ID NO:

47.

32. A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide lacks all or part of a basic-rich stretch (BRS) region, wherein the BRS region is BRS1, BRS2 and BRS3.

33. The CAR of claim 32, wherein the modified CD3ζ polypeptide lacks BRS2 or a portion thereof.

34. The CAR of claim 33, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof.

35. The CAR of claim 34, wherein the modified CD3ζ polypeptide further lacks BRS1 or a portion thereof.

36. The CAR of claim 35, wherein the modified CD3ζ polypeptide lacks BRS1 or a portion thereof.

37. The CAR of claim 36, wherein the modified CD3ζ polypeptide further lacks BRS3 or a portion thereof.

38. The CAR of claim 37, wherein the modified CD3ζ polypeptide lacks BRS3 or a portion thereof.

39. The CAR of claim 32, wherein the modified CD3ζ polypeptide lacks BRS1 or a portion thereof, BRS2 or a portion thereof, and BRS3 or a portion thereof.

40. A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises a BRS variant selected from a BRS1 variant, a BRS2 variant, and a BRS3 variant, wherein the BRS variant comprises one or more loss-of-function mutations.

41. The CAR of any one of claims 1-40, further comprising a hinge / spacer, wherein the hinge / spacer comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, a NKGD2 peptide, or a combination thereof.

42. CAR according to claim 41, wherein the hinge / spacer comprises CD166 polypeptide.

43. CAR according to claim 42, wherein the CD166 polypeptide has amino acids 489 to 527 of SEQ ID NO:

3.

44. A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a hinge / spacer, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3zeta polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant, and Wherein the hinge / spacer comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, a NKGD2 peptide, or a combination thereof.

45. The method of claim 44, wherein the modified CD3zeta polypeptide comprises an ITAM2 variant and an ITAM3 variant.

46. ​​The method of claim 45, wherein the ITAM2 variant has the amino acid sequence shown in SEQ ID NO:

29.

47. The method according to claim 45 or 46, wherein the ITAM3 variant has the amino acid sequence shown in SEQ ID NO:

33.

48. The CAR of any one of claims 44-47, wherein the modified CD3zeta polypeptide comprises or consists of amino acids 374 to 485 of SEQ ID NO:

43.

49. The CAR of any one of claims 44-48, wherein the CAR comprises the amino acid sequence shown in SEQ ID NO:

43.

50. The method of any one of claims 45-49, wherein one or both of the ITAM2 variant and the ITAM3 variant comprise two loss-of-function mutations.

51. The method of any one of claims 44-50, wherein the one or more loss-of-function mutations are located at a tyrosine amino acid residue.

52. The CAR of any one of claims 1-51, wherein the transmembrane domain comprises a CD8 polypeptide, a CD28 polypeptide, a CD3ζ polypeptide, a CD4 polypeptide, a 4-1BB polypeptide, an OX40 polypeptide, a CD166 polypeptide, a CD166 polypeptide, a CD8a polypeptide, a CD8b polypeptide, an ICOS polypeptide, an ICAM-1 polypeptide, a CTLA-4 polypeptide, a CD27 polypeptide, a CD40 / My88 peptide, a NKGD2 peptide, or a combination thereof.

53. CAR according to claim 52, wherein the membrane spaning domain comprises the CD166 polypeptide.

54. according to the CAR described in claim 53, wherein said CD166 polypeptide comprises SEQ ID NO:3 amino acid 528 to 553.

55. The CAR of any one of claims 44-54, wherein the transmembrane domain and the hinge / spacer region are derived from the same molecule.

56. The CAR of any one of claims 44-55, wherein the hinge / spacer comprises a CD28 polypeptide and the transmembrane domain comprises a CD28 polypeptide.

57. The CAR of any one of claims 44-56, wherein the hinge / spacer comprises a CD84 polypeptide and the transmembrane domain comprises a CD84 polypeptide.

58. according to the CAR described in any one of claim 44-57, wherein the hinge / spacer comprises the CD166 polypeptide, and the membrane spaning domain comprises the CD166 polypeptide.

59. The CAR of claim 58, wherein the CAR comprises amino acids 489 to 553 of SEQ ID NO:

3.

60. The CAR of any one of claims 44-59, wherein the hinge / spacer comprises a CD8a polypeptide and the transmembrane domain comprises a CD8a polypeptide.

61. The CAR of any one of claims 44-60, wherein the hinge / spacer comprises a CD8b polypeptide and the transmembrane domain comprises a CD8b polypeptide.

62. The CAR of any one of claims 44-54, wherein the transmembrane domain and the hinge / spacer region are derived from different molecules.

63. The CAR of claim 62, wherein the hinge / spacer comprises a CD28 polypeptide and the transmembrane domain comprises an ICOS polypeptide.

64. The CAR of any one of claims 1-63, wherein the intracellular signaling domain further comprises a co-stimulatory signaling domain.

65. The CAR of claim 65, wherein the co-stimulatory signaling domain comprises a CD28 polypeptide.

66. An immune response cell comprising the CAR of any one of claims 1-65.

67. The immune response cell of claim 66, wherein the CAR is recombinantly expressed.

68. The immune response cell of claim 66 or 67, wherein the CAR is expressed by a vector.

69. An immune response cell according to any one of claims 66-68, wherein the CAR is placed at an endogenous locus of the immune response cell.

70. The immune response cell of claim 69, wherein the endogenous locus is a TRAC locus, a TRBC locus, or a TRGC locus.

71. An immune response cell according to claim 69 or 70, wherein the endogenous locus is the TRAC locus.

72. An immune response cell according to any one of claims 69-71, wherein the placement of the CAR disrupts or eliminates endogenous expression of the TCR.

73. The immune response cell of any one of claims 66-72, wherein the cell is selected from T cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), regulatory T cells, natural killer T (NKT) cells, myeloid cells, human embryonic stem cells, and pluripotent stem cells from which lymphoid cells can be differentiated.

74. The immune response cell of any one of claims 66-73, wherein the immune response cell is autologous.

75. An immune response cell according to any one of claims 66-74, wherein the antigen is a tumor antigen.

76. The immune response cell of claim 75, wherein the tumor antigen is selected from the group consisting of CD19, MUC16, MUC1, CA1X, CEA, CD8, CD7, CD10, CD20, CD22, CD30, CLL1, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD74, CD133, CD138, EGP-2, EGP-40, EpCAM, erb-B2,3,4, FBP, fetal acetylcholine receptor, folate receptor-a, GD2, GD3, HER-2, hTERT, IL-13R-a2, K-light chain, KDR, LeY, L1 cell adhesion molecule, MAGE-A1, mesothelin, ERBB2 , MAGEA3, p53, MART1, GP100, proteinase 3 (PR1), tyrosinase, survivin, hTERT, EphA2, NKG2D ligand, NY-ES0-1, carcinoembryonic antigen (h5T4), PSCA, PSMA, ROR1, TAG-72, VEGF-R2, WT-1, BCMA, CD123, CD44V6, NKCS1, EGF1R, EGFR-VIII, and CD99, CD70, ADGRE2, CCR1, LILRB2, PRAME, CCR4, CD5, CD3, TRBC1, TRBC2, TIM-3, integrin B7, ICAM-1, CD70, Tim3, CLEC12A, and ERBB.

77. The immune response cell of claim 77, wherein the antigen is CD19.

78. A pharmaceutical composition comprising an effective amount of the immune response cell of any one of claims 66-77 and a pharmaceutically acceptable excipient.

79. The pharmaceutical composition according to claim 78, for use in treating tumors.

80. A method of reducing tumor burden in a subject, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 66-77 or the pharmaceutical composition of claim 78 or 79.

81. A method of reducing tumor burden in a subject, the method comprising administering to the subject an effective amount of immune response cells or a pharmaceutical composition comprising the same, wherein the immune response cells comprise: A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide comprises one or more ITAM variants, the ITAM variants comprising one or more loss-of-function variants, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant.

82. The method of claim 81 or 82, wherein the method reduces the number of tumor cells.

83. The method of any one of claims 81-83, wherein the method reduces tumor size.

84. The method of any one of claims 81-84, wherein the method eradicates the tumor in the subject.

85. A method for treating or preventing a tumor, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 66-77 or the pharmaceutical composition of claim 78 or 79.

86. A method for treating or preventing a tumor, the method comprising administering to the subject an effective amount of immune response cells or a pharmaceutical composition comprising the same, wherein the immune response cells comprise: A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant.

87. The method of any one of claims 80-86, wherein the tumor or neoplasm is selected from a blood cancer, a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer.

88. The method of any one of claims 80-87, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds CD19.

89. The method of any one of claims 80-87, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to BCMA, ADGRE2, MSLN, PSMA, or a combination thereof.

90. A method for treating a subject with tumor recurrence, wherein the subject suffers from recurrence of the disease, wherein the subject has received treatment resulting in residual tumor cells, or the subject has received an immune response cell comprising an antigen recognition receptor, wherein the antigen recognition receptor comprises a 4-1BB co-stimulatory signal, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 66-77 or the pharmaceutical composition of claim 78 or 79.

91. A method for treating a subject with tumor recurrence, wherein the subject has recurrence of the disease, wherein the subject has received treatment resulting in residual tumor cells, or the subject has received immune response cells comprising antigen recognition receptors, wherein the antigen recognition receptors comprise 4-1BB co-stimulatory signals, the method comprising administering to the subject an effective amount of immune response cells or a pharmaceutical composition comprising the same, wherein the immune response cells comprise: A chimeric antigen receptor (CAR) comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a modified CD3 zeta polypeptide, wherein the modified CD3 zeta polypeptide comprises one or more ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from an ITAM1 variant, an ITAM2 variant, and an ITAM3 variant.

92. The method of claim 90 or 91, wherein the tumor is selected from the group consisting of blood cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.

93. The method of any one of claims 90-92, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19.

94. The method of claims 90-93, wherein the tumor is CD19+ALL.

95. The method of claims 90-94, wherein the tumor comprises tumor cells having a low density of tumor-specific antigens on the surface of the tumor cells.

96. The immune response cell of any one of claims 66-77 or the pharmaceutical composition of claim 78 or 79 for use in reducing tumor burden, treating or preventing tumors, and / or treating a subject suffering from tumor recurrence.

97. A chimeric antigen receptor (CAR), comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signaling domain comprising a modified CD3ζ polypeptide, wherein the modified CD3ζ polypeptide comprises one or more ITAM variants, the ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from ITAM1 variants, ITAM2 variants and ITAM3 variants, and the CAR is used to reduce tumor burden, treat or prevent tumors, and / or treat subjects with tumor recurrence.

98. A method for producing antigen-specific immune response cells, the method comprising introducing a nucleic acid sequence encoding a CAR described in any one of claims 1-65 into the immune response cells.

99. The method of claim 98, wherein the nucleic acid sequence is contained in a vector.

100. The method of claim 99, wherein the vector is a retroviral vector.

101. An isolated nucleotide encoding the CAR of any one of claims 1-65.

102. The isolated nucleotide according to claim 101, comprising the nucleotide sequence shown as SEQ ID NO: 45 and SEQ ID NO:

47.

103. A nucleic acid composition comprising the CAR of any one of claims 1-65.

104. The nucleic acid composition of claim 103, wherein the nucleic acid sequence is contained in a vector.

105. The nucleic acid composition of claim 104, wherein the vector is a retroviral vector.

106. A vector comprising the nucleic acid composition of any one of claims 103-105.

107. A kit comprising the CAR of any one of claims 1-65, the immune response cell of any one of claims 66-77, the pharmaceutical composition of claim 78 or 79, the nucleic acid composition of any one of claims 103-105, or the vector of claim 106.

108. The kit of claim 107, wherein the kit further comprises written instructions for treating and / or preventing tumors, pathogen infections, autoimmune diseases, or allogeneic transplantation.

109. An immune response cell comprising a) a first CAR comprising a first extracellular antigen binding domain that binds to a first antigen, a first transmembrane domain, and a first intracellular signaling domain; b) a second CAR comprising a second extracellular antigen binding domain that binds to a second antigen, a second transmembrane domain, and a second intracellular signaling domain, wherein the first CAR is the CAR of any one of claims 1-65, or the first intracellular signaling domain comprises a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprises one or more ITAM variants, the ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from ITAM1 variants, ITAM2 variants, and ITAM3 variants.

110. The immune response cell of claim 109, wherein the second CAR is the CAR of any one of claims 1-65.

111. The immune response cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3ζ polypeptide, the modified CD3ζ polypeptide comprising one or more ITAM variants, the ITAM variants comprising one or more loss-of-function mutations, wherein each of the one or more ITAM variants is independently selected from ITAM1 variants, ITAM2 variants, and ITAM3 variants.

112. The immune response cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3 zeta polypeptide that is identical to the modified CD3 zeta polypeptide contained in the first intracellular signaling domain in the first CAR.

113. The immune response cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a modified CD3 zeta polypeptide that is different from the modified CD3 zeta polypeptide contained in the first intracellular signaling domain in the first CAR.

114. The immune response cell of claim 109, wherein the second intracellular signaling domain of the second CAR comprises a native CD3 zeta polypeptide.

115. The immune response cell of any one of claims 109-113, wherein the first intracellular signaling domain of the first CAR is the same as the second intracellular signaling domain of the second CAR.

116. The immune response cell of any one of claims 109-114, wherein the first intracellular signaling domain of the first CAR is different from the second intracellular signaling domain of the second CAR.

117. An immune response cell according to any one of claims 109-116, wherein the first antigen is different from the second antigen.

118. An immune response cell according to any one of claims 109-117, wherein the first CAR further comprises a first hinge / spacer region.

119. An immune response cell according to any one of claims 109-118, wherein the second CAR further comprises a second hinge / spacer region.

120. The immune response cell of any one of claims 109-119, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof.

121. The immune response cell of any one of claims 109-119, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, and the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

122. The immune response cell according to any one of claims 109-121, further comprising a third CAR comprising a third extracellular antigen binding domain that binds to a third antigen, a third transmembrane domain, and a third intracellular signaling domain.

123. The immune response cell of claim 122, wherein the first intracellular signaling domain comprises or has an ITAM2 variant and an ITAM3 variant, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

124. The immune response cell of claim 122, wherein the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

125. The immune response cell of claim 122, wherein the first intracellular signaling domain comprises or has a deletion of ITAM2 or a portion thereof and a deletion of ITAM3 or a portion thereof, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

126. The immune response cell of claim 122, wherein the first intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, the second intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant, and the third intracellular signaling domain comprises or has an ITAM1 variant and an ITAM2 variant.

127. A pharmaceutical composition comprising an effective amount of the immune response cell of any one of claims 109-126 and a pharmaceutically acceptable excipient.

128. The immune response cell according to any one of claims 109-126 or the pharmaceutical composition according to claim 127, for use in reducing tumor burden, treating or preventing tumors, and / or treating subjects suffering from tumor recurrence.

129. A method of reducing tumor burden in a subject, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 109-126 or the pharmaceutical composition of claim 127.

130. The method of claim 129, wherein the method reduces the number of tumor cells, reduces the size of a tumor, and / or eradicates a tumor in the subject.

131. A method for treating or preventing a tumor, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 109-126 or the pharmaceutical composition of claim 127.

132. The method of claim 131, wherein the tumor or neoplasm is selected from the group consisting of blood cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and ovarian cancer.

133. The method of claim 131 or 132, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19.

134. The method of any one of claims 131-133, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to BCMA, ADGRE2, MSLN, PSMA, or a combination thereof.

135. A method for treating a subject with tumor recurrence, wherein the subject suffers from recurrence of the disease, wherein the subject has received treatment resulting in residual tumor cells, or the subject has received an immune response cell comprising an antigen recognition receptor, wherein the antigen recognition receptor comprises a 4-1BB co-stimulatory signal, the method comprising administering to the subject an effective amount of the immune response cell of any one of claims 109-126 or the pharmaceutical composition of claim 127.

136. The method of claim 135, wherein the tumor is selected from the group consisting of blood cancer, B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, and non-Hodgkin's lymphoma.

137. The method of claim 135 or 136, wherein the tumor is a B-cell leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia, or non-Hodgkin's lymphoma, and the CAR binds to CD19.

138. The method of claims 135-137, wherein the tumor is CD19+ALL.

139. The method of claims 135-138, wherein the tumor comprises tumor cells having a low density of tumor-specific antigens on the surface of the tumor cells.